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ABSTRACT 
Background 
The purpose of this study was to develop and test a measure of outpatient prescription 
utilization (medication exposure measure, or MEM) that may be coupled with the CMS-HCC and 
CMS-RxHCC methodologies to improve risk-adjusted payments to Medicare Part C and Part D 
plans. Studies have identified prescription measures that predict future expenditures; however, 
many are easily manipulable by health plans or practitioners, thus limiting their utility as 
risk-adjusters. The addition of a non-manipulable prescription utilization measure to existing 
risk-adjustment models may improve prediction, reducing adverse risk selection incentives by 
health plans. A secondary objective of this study was to evaluate the utility of adding prescription 
measures to the Charlson’s Comorbidity Index, Elixhauser’s Index, and RxRisk to predict year-2 
expenditures, hospitalization counts, emergency department visits, and mortality. 
Study Design 
The study design utilized a retrospective cohort from the 5% Medicare national sample, 
which used year-1 (2007) inputs to predict the year-2 (2008) economic and clinical outcomes. The 
sample included beneficiaries with continuous enrollment in fee-for-service Medicare Parts A, B, 
and D for a minimum of 12 months in the base year and a minimum of 1 month in year-2. An 
interaction between the end-of-year Medicare Part D benefit phase and the prescription measures 
 iii 
was included to account for the influence of the coverage gap (i.e., “donut hole”) on the 
prescription measures. 
Results 
Overall, the addition of the prescription-based measures to risk-adjustment models resulted 
in enhanced predictive validity for the economic and clinical outcomes tested compared to the 
risk-adjustment model alone. The addition of any prescription measure to the risk-adjustment 
models did not meaningfully improve model performance in predicting year-2 medical 
expenditures; however, the prescription measures, particularly the MEM, markedly improved 
prediction of year-2 pharmacy expenditures.  
Conclusions 
Although adding MEM to the HCC models used to predict medical expenditures does not 
appear to be a useful method of enhancing risk-adjusted payments, the MEM performed 
particularly well with the RxHCC predicting year-2 pharmacy expenditures. Incorporating the 
MEM into Medicare Part D risk-adjustment models (i.e., with RxHCC) would improve 
risk-adjusted capitated payments from both the perspectives of CMS and the health plans.  
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CHAPTER I - INTRODUCTION 
Background 
Medicare Prospective Payment System 
When Medicare was established in 1965, hospital payments were based on 
“fee-for-service” reimbursements modeled after the private health insurance sector’s 
“retrospective cost-based reimbursement” payment methodology (Office of Inspector General, 
2001). Because reimbursements were directly related to the services performed, this 
reimbursement method left little reason for hospitals to control costs. To help curtail the growing 
cost of the Medicare hospital benefit (Medicare Part A), Congress enacted The Social Security 
Amendments of 1983, which created the first prospective payment system in which hospitals 
would receive a prospective payment based on a risk adjustment process which grouped medical 
services into diagnosis-related groups (DRGs) (Fetter, 1991). This allowed Medicare to adjust 
payments based on the patient’s condition while incentivizing the hospital to become more cost 
effective. 
In 1982, Congress passed the Tax Equity and Fiscal Responsibility Act (TEFRA), which 
allowed for demonstration projects involving risk contracts with full prospective payments to 
health maintenance organizations (HMOs) (Ash, Porell, Gruenberg, Sawitz, & Beiser, Adjusting 
Medicare capitation payments using prior hospitalization data, 1989). The TEFRA Medicare 
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HMO demonstration projects laid the foundation for the creation of Medicare+Choice (Medicare 
Part C) by the Balanced Budget Act of 1997. The original Medicare+Choice set capitated 
payments at 95 percent of an enrollee’s county’s adjusted average per capita cost (AAPCC) based 
on fee-for-service (FFS) expenditures by geographic area and adjusted for age, gender, welfare 
status, and institutional status (Pope et al., 2004). A major limitation of the AAPCC formula was 
the inability to adjust capitated payments to account for differences in health status of enrolled 
members, and as a result, health plans disproportionately sought out healthier individuals in the 
years following the implementation of the AAPCC payment methodology (Thomas, Lichtenstein, 
& Wyszewianski, 1986). New payment methodologies that accounted for differences in health 
status were implemented by the Centers for Medicare and Medicaid Services (CMS) to incentivize 
Medicare+Choice plans to enroll sicker beneficiaries. These enhanced payment methodologies 
used diagnostic data to categorize individuals based on their health conditions and some models 
also provided estimates of disease severity. Risk-adjustment models using demographic 
information in combination with year-1 diagnostic data have been found to predict year-2 costs 
better than demographic models alone (Ash, Porell, Gruenberg, Sawitz, & Beiser, Adjusting 
Medicare capitation payments using prior hospitalization data, 1989). 
Diagnosis-Based Input Models 
The conceptual justification for including diagnoses in risk-adjustment methods is that 
certain diagnoses are associated with predictable higher levels of health care needs and ultimately, 
higher expenses (Ellis & Ash, 1995/96). Diagnosis-based inputs for risk-adjustment models often 
include the basic information included in the demographic-based models, but as the name implies 
they also incorporate diagnosis-based information. Examples of diagnosis-based models include 
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adjusted clinical groups (ACG), ambulatory diagnostic groups (ADG), Charlson’s comorbidity 
index (CCI), diagnostic cost groups (DCG), diagnosis-related groups (DRG), Elixhauser’s index, 
and diagnostic cost group-hierarchical condition category (DCG-HCC) models (Pope et al., 2004). 
The commonality among diagnosis-based models is that they all use International Classification 
of Diseases, 9
th
 Revision, Clinical Modification (ICD-9-CM) codes as the basis for inferring 
diagnoses, with the main differences between the methodologies being the approach for disease 
groupings and the conditions which are selected for model inclusion (Greenwald, 2000). 
DCG-HCC-based models are generally considered to be the most accurate of the risk-adjustment 
models at predicting year-2 medical costs and mortality (Pope, Adamache, Walsh, & Khandker, 
1998; Rosen et al., 2001; Sales et al., 2003; Li, Kim, & Doshi, 2010). An amended DCG-HCC 
model, referred to as CMS-HCC, has been used by Medicare since 2004 to calculate 
risk-adjustment payments to Medicare Advantage plans (Pope et al., 2011). Predecessors to the 
DCG-HCC model have been used by CMS since 2000 (Ash et al., 2000; Pope et al., 2000a). Since 
the implementation of Medicare Part D in 2006, CMS has used another diagnosis-based model 
based on the DCG-HCC model to risk adjust capitated payments to Medicare Part D plans. This 
model, called CMS-RxHCC, uses diagnoses that are predictive of drug expenditures (Robst, Levy, 
& Ingber, 2007). 
Pharmacy-Based Input Models 
Risk-adjustment models that use pharmacy-based inputs infer a disease state or condition 
from prescription claims to predict future outcomes or expenditures. There are several benefits to 
utilizing pharmacy data to calculate risk-adjustment scores. Compared to diagnostic claims data, 
pharmacy claims are often more readily available, more timely, and more complete than diagnostic 
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data (Von Korff, Wagner, & Saunders, 1992). Initial work on the Chronic Disease Score (CDS) 
pharmacy-based risk-adjustment model by Von Korff et al. (1992) served as the foundation for 
several other risk-adjustment models using pharmacy-based inputs, including MedicaidRx and 
RxRisk (Gilmer, Kronick, Fishman, & Ganiats, 2001; Fishman, Goodman, Hornbrook, Meenan, 
Bachman, & O'Keeffe Rosetti, 2003). Inferring conditions from prescription claims presents some 
problems with pharmacy-based inputs compared to diagnosis-based inputs. Some drugs may be 
used for multiple conditions or may not be linked to a condition at all, leading to misclassifications 
or the inability to classify patients into a condition category. Several studies have found evidence 
to suggest that models using year-1 diagnostic and pharmacy data predict year-2 drug costs better 
than diagnostic data alone, possibly because of the enhanced ability to assign conditions using both 
diagnostic- and pharmacy-based inputs (Schneeweiss et al., 2001; Zhao et al., 2005).  
Incorporating Prior Costs and Healthcare Utilization 
A study conducted by the Society of Actuaries found that adding prior costs as an 
independent variable to risk-adjustment models used for underwriting, not for prospective 
payment, significantly increased the predictive accuracy of the models (Winkelman & Mehmud, 
2007). While prior costs predict future expenditures, they are not included in risk adjustment used 
for prospective payment because of the potential for manipulation from health plans (Ash, Zhao, 
Ellis, & Kramer, 2001; Zhao, Ash, Haughton, & McMillan, 2003). 
Simple counts of health care utilization, including counts of physician visits, hospital 
claims, and unique prescriptions, have also been found to improve the predictive validity of 
risk-adjustment models when coupled with common risk adjusters (Farley, Harley, & Devine, 
2006; Perkins, et al., 2004; Schneeweiss, Seeger, Maclure, Wang, Avorn, & Glynn, 2001). Farley 
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et al. (2006) posit that the addition of simple counts to comorbidity measures, including 
prescription counts, more accurately account for disease severity by capturing the intensity of 
resource utilization. Another potential explanation is that simple prescription counts add a unique 
dimension of medication utilization to a diagnosis-based risk adjuster, thus improving the 
predictive ability of the measures when the two are used in concert. 
Prescription-based Count Measures 
Farley et al. (2006) defined unique prescription count as the number of unique prescription 
classes filled in a one-year period. The count of unique prescriptions over the course of one year 
outperformed simple prescription count, physician visit count, and hospitalization count in 
predicting year-2 expenditures, with diagnosis cluster count being the only count variable to 
perform better (Farley, Harley, & Devine, 2006). A study that used the number of distinct 
prescription drugs (distinct chemical entities) found that it was the best predictor of future 
physician visits and expenditures compared to several diagnosis- and pharmacy-based variables  
(Schneeweiss et al., 2001). Perkins et al. (2004) found that a count of the number of prescription 
subclasses had similar predictive ability compared to prescription count, and was a better predictor 
of future expenditures compared to several diagnosis- and pharmacy-based risk adjusters. 
Prescription-based count measures are a useful addition to models predicting future healthcare 
utilization; however, they have not been incorporated into current capitated payment 
risk-adjustment models. 
Operational Criteria for Evaluating Risk-Adjustment Methods 
While prior costs and utilization add predictive validity to risk-adjustment models, these 
measures have not been included in risk-adjusted payment models. This is partly due to the ability 
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of health plans and providers to manipulate current costs and utilization in an effort to increase 
future prospective payments. In 1994, the General Accounting Office, now called the Government 
Accountability Office (GAO), identified a set of operational criteria for evaluating risk-adjustment 
methods, noting that a good risk-adjustment method would: 
1. be able to predict health care costs with accuracy, 
2. treat participating HMOs reasonably and fairly, 
3. be difficult for participating health plans to manipulate, 
4. respect patient privacy and confidentiality, 
5. create incentives for appropriate care, and 
6. be feasible and inexpensive to administer (U.S. GAO, 1994a). 
Given these guidelines, developing an intractable, claims-based measure to augment 
current diagnosis- and pharmacy-based input models, while also capturing resource intensity in the 
same manner as the previously described simple count measures, would be ideal. A measure that 
approximates medication utilization, which is dependent on both prescribing behavior and patient 
medication consumption behavior, would be less susceptible to manipulation (i.e., unlike unique 
prescription count) and could create incentives for appropriate care through medication 
management. 
Statement of Problem 
Risk-adjustment models and comorbidity measures in health research use diagnosis- and 
pharmacy-based inputs to arrive at a health condition attributed to individuals in the population. 
Medication utilization has not been routinely incorporated into these models, even for pharmacy 
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benefit-based prospective payment calculations (i.e., CMS payments to Medicare Part D plans) 
where such inclusion would seem sensible. Measures similar to unique drug count, defined here as 
the number of unique chemical entities captured in an administrative claims database over a given 
time period, have been found to improve the predictive ability of common risk adjusters. While 
unique prescription counts provide some estimate of medication use or resource utilization, they 
are an imprecise global measure, often misestimating true medication exposure. Little work has 
been conducted using administrative claims data to develop and refine a medication utilization 
measure. This study seeks to develop and test a novel measure that will conceptually reflect 
medication exposure better than prescription counts. As a corollary, the medication exposure 
measure should outperform prescription counts in predicting clinical and economic outcomes 
when coupled with select risk-adjustment measures. 
Conceptual Framework 
Study Purpose 
 The primary purpose of this study is to develop and test a measure of outpatient medication 
exposure, which may be used to risk-adjust Medicare payments to health and pharmacy plan 
participants. The medication exposure measure: 1) will better reflect medication exposure 
compared to current methods, 2) should outperform other prescription-based count measures in the 
prediction of health and economic outcomes, 3) will be reasonably straightforward to calculate, 
and 4) will not be easily manipulable by health plans or practitioners. 
 The specific objectives of this study were to develop and describe a global measure of 
medication exposure using administrative claims data and to test the predictive validity of this 
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measure when coupled with diagnosis- and pharmacy-based risk-adjustment measures. While the 
primary purpose of this study is to test a medication exposure measure with Medicare payment risk 
adjusters (CMS-HCC and CMS-RxHCC), relevant comorbidity estimates common in the 
literature, including Charlson’s Comorbidity Index, Elixhauser’s Index and RxRisk, will be 
included because of the potential interest of a medication exposure measure to researchers utilizing 
these comorbidity estimates. Risk adjusters were selected for this study based on their prevalence 
in the literature, on the expected influence that the medication exposure measure would have on 
the predicted outcomes, and on the availability of code and required variables to calculate the risk 
adjuster. This study will provide information to better understand the utility of this measure on 
predicting health and economic outcomes. 
Study Aims and Research Questions 
The specific aims of this study were designed to: 1) examine the relationship between the 
outpatient medication exposure measure and the prescription-based count measures unique drug 
count and simple prescription count, 2) examine the predictive validity of the medication exposure 
measure when coupled with CMS risk-adjustment models (i.e., CMS-HCC and CMS-RxHCC), 
and 3) examine the predictive validity of the medication exposure measure when coupled with 
non-CMS diagnosis-based (i.e., Charlson’s Comorbidity and Elixhauser Indices) and 
pharmacy-based risk-adjustment models (i.e., RxRisk). 
The central hypothesis is that the outpatient medication exposure measure will be distinct 
from a unique drug count and a simple prescription count measure and when added to diagnosis- 
and pharmacy-based risk adjusters, the combined model will explain more variance and will more 
accurately predict health and economic outcomes compared to diagnosis- and pharmacy-based 
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risk-adjustment measures alone. This central hypothesis is based on evidence in the extant 
literature that suggests the addition of simple count variables, such as unique drug and 
conventional prescription counts, to risk-adjustment models result in enhanced predictive validity 
and variance explanation compared to the risk-adjustment model alone (Farley, Harley, & Devine, 
2006; Perkins, et al., 2004; Schneeweiss, Seeger, Maclure, Wang, Avorn, & Glynn, 2001). It is 
also based on the observation that prescription count-based measures often misestimate actual 
medication exposure. The basis for the proposed research is to provide insight to health plan 
risk-adjustment procedures as well as to provide a medication utilization-based covariate for 
health outcomes researchers. 
Specific Aim 1 
The objective of specific aim 1 is to develop an outpatient medication exposure measure 
using retrospective administrative claims data and to compare this measure to prescription-based 
count measures, including a count of unique drugs and a simple prescription count calculated for 
the same individual. 
Research Question 1: What is the relationship between the medication exposure measure 
and the prescription-based count measures, unique drug count and 
simple prescription count? 
Specific Aim 2 
The objective for specific aim 2 is to evaluate the predictive validity of the outpatient 
medication exposure measure for health and economic outcomes compared to unique drug count 
and simple prescription count for Medicare risk-adjustment models. Comparisons will be made 
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between the medication exposure measure and the other prescription count measures when 
coupled with the CMS-HCC and CMS-RxHCC models. 
Research Question 2:  Will the outpatient medication exposure measure provide better 
predictive validity of health and economic outcomes compared to 
the prescription-based count measures, unique drug count and 
simple prescription count, when combined with the CMS-HCC 
model? 
Research Question 3:  Will the outpatient medication exposure measure provide better 
predictive validity of health and economic outcomes compared to 
the prescription-based count measures, unique drug count and 
simple prescription count, when combined with the CMS-RxHCC 
model? 
Specific Aim 3 
The objective for specific aim 3 is to evaluate the predictive validity of the outpatient 
medication exposure measure on health and economic outcomes compared to the 
prescription-based count measures, unique drug count and simple prescription count, on non-CMS 
risk-adjustment models. Comparisons will be made between the medication exposure measure and 
the prescription-based count measures when coupled with the diagnosis-based risk adjusters, 
Charlson’s Comorbidity and Elixhauser’s Index, and with the pharmacy-based risk adjuster, 
RxRisk. 
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Research Question 4:  Will the outpatient medication exposure measure provide better 
predictive validity of health and economic outcomes compared to 
the prescription-based count measures, unique drug count and 
simple prescription count, when combined with the Charlson 
Comorbidity Index risk-adjustment model? 
Research Question 5:  Will the outpatient medication exposure measure provide better 
predictive validity of health and economic outcomes compared to 
the prescription-based count measures, unique drug count and 
simple prescription count, when combined with the .Elixhauser 
Index risk-adjustment model? 
Research Question 6:  Will the outpatient medication exposure measure provide better 
predictive validity of health and economic outcomes compared to 
the prescription-based count measures, unique drug count and 
simple prescription count, when combined with the RxRisk 
risk-adjustment model? 
Study Significance 
The results of this study may be used to enhance risk adjustment for payment models and 
for researchers to use in studies requiring risk-adjusted estimates of some health or economic 
outcome. 
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Limitations 
All conditions included in the risk-adjustment models tested do not warrant drug treatment, 
so adding a measure of medication exposure will not contribute to the predictive validity of those 
diseases. By design, the disease categories selected for the CMS-RxHCC model should include 
more diseases that warrant drug therapy compared to the CMS-HCC model. The medication 
exposure measure only includes outpatient drugs which are submitted to Medicare Part D plans for 
reimbursement, and does not include J-code billed drugs or drugs received during inpatient 
hospital stays. 
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CHAPTER II - LITERATURE REVIEW AND CONCEPTUALIZATION  
Overview 
This chapter will provide an overview of the risk-adjustment literature, including methods 
used to adjust capitated payments and those used as comorbidity estimates or covariates in 
research studies. Statistical analysis unique to the risk-adjustment for capitated payments literature 
will be contrasted with methods common in the research literature. The risk-adjustment literature 
overview will contain both diagnosis- and pharmacy-based input models, as well as a review of the 
resource utilization-based predictors that have been studied in risk-adjustment models. A cursory 
discussion of laws and regulations affecting risk-adjusted payments will be included when 
relevant. Finally, the chapter will conclude with the conceptualization of the medication exposure 
measure. 
Risk-adjustment Models 
There are three basic sources of inputs for the risk-adjustment models discussed in this 
manuscript: 1) demographic-based inputs including variables like gender and age, 2) 
diagnosis-based inputs using codes from medical records that are mapped to diagnostic categories, 
and 3) pharmacy claims-based inputs using prescription claim data mapped to diagnostic 
categories. Common outcomes predicted by risk-adjustment models are outlined in Table 1. 
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Table 1 – Common Outcomes Predicted by Risk-adjustment models 
Costs  Clinical 
Prescription  Hospitalizations 
Medical  Emergency Department Visits 
Total Costs  Mortality 
 
Risk adjustment can occur retrospectively, concurrently, or prospectively. Prospective 
risk-adjustment models are used to calculate capitated payments to health plans, whereas 
retrospective models may be estimated to adjust previous payments or in the context of 
reinsurance (U.S. GAO, 1994b). Concurrent models are useful for provider profiling and 
interventions orchestrated by the health plan and typically have more predictive power compared 
to prospective risk-adjustment models (Cucciare & O'Donohue, 2006; Ash et al., 2000). 
Risk of What? 
From the perspective of adjusting capitated payments, risk adjustment has been defined as 
“the process of adjusting health plan payments, health care provider payments and individual or 
group premiums to reflect the health status of the plan members” (Cumming, Knutson, Cameron, 
& Derrick, 2002; Winkelman & Mehmud, 2007). However, not all risk-adjustment models are 
used to adjust capitated payments. Risk adjustment is also used to account for patient-related 
factors when examining outcomes of medical care (Iezzoni, 2003). Other terms to describe this 
same concept include case-mix adjustment, comorbidity estimation, and severity of illness, among 
others (Greenwald, 2000; Duncan, 2011). Deciding on a proper definition of risk adjustment is 
largely dependent on perspective. Health plans are primarily concerned with financial loss, 
whereas clinicians and patients are more concerned with clinical loss, such as a decrease in 
functional status (Duncan, 2011). The perspective of this study is that of a researcher, who may be 
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concerned with predicting both financial and clinical loss. As such, the term “risk adjustment” will 
be used throughout this manuscript regardless of the perspective or outcome of interest. 
Resource Distribution 
Many researchers reference the “Pareto Principle” or “80/20 Rule” when describing how 
resources are utilized or distributed throughout a population (Institute of Medicine, 2002). 
Analysis of healthcare spending has found a similar, “Pareto-like” principle in effect. A study 
conducted by Berk & Monheit (2001) reported the distribution of United States health 
expenditures has remained relatively static since as early as the 1960s; with the top 10 percent of 
individual expenditures accounting for 60 to 70 percent of total expenditures and the top 30 
percent accounting for about 90 percent of total expenditures. Another study found that 30% of a 
company’s employees accounted for 80% of their medical spending; with the mean cost for 70% 
of the company’s employees was $901, whereas the average cost for the total study sample was 
$3,150. (Rula, Hobgood, Hamlet, Zeng, & Montijo, 2009). This type of expense distribution 
remains relatively static from year to year; however, most patients do not stay in the same 
“bracket” for consecutive years. In a study of a large employee group, researchers found that the 
high-cost bracket consisted of 73% to 83% “first-timers” and only 12% to 18% of those 
individuals remained in the high-cost bracket the next year (Lynch & Gardner, 2009). In fact, less 
than 1% of the total study sample remained in the high-cost bracket for two or more consecutive 
years (Lynch & Gardner, 2009). Ash et al. (2001) had a similar finding when using year-1 costs 
and diagnostic information to predict year-2 expenditure group membership. Patient flow between 
expense brackets is dynamic because high-cost events are episodic (Rula, Hobgood, Hamlet, 
Zeng, & Montijo, 2009). In a disease-specific sample, about 30% of individuals with diabetes were 
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re-hospitalized over a one-year period; however, these individuals accounted for more than 50% of 
all diabetes-related hospital expenses (Agency for Healthcare Research and Quality, 2005).  
Individuals with repeat, same year hospitalizations cost nearly three times as much as individuals 
with a single hospital stay ($23,100 vs. $8,500) (Jiang, Stryer, Friedman, & Andrews, 2003). The 
dynamic nature of individual health expenditures highlights the importance of building models to 
accurately predict future healthcare expenditures at the group level. 
Analyses of Risk-adjustment Models 
Risk-adjusted models for capitated payments are typically estimated as ordinary least 
squares (OLS) regression models, which predict total health care expenditures for an individual 
over a given time period (usually one year) using a number of demographic and diagnosis-related 
variables (Axelrod & Vogel, 2003; Iezzoni, 2003). The purpose of these models is to predict 
next-year costs for managed care organizations or to aid in forecasting capitated payments. The 
performance of risk-adjusted models is typically assessed using the R-square statistic and the 
predictive ratio (Iezzoni, 2003; Pope et al., 2004; Cucciare & O'Donohue, 2006). 
Regression 
The R-square statistic represents the proportion of variance in the dependent variable 
explained by the variables included in the model. Several approaches have been suggested to 
selecting an appropriate R-square based on the study purpose. The R-square from OLS regression 
has been used frequently in reporting the variance explained in risk-adjustment models; however, 
several authors have questioned whether it is appropriate for risk-adjustment models (Ash, Porell, 
Gruenberg, Sawitz, & Beiser, Adjusting Medicare capitation payments using prior hospitalization 
data, 1989; Ash & Byrne-Logan, 1998; Iezzoni, 2003). The criticism is based on the way that 
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R-square from OLS regression is calculated, with the error from each individual’s expected and 
observed costs contributing to the error term of the model. Because individual prediction of 
healthcare expenses is fraught with error and the level of granularity that individual predictions 
offer is often unnecessary for risk-adjusted payment models, some authors have suggested the use 
of grouped R
2
 as an alternative (Ash, Porell, Gruenberg, Sawitz, & Beiser, Adjusting Medicare 
capitation payments using prior hospitalization data, 1989; Ash & Byrne-Logan, 1998; Iezzoni, 
2003). The error for grouped R
2
 is based on the difference between the expected and observed 
costs for predetermined groups. The formula for grouped R
2
 is (Ash, McCall, Fonda, Hanchate, & 
Speckman, November 2005): 
Equation 1 – Grouped R2 
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Where: 
b = 1,2,…,B are partitions in the sample 
   = weight for each partition b (determined by partition size) 
      = the mean of actual costs for each partition b 
    ̂  = the mean of predicted costs for each partition b 
 ̅ = the mean for the entire sample  
A final model summary statistic that has been suggested is the adjusted R
2
 (U.S. GAO, 
1994b; Duncan, 2011). The adjusted R
2
 protects against model over-fitting and allows for 
comparisons to be made between models with different numbers of predictor variables by 
normalizing R
2
 with degrees of freedom (Duncan, 2011). The formula for adjusted R
2
 is: 
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Equation 2 – Adjusted R2 
              (    )  
   
     
 
Where: 
N = the number of observations, and 
k = is the number of parameters in the model 
Selecting the “most appropriate” statistic to measure a model’s predictive power largely 
depends on the research question. Unfortunately, there are inconsistencies in the risk adjustment 
literature for which R
2
 statistic is reported, making meaningful comparisons across published 
papers difficult.  
Predictive Ratio 
The predictive ratio, a ratio of the model predicted costs to the actual costs of the target 
population, is also used to examine the accuracy of a risk-adjustment model (Iezzoni, 2003; 
Cucciare & O'Donohue, 2006). A calculated predictive ratio equal to 1 would signify that the 
risk-adjusted model predicted costs perfectly. Accordingly, values less than 1 would mean that the 
model under-predicted costs and values over 1 would suggest the model overpredicted costs (Ash 
et al., 2000). 
Equation 3 – Predictive Ratio 
                  
                                 
                           
 
Demographic and diagnosis-based risk models perform well when calculated for large 
groups (i.e., not broken down into cost groups); however, the prediction of individual deciles is 
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relatively poor. These models typically overpredict costs for lower cost deciles and underpredict 
costs for higher cost deciles (Ash et al., 2000). When calculated across a population, the predictive 
ratios for diagnosis-based models typically range between 0.95 to1.05 (Ash et al., 2000). Thus, if a 
managed care organization covers a sufficiently large group of recipients whose health care 
utilization follows a normal distribution (based on costs), then the predictive ratio should be close 
to 1.   
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Evolution of Risk-adjustment Models Used by CMS 
Average Adjusted Per Capita Costs (AAPCC) 
Medicare has had HMO-type contractors in place since its implementation on July1, 1966. 
The predecessors to HMOs were essentially cost contractors, who were reimbursed on a 
cost-basis, similar to private health plans at the time. The HMO Act of 1973 introduced risk 
sharing and the concept of prospective payments. These prospective payments were based on the 
average adjusted per capita cost (AAPCC) methodology, which was further refined in 1982 when 
the Tax Equity and Fiscal Responsibility Act (TEFRA) was introduced. The TEFRA set 
prospective payments to health plans at 95 percent of the AAPCC. The AAPCC model is 
essentially a demographics-based risk-adjustment model, which includes age, gender, institutional 
status, and Medicaid status, with adjustments made for end-stage renal disease (ESRD) and for the 
disabled (Zarabozo, 2000). Table 2 provides an overview of relevant legislation that affects CMS 
risk-adjusted capitated payments to Medicare Advantage and Part D plans (Weissman, 
Wachterman, & Blumenthal, 2005). 
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Table 2 – Abridged Legislative History of CMS Risk-Adjustment Methodologies 
Related 
Legislation 
HCFA/CMS 
Implementation 
Risk Adjustment 
Methodology 
Original 
Research 
Author(s) 
Variance 
Explained (R
2
)† 
TEFRA 1982 1985 
Adjusted Average 
per Capita Cost 
(AAPCC) 
HCFA ≈ 0.5-2% 
BBA 1997 2000 
Principal Inpatient 
Diagnostic Cost 
Group (PIP-DCG) 
(Pope et al., 
2000b) 
≈ 6% 
  
Diagnostic Cost 
Group/Hierarchical 
Condition 
Category 
(DCG/HCC) 
(Ash et al., 
2000) 
≈ 8-9% 
 2004 
CMS-Hierarchical 
Condition 
Category 
(CMS-HCC) 
(Pope et al., 
2004) 
≈ 9% 
MMA 2003 2006 
CMS-Rx 
Hierarchical 
Condition 
Category 
(CMS-RxHCC) 
(Robst, Levy, & 
Ingber, 2007) 
≈ 12% 
† Variance explained using a Medicare sample 
TEFRA 1982: Tax Equity and Fiscal Responsibility Act of 1982 
BBA 1997: Balanced Budget Act of 1997 
MMA 2003: Medicare Modernization Act of 2003 
Age is a very common predictor of health outcomes and expenses because many 
conditions, and thus expenses through treatment, are a result of the aging process (Fisher, 1980; 
Meara, White, & Cutler, 2004). Also, age is unaffected by disease processes or treatments, which 
makes it an ideal, stable variable to include in research (Iezzoni, 2003). Gender is another common 
predictor of health outcomes due to biologic differences, but there may also be behavioral 
differences between males and females. There is evidence that women are more likely to perform 
health-protective behaviors compared to men, which might suggest that women place a greater 
 22 
value on their health and may seek health services in a different manner than men (Felton, Parsons, 
& Bartoces, 1997; Liang, Shediac-Rizkellah, Celentano, & Rohde, 1999; Ungemack, 1994). One 
study found that age, sex, and race were predictors of the number of prescriptions used by 
Medicaid recipients, with older Caucasian females having the greatest number of prescriptions 
filled (Kotzan, Carroll, & Kotzan, 1989). 
Institutional and Medicaid status, as well as ESRD and disability status, are important 
predictors of future health costs because members of these groups historically have more 
expenditures relative to their peers (Newhouse, Manning, Keeler, & Sloss, 1989; Zarabozo, 2000). 
Despite the inputs included, AAPCC models only explain about 1-2 percent of the variance in 
future medical costs and no health status adjusters are included (Thomas, Lichtenstein, & 
Wyszewianski, 1986). The inability of AAPCC models to explain variability in health status led 
plans to selectively enroll healthier individuals and to avoid sicker ones (Dowd et al., 1996). 
Including Prior Utilization and Costs 
Including prior healthcare utilization and prior costs in diagnosis-based and 
pharmacy-based risk-adjustment models have been found to explain more variance and improve 
predictive validity of the risk-adjustment models (Ash, Porell, Gruenberg, Sawitz, & Beiser, 
Adjusting Medicare capitation payments using prior hospitalization data, 1989; Zhao et al., 2005). 
Numerous studies have found that prior utilization models outperform AAPCC risk-adjustment 
models in predicting year-2 costs (McCall & Wai, 1983; Anderson & Knickman, 1984; Beebe, 
Lubitz, & Eggers, 1985; Thomas, Lichtenstein, & Wyszewianski, 1986; Ash, Porell, & Gruenberg, 
1986). A study conducted by Beebe et al. (1985) sought to augment the AAPCC payment 
methodology by assessing the feasibility of including prior Medicare use, which provided better 
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explanatory power than the AAPCC model alone. The payment methodology including prior 
Medicare use was being tested in one of the Medicare HMO demonstration projects initiated by 
TEFRA (Beebe, Lubitz, & Eggers, 1985). The study authors acknowledged a major concern of 
prior-use models was the ability to “game the system.” Similarly, prior costs have not been 
incorporated into risk-adjustment models used for estimating capitated payments because prior 
costs can be manipulated by health plans and health care practitioners. 
Functional Status and Objective Health Measures 
In addition to including prior use, attempts have been made to include functional status 
health measures, such as instrumental activities of daily living scores, to enhance HMO capitation 
payments (Thomas & Lichtenstein, 1986). Another study included perception-based inputs to 
adjust capitated payments, including perceived health status and functional health status, along 
with prior utilization in the AAPCC model (Epstein & Cumella, 1988). Another study found 
evidence that the AAPCC model was improved by including prior use and objective health status 
measures, such as indicators for elevated cholesterol or blood pressure levels (Newhouse, 
Manning, Keeler, & Sloss, 1989). Despite the increased predictive ability of including 
perception-based and objective health status inputs, the Health Care Financing Administration 
(HCFA – the forerunner to CMS) has chosen not to incorporate these into risk-adjustment models 
used for capitated payments, possibly due to the difficulty of gathering such information as 
compared to claims-based information (U.S. GAO, 1994b). 
Diagnostic Cost Groups (DCG) 
Ash et al. (1989) refined the AAPCC model by including diagnosis-based inputs for risk 
adjustment, grouping diagnosis codes from hospitalizations into clinically meaningful groups 
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called diagnostic cost groups (DCGs). These DCGs were first organized into 78 diagnostic 
subgroups, which were pooled based on the three-digit International Classification of Diseases, 8
th
 
Revision – Clinical Modification (ICD-8-CM). The 78 diagnostic subgroups were then aggregated 
into nine DCGs, no longer clinically similar, based on similar average total costs in the study year. 
Individuals were then classified into one of 10 DCGs based on their hospitalizations during the 
study year, with an additional category representing DCG 0 indicating no hospitalization. The 
relatively costliness of the DCGs increases from DCG 1 to DCG 9. Individuals are classified into 
the highest DCG if multiple diagnoses are found. However, only one principal diagnosis 
contributes to a DCG for each hospitalization. The DCG model was able to explain about 4% of 
the model variance compared to about 0.5% with the AAPCC model (Ash, Porell, Gruenberg, 
Sawitz, & Beiser, Adjusting Medicare capitation payments using prior hospitalization data, 1989). 
In a follow-up study to Ash et al. (1989), refinements to the DCG model were made to 
include a discretionary component to hospitalizations and requiring a length of stay of at least 3 
days before qualifying a hospitalization for a DCG (Ellis & Ash, 1995/96). In order to determine 
which diagnoses should be considered towards DCG categorization, physicians were asked to rank 
diagnoses based on the level of “inappropriate admissions” that might arise if it were included in a 
payment model. The main findings of this study were that the DCG categories remained stable 
compared to the Ash et al. (1989) study, suggesting that the DCG would be a reasonable candidate 
to risk adjust Medicare capitated payments. Additionally, the exclusion of discretionary 
hospitalizations from the model severely decreased the predictive power of the model. Finally, 
dropping the short-stay hospitalizations (length of stay less than 3 days) from the model did not 
lead to a meaningful difference in explanatory power (Ellis & Ash, 1995/96). 
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Principal Inpatient Diagnostic Cost Group Model (PIP-DCG) 
A study conducted by Ellis et al. (1996) compared the AAPCC model to two DCG models: 
one that only used the principal inpatient diagnosis to assign the DCG (PIP-DCG) and a second 
that used all diagnoses from inpatient, outpatient, and physician sources (ADDCG). The PIP-DCG 
OLS model explained more variance in year-2 expenditures compared to the AAPCC model 
(AAPCC R
2
 = 1.02%; PIP-DCG R
2
 = 5.53%) and did not suffer significantly for not including 
other sources of diagnoses (ADDCG R
2
 = 6.34%). This study updated the DCG model to use 
International Classification of Diseases, 9
th
 Revision – Clinical Modification (ICD-9-CM) codes. 
As a result of the Balanced Budget Act of 1997, CMS moved from AAPCC-based 
payments to a model which used the principal inpatient diagnostic cost group (PIP-DCG) in 2000. 
This was the first time that CMS used health status measures along with demographic information 
(age, sex, status of Medicaid eligibility, and original reason for Medicare eligibility) to adjust 
capitated payments using diagnostic data from inpatient admissions. Pope et al. (2000b) refined 
the PIP-DCG model initially proposed by Ellis et al. (1996). This refined model contained 29 
mutually exclusive cost categories for hospitalizations that are predictive of future costs (AAPCC 
R
2
 = 1.5%; PIP-DCG R
2
 = 6.2%). These PIP-DCG categories were ranked similar to the original 
DCG model proposed by Ash et al. (1989). This model was intended as a transition model until the 
DCG/HCC model would be put in place (Pope et al., 2000b). 
Diagnostic Cost Group/Hierarchical Condition Category Model (DCG/HCC) 
Building on the Ash et al. (1989) DCG model, Ellis et al., (1996) expanded the DCG 
framework to allow for a secondary diagnosis from the inpatient hospital claims to be included in 
the model, allowed for life-sustaining medical procedures to classify individuals into groups, and 
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organized the DCG framework to allow for multiple coexisting conditions called DxGroups. The 
DxGroups allowed for multiple coexisting conditions to be grouped together and, in contrast to 
DCGs, assigning individuals to none, one, or multiple DxGroups. A hierarchy is then placed on 
related DxGroups, called hierarchical coexisting conditions (HCC), so that only the most costly, 
and usually most severe manifestation of a condition, is considered for payment. An example of 
this coding system would be an individual having a diagnosis of diabetes without complications 
and a subsequent diagnosis for diabetes with renal manifestations. The diagnosis with renal 
manifestation would override the diagnosis without complications. This same patient might have a 
diagnosis for some type of cancer, which would be in a separate DxGroup and count independent 
of the diabetes diagnosis in the model. The hierarchical model (R
2
 = 8.08%) outperformed the 
AAPCC model (R
2
 = 1.02%) (Ellis et al., 1996). Pope et al. (2004) provides an example of how the 
hierarchies are applied. 
Ash et al. (2000) further refined the DCG/HCC model by updating the ICD-9-CM coding 
for the DxGroups (n=543) and grouping them into medically related groups with similar expected 
costs called condition categories (CC) (n=118) and then imposing a hierarchy on these condition 
categories, which are now called hierarchical condition categories (HCC) rather than hierarchical 
coexisting conditions. The DCG/HCC model performed better than the PIP-DCG and Age/Sex 
models based on the reported predictive ratios (Ash et al., 2000). Another study found the 
DCG/HCC-based model to be at least as powerful as prior costs in predicting future high-cost 
cases, and the combination of prior costs and diagnostic data was found to provide even more 
explanatory power (Ash, Zhao, Ellis, & Kramer, 2001). 
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CMS-Hierarchical Condition Category (CMS-HCC) 
The CMS-HCC was implemented in 2004 to adjust Medicare capitated payments to 
Medicare Advantage plans. Pope et al. (2004) describe the modifications to the DCG/HCC model, 
which primarily included refining the DxGroups (n=804) and the condition categories (n=189), 
before CMS finally reduced the condition categories to 70 total categories. CMS makes 
adjustments to the condition categories each year, omitting ones which result in negative 
payments. The diagnoses from the HCCs in the CMS-HCC model may come from five sources: 1) 
principal hospital inpatient; 2) secondary hospital inpatient; 3) hospital outpatient; 4) physician; 
and 5) clinically trained non-physicians. 
CMS-RxHCC 
The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 
created the Medicare drug benefit (Part D). Similar to Medicare+Choice (renamed Medicare 
Advantage by the MMA), CMS was to make capitated payments to private health plans to 
managed the drug benefit for eligible Medicare beneficiaries who opted for a Part D plan. The 
risk-adjustment model for these capitated payments was developing using the CMS-HCC 
methodology, using diagnoses from a baseline year to predict year-2 expenses. However, this 
model was designed using diagnoses groupings (RxHCCs) that would predict year-2 prescription 
drug costs, rather than medical costs (Robst, Levy, & Ingber, 2007). The CMS-RxHCC explains 
about 12% of the variance in year-2 prescription drug costs (Hsu et al., 2009). One contrast 
between the CMS-HCC model and the CMS-RxHCC model is that individual drug costs remain 
relatively stable from year to year, which is not the case with medical expenses. Hsu et al. (2009) 
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found that 88% of beneficiaries had year-2 expenditures within two deciles of their year-1 
expenditures. 
Non-CMS Diagnosis-Based Risk Adjusters 
Diagnosis-Based Measures 
 The primary purpose of this study is to enhance measures used for risk-adjusted capitated 
payment. However, there are several non-CMS risk-adjustment measures that are common in the 
literature that may benefit from including a medication exposure measure. These measures use 
diagnosis and/or pharmacy information as inputs to predict not only costs, but also health 
outcomes such as hospitalizations and mortality. Two diagnosis-based models, including the 
Charlson Comorbidity Index and the Elixhauser Index, and one pharmacy-based model, RxRisk, 
will be discussed here and included in the study. 
 The Charlson Comorbidity Index (CCI) was initially developed by subjective physician 
estimates of comorbidity to predict one-year mortality for individuals being considered for a breast 
cancer clinical trial (Charlson, Pompei, Ales, & MacKenzie, 1987). Since its introduction, it has 
been validated by numerous studies (Romano, Roos, & Jollis, 1993a; Romano, Roos, & Jollis, 
1993b) and widely used in the literature to predict mortality, hospitalizations, and resource use 
(Charlson, Pompei, Ales, & MacKenzie, 1987; Dominick, Dudley, Coffman, & Bosworth, 2005; 
Klabunde, Legler, Warren, Baldwin, & Schrag, 2007). The original CCI used information from 
patient medical charts to arrive at a physician assigned weight for 19 conditions. These weights are 
summed to arrive at the CCI. Later studies have adapted the CCI to use administrative claims data 
(Deyo, Cherkin, & Ciol, Adapting a clinical comorbidity index for use with ICD-9 administrative 
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databases, 1992; D’Hoore, Sicotte, & Tilquin, 1993; D'Hoore, Bouckaert, & Tilquin, 1996). 
Schneeweiss et al. (2004) found that the Romano, Deyo, D’Hoore, and Ghali adaptations of the 
CCI performed similarly in predicting one-year mortality. Given the similar performance of these 
adaptations, the Deyo et al. (1992) adaptation will be adopted for this study simply because it is 
more commonly used in the literature. 
Elixhauser et al. (1998) extended the work of Charlson et al. (1987) and developed a 
comorbidity measure to predict inpatient outcomes including length of stay, hospital charges and 
in-hospital mortality. The Elixhauser Index uses a set of 30 comorbidities that were found to be 
associated with increases in length of hospital stay (Elixhauser, Steiner, Harris, & Coffey, 1998). 
Calculation of the Elixhauser Index requires diagnosis-related groups (DRGs) from the hospital 
inpatient claim. 
Pharmacy-Based Measures 
 Like diagnosis-based inputs, pharmacy-based inputs have been used to develop 
risk-adjustment measures. Most of the pharmacy-based inputs use the national drug code (NDC) 
from administrative claims data to infer that an individual has a certain condition. The chronic 
disease score (CDS) was the first of these models to be developed (Von Korff, Wagner, & 
Saunders, 1992). A group of medications intended to treat chronic diseases were identified and 
mapped to the corresponding condition that they were intended to treat. The medications were then 
assigned a subjective weight based on expert judgment as to the severity of disease based on the 
drug therapy. The CDS was found to be correlated with physician rating of the patient’s health 
status (r=0.57) and with the patient’s self-rated health status (r=0.23) (Von Korff, Wagner, & 
Saunders, 1992). The CDS methodology has been replicated (Johnson, Hornbrook, & Nichols, 
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1994) and extended by other authors into pediatric populations (Fishman & Shay, 1999). In order 
to make the CDS measure less subjective, a follow up study derived empirical weights for the 
chronic conditions and found that the revised CDS explained more variance in total cost than the 
original CDS (revised CDS R
2
 = 19%; CDS R
2
 = 9%) (Clark, Von Korff, Saunders, Baluch, & 
Simon, 1995). The study compared the CDS to ambulatory care groups, finding that the CDS was 
a better predictor of mortality than the ambulatory care groups. 
The RxRisk model was developed based on the CDS framework. Similar to the CDS, it 
uses chronic condition drugs from ambulatory pharmacy claims data to predict health care costs 
(Fishman et al., 2003). The RxRisk model was developed by the same researchers who extended 
the CDS into a pediatric population. As a result, the RxRisk model included pediatric and adult 
individuals in its development. The authors sought to expand the CDS by having the RxRisk 
model include a more broad set of drugs and to make comparisons to ambulatory clinical groups 
(ACG) and hierarchical condition category (HCC) risk-adjustment models. Fishman et al. (2003) 
found that the HCC explained the most variance in healthcare costs (R
2
 = 15.4%), followed by 
ACG (R
2
 = 10.2%), and then by RxRisk (R
2
 = 8.7%). Although RxRisk did not explain much 
variance relative to the other models, combining a pharmacy-based model with other 
diagnosis-based models or a medication exposure measure may explain more variance than the 
model tested alone. An extension of the RxRisk model was developing using a Veterans Health 
Administration (VHA) population (Sloan et al., 2003). This updated model, called RxRisk-V, 
accounted for more conditions than the original model and was able to explain 10% of the variance 
in health costs. Because the RxRisk-V model was not tested in the same sample as the original 
RxRisk, drawing conclusions about which model has superior predictive power must be done with 
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caution. The non-weighted RxRisk-V was found to be strongly correlated (Spearman’s rho=0.848) 
with unique prescriptions (Farley, Harley, & Devine, 2006). Therefore, combining RxRisk-V with 
the medication exposure measure may not explain much additional variance, but it may be seen 
that the medication exposure measure will have similar explanatory power as the RxRisk-V. 
Comparison Studies 
Farley et al. (2006) found that the CCI and Elixhauser Index explained around 6 to 9% of 
the variance in log-transformed healthcare expenditures, which was the lowest of any other 
comorbidity estimator used in the study, including RxRisk-V, diagnosis clustering and simple 
resource counts. However, the variance explained for both CCI and Elixhauser increased to about 
20% when those measures were coupled with count measures, including simple and unique 
prescription count (Farley, Harley, & Devine, 2006). Another study found that the CMS-HCC 
model performed better than Charlson’s and Elixhauser’s indices in predicting in-hospital and six 
month mortality (Li, Kim, & Doshi, 2010). This is likely due to the limited conditions that are 
included in the CCI and Elixhauser Index. However, researchers may still be interested in the 
performance of these risk adjusters when coupled with the medication exposure measure. 
A study comparing Charlson’s Comorbidity Index, Elixhauser’s Index, and RxRisk-V on 
predicting physician visits, prescription drug use, and hospitalization in a sample with 
osteoarthritis found that all three significantly predicted health service use (Dominick, Dudley, 
Coffman, & Bosworth, 2005). This study found RxRisk-V to be a better predictor of prescription 
medication use, while the Elixhauser Index was better for predicting physician visits, and the 
Charlson better at predicting hospitalization (Dominick, Dudley, Coffman, & Bosworth, 2005). 
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Zhao et al. 2005 developed a framework similar to DxGroups that uses the national drug 
codes from prescription claim data to infer a RxGroup based on a drug’s therapeutic function, 
making this distinct from the CDS-based models. The RxGroups are then placed in a hierarchy, 
similar to the DCG/HCC models, and used to predict costs, both alone and in combination with 
DCGs. By combining diagnostic (DCGs) and pharmacy data (RxGroups), the Zhao et al. (2005) 
model outperformed either source alone (RxGroup R
2
 = 7.1%; DCG/HCC R
2
 = 11.6%; 
RxGroups+DCG/HCC R
2
 = 12.4%). The algorithms to produce RxGroups is proprietary; 
however, this study does provide evidence that combining diagnoses- and pharmacy-based inputs 
increases predictive power of risk-adjustment models (Zhao et al., 2005). In closing, the authors 
also suggested that including number of prescriptions, or some other utilization measure to their 
RxGroup model would further enhance the predictive power of the model (Zhao et al., 2005). 
Simple Resource Counts 
Researchers have used simple resource counts, such as unique prescriptions, physician 
visits, and hospitalizations, as a comorbidity measures to predict health and economic outcomes, 
likely because it is a simple measure to calculate and, in some way, represents resource intensity 
that may not be captured in demographic or diagnostic measures. Farley et al. (2006) defined 
unique prescription count as the number of unique drug classes filled in a one year period. The 
count of unique prescriptions over the course of one year outperformed simple prescription count, 
physician visit count, and hospitalization count in predicting year-2 expenditures, with diagnosis 
cluster count being the only count variable to perform better (Farley, Harley, & Devine, 2006). A 
study that used the number of distinct prescription drugs (distinct chemical entities) found that it 
was the best predictor of future physician visits and expenditures compared to several diagnosis- 
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and pharmacy-based variables  (Schneeweiss et al., 2001). Perkins et al. (2004) found that a count 
of the number of prescription subclasses had similar predictive ability compared to prescription 
count, and was a better predictor of future expenditures compared to several diagnosis- and 
pharmacy-based risk adjusters. When used for predicting ambulatory visits, the number of 
prescribed medications (R
2
=15%) performed similarly to ambulatory care groups (R
2
=16.4%), 
and had higher predictive validity compared to the Charlson Comorbidity Index, the chronic 
disease score (CDS), and the number of chronic diseases (Perkins et al., 2004).  
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Development of the Medication Exposure Measure 
Medication Exposure is Related to Health Outcomes 
Although medication-based measures, including unique drug counts, have added 
predictive power to risk-adjustment models, they do not provide much insight into actual 
medication exposure, which should be more closely linked to health outcomes. Medication 
adherence is a type of medication exposure measure. Several studies have found that poor 
medication adherence negatively impacts clinical biomarkers, increases the risk of hospitalizations 
and rehospitalizations, and increases mortality (Nieuwkerk et al., 2001; Weiden, Kozma, Grogg, 
& Locklear, 2004; Simpson et al., 2006). Medication adherence has been studied using methods 
including pill counts, survey instruments, and administrative claims data. Medication exposure 
measurement using administrative pharmacy records has been validated against home inventories 
of medications (Lau, de Boer, Beuning, & Porsius, 1997; Steiner & Prochazka, 1997). Medication 
adherence measures using claims data are generally calculated for a single drug or a 
disease-specific therapy regimen and do not account for acute medications (Martin et al., 2009). 
Fincke et al. (2005) conducted a study to refine the concept of polypharmacy using a large 
prescription database. Of the three polypharmacy measures that they proposed, the 
operationalization of a measure they called simultaneous polypharmacy is of particular interest. 
Fincke et al. (2005) define simultaneous polypharmacy as “the number of prescriptions active on a 
particular day, as determined by fill dates and amount of medication given.” To calculate this 
measure, the authors used the fill date of the medication as the start date and added the 
corresponding days supply, including a multiplier of 1.5 to adjust for poor adherence, to arrive at a 
stop date for each prescription. This essentially creates a matrix of ‘active’ prescriptions, and 
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summing the ‘active’ prescriptions for each day arrives at the simultaneous polypharmacy 
measure. Prescriptions for a previous drug therapy were counted as a new therapy unless the new 
prescription falls within the ‘active’ period of the older prescription. Prescriptions for the same 
medication but differing in strength were considered part of the same therapy. Combination 
medications (i.e., lisinopril and hydrochlorothiazide in a single dosage form) were only counted as 
one medication and only oral medications were included in the simultaneous polypharmacy 
calculation (Fincke et al., 2005). Figure 1 is an example of a medication exposure matrix 
representing a 30 day span for three different hypothetical individuals. 
 
Figure 1 – Medication Exposure Explanation 
The unique drug count depicted in Figure 1 arrives at the same value for each of these 
individuals; however, there is something fundamentally different about each of them based on 
their medication exposure (indicated by the dark boxes). This point might be more poignant if 
these three individuals were diagnosed with the same disease and hypothetically should be 
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receiving the same or similar treatment. These differences may be related to adherence, to the 
proportion of acute to chronic medications, to therapy switches, to persistency, or to some other 
factor. An estimate of medication exposure should relate more directly to outcomes associated 
with the medication, whether positive or negative, compared to unique drug count. As a result, a 
medication exposure estimate should outperform (i.e., provide better predictive ability) unique 
drug count, particularly when coupled with a diagnosis-based risk adjuster. 
Fincke et al. (2005) reported the mean number of medications over 40, two-week intervals 
of daily simultaneous polypharmacy measures was 2.63 (95% CI 2.61-2.65), with the mean 
minimum number of medications being 1.09 (95% CI 1.08-1.10) and the mean maximum number 
of medications being 4.94 (4.92-4.96) (Fincke et al., 2005). The 95% confidence intervals being so 
close to the mean suggests that the simultaneous polypharmacy measure is relatively stable over 
the two-week intervals was measured in the study. 
Extending the Simultaneous Polypharmacy Measure 
As an extension of work by Fincke et al. (2005), the medication exposure measure (MEM) 
is operationalized as the number of unique medications that an individual possesses on any given 
day, as estimated from the index fill date – the first day medication exposure begins – plus the days 
supply of the prescription. Calculating medication exposure allows the researcher to record a daily 
“medications on hand” measure for each individual, which may be averaged over a period of time 
to arrive at the average medication exposure. Although collectively called the medication exposure 
measure, the average medication exposure will be useful for making comparisons between 
medication-based measures like unique drug counts that are based on monthly or yearly 
prescription fills. 
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Equation 4 – Medication Exposure 
Medication Exposure = ∑  
 
   
 
Equation 5 – Average Medication Exposure 
Average Medication Exposure = 
 
 
∑∑   
 
   
 
   
 
Where: 
 a = binary indicator of medication possession 
 m = number of drugs (rows) 
 n = number of days in period (columns) 
 
The purpose of the Fincke et al. (2005) study was to operationalize and to provide a 
descriptive analysis of the simultaneous polypharmacy measure. Accordingly, the authors did not 
attempt to compare their measure to contemporary measures of prescription count or attempt to 
relate this measure to any health or economic outcomes. There are several positive attributes of the 
simultaneous polypharmacy measure that are distinct from a unique drug count or medication 
adherence measures. However, a few adjustments must be made in order to more accurately reflect 
true medication exposure. 
First, the adherence adjustment using a multiple of the days supply falsely inflates the 
measure. Medication utilization estimates based on administrative claims data must assume that 
patients are in possession of the drug(s) on the day of dispensing, consume the medication exactly 
as prescribed, and subsequently, their supply ends at the calculated date based on days supply from 
the initial fill date. Therefore, calculating medication utilization-based measures from 
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administrative claims data provides an estimate of utilization with high specificity (Hess, Raebel, 
Conner, & Malone, 2006). That is, it estimates the upper bound of possible medication exposure 
that an individual could have received, given the information inferred from the claims data. The 
individual may have ultimately taken more medication than is expressed in the medication 
exposure measure, possibly due to receiving sample medications from a provider or using 
medications obtained from another source, such as a prior prescription fill or another pharmacy. 
On the other hand, the individual likely had less medication exposure due to poor adherence to the 
medication. In order to best predict health and economic outcomes, the medication exposure 
measure should only account for drugs that the individual reasonably may be taking. As a result, 
the calculation for medication exposure will not include an adherence adjuster. 
Second, rather than undercounting combination medications like the simultaneous 
polypharmacy measure, each drug product will be included in the medication exposure measure 
and combination medications will count as multiple drug products. The term “drug product” is 
defined as “an active ingredient in dosage form that has been approved or otherwise may be 
lawfully marketed under the Food, Drug, and Cosmetic Act for distribution in the United States” 
(Food, Drug, & Cosmetics Act, 2010). Dose changes within the same active ingredient will be 
counted towards the same drug product, whereas therapy changes resulting in a new active 
ingredient will count towards a distinct drug product. 
Third, the simultaneous polypharmacy measure does not address medication stockpiling 
(i.e., “adding on” extra drug supply to the end of the fill dates), likely because of the limited time 
period in which the measure was calculated. The medication exposure measure will account for 
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medication stockpiling by adding any overlapping drug products to the end of the last calculated 
stop date for that drug product. 
Fourth, the medication exposure measure estimates possible medication exposure over a 
period of time and, unlike the simultaneous polypharmacy or medication adherence measures, an 
index prescription does not dictate the beginning date of medication exposure estimation. Instead, 
a point in time is selected as the index date. In order to account for medication already on hand at 
the index date, a lead-in period will be employed at least equal to the highest anticipated days 
supply for medications considered in the calculation. Otherwise, the medication exposure measure 
will be artificially low for the first few months following the index date. 
Medication Exposure is Not an Adherence Estimate 
The medication exposure measure is related to measures of medication refill adherence and 
proportion of days covered (PDC), depending on whether values are capped at 100% (like PDC) or 
whether they are free to exceed 100% (Hamilton & Briceland, 1992). As it is operationalized here, 
the proportion of days covered may be considered a special case of the medication exposure 
measure. Contemporary calculation of proportion of days covered (PDC) does not account for 
multiple drugs or combination medications. It results in a binary measure which indicates the 
presence or absence of a drug of interest for each day. Some studies have calculated a mean PDC 
combining several drugs (Patel et al., 2008). 
Value of the Medication Exposure Measure 
The medication exposure measure is important because it is the driving factor behind drug 
response and related outcomes, whether the outcomes are positive or negative. Evidence for 
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dose-dependent relationships between drug use and outcomes and the influence of adherence on 
relevant clinical outcomes supports this claim. The key distinguishing feature of the medication 
exposure measure compared to unique drug count, or other drug-based utilization counts, is that 
medication exposure measure is less susceptible to manipulation. Other simple count measures 
may prove to be valuable in predicting health and economic outcomes; however, counts are 
manipulatable by providers and health plans. The medication exposure measure is less likely than 
drug counts to be manipulated because of shared responsibility among the patient, prescriber and 
pharmacist. A measure being less susceptible to manipulation may be of little interest to those 
conducting research outside the context of risk-adjusting capitated payments; however, the 
medication exposure measure should outperform unique drug count, and other related count 
measures, because it more accurately reflects medication exposure. Other studies that have used a 
count of unique drugs will tend to over-estimate actual medication exposure when counting acute 
medications, because they are equally weighted with chronic medications, and do not account for 
gaps in therapy. 
 41 
CHAPTER III – RESEARCH METHODOLOGY 
Study Design 
This study was a retrospective cohort design, which used year-1 (2007) diagnostic and 
pharmacy-based inputs to predict the year-2 (2008) economic and clinical outcomes (Figure 2). In 
the context of risk-adjustment models, this is considered a prospective model (Cucciare & 
O'Donohue, 2006). The calculation of medication exposure began in the last 3-months of 2006 in 
order to have a stable medication exposure measure beginning on January 1, 2007. 
 
Figure 2 – Project Study Period 
Data Source 
This study used the 5% Medicare national sample for the years 2006-2008 from the CMS 
Chronic Condition Data Warehouse (CCW), including the Beneficiary Summary File with Part D, 
Medicare Provider Analysis and Review (MEDPAR) file, Carrier Standard Analytical File (SAF), 
 42 
Outpatient SAF, and Prescription Drug Event (PDE) file. The International Classification of 
Diseases, Ninth Revision – Clinical Modifications (ICD-9-CM) was used to for all diagnosis codes 
and the Multum Lexicon Drug Database was used to identify national drug codes and active 
ingredients for all pharmacy-based measures (Cerner Multum, 2011). This data was made 
available for research purposes to the Center for Pharmaceutical Marketing and Management at 
The University of Mississippi (DUA #21594) and a data reuse of the data was granted by CMS 
(DUA #22762). This study was reviewed and approved by the University of Mississippi 
Institutional Review Board (IRB Protocol 12-199). 
Sample Selection 
The sample included beneficiaries with continuous eligibility in fee-for-service (FFS) 
Medicare Parts A & B and Medicare Part D for a minimum of 12 months in the base year (2007) 
and a minimum of 1 month in year-2 (2008). Eligibility for partial months due to disenrollment or 
mortality in year-2 was rounded up to the next nearest month (Pope et al., 2004). Beneficiaries 
with enrollment in Medicare Advantage plans for any portion of the base year were excluded 
(Pope et al., 2000a). Beneficiaries were excluded for those conditions included in the CMS frailty 
adjustment model (Kautter & Pope, 2004-2005). Beneficiaries were also excluded from the study 
if their Medicare eligibility was due to end-stage renal disease (ESRD), or if they are considered 
long-term institutionalized (LTI) (Levy, Robst, & Ingber, 2006; Kautter, Ingber, & Pope, 
2008-2009). LTI beneficiaries were defined as those with skilled nursing facility (SNF) or 
long-term stay in the MedPAR file with a length of service count greater than or equal to 30 days 
(Pope et al., 2004). Medicare risk-adjustment models typically use around one million 
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beneficiaries for their estimation due to the large number of variables included in the model and to 
ensure adequate cell size for the HCC-based variables (Pope et al., 2011). 
To examine the potential influence of the donut hole on this study, beneficiaries were 
categorized based on four (4) end-of-year Medicare Part D benefit phases: pre-donut hole, donut 
hole, catastrophic coverage, and prescription non-users during the base year. Descriptive statistics 
were conducted to determine the potential influence of benefit phase on the medication exposure 
measure. An interaction model was specified between the prescription measures and the benefit 
phases for expenditure outcomes. Additionally, low-income subsidy status was also examined. 
SPECIFIC AIM 1 – THE MEDICATION EXPOSURE MEASURE 
Measures 
Medication Exposure Measure 
Medication exposure is operationalized as the number of unique drugs that an individual 
possesses on any given day, as estimated from the initial fill date plus the days supply of each drug 
product found in the pharmacy claims data. The medication exposure measure is dependent on 
prescription fills and days supply information prior to the index date to estimate the medication 
exposure measure for the study period. Each active ingredient included in combination 
medications was counted as if the beneficiary received them as separate drugs. An approximate 90 
day lead-in period beginning October 1, 2006 should suffice for most medications filled under 
Medicare Part D and for the majority of health plans. Days supply outliers beyond 100 days were 
truncated to 100 in order to reduce pharmacy claims submission errors from adversely influencing 
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the measure. Once the daily medication exposure was calculated, the measure was averaged over a 
calendar year to allow for direct comparisons to the other prescription-based measures (i.e., simple 
prescription count and unique drug count over one year). The average medication exposure is the 
average number of unique drugs that an individual possesses over one year. 
Unique Drug Count 
A unique drug is the number of distinct drug products, as defined by the U.S. Food, Drug, 
& Cosmetic Act, that an individual receives over a given time period (Food, Drug, & Cosmetics 
Act, 2010). The term “drug product” is defined as “an active ingredient in dosage form that has 
been approved or otherwise may be lawfully marketed under the Food, Drug, and Cosmetic Act for 
distribution in the United States” (Food, Drug, & Cosmetics Act, 2010). Active ingredients will be 
identified by the “active_ingredient” field of Multum Lexicon drug database (Cerner Multum, 
2011). This definition of “unique drug” most closely resembles the operationalization provided by 
Schneeweiss et al. (2001), who defined “distinct prescription drugs” as “distinct chemical 
entities.” 
Simple Prescription Count 
Because of its potential value as predictor, simple prescription count was be included in 
this study as a comparator to unique drug count and to the medication exposure measure. Simple 
prescription count will be the sum of the number of prescriptions that a beneficiary receives over 
the course of one year (Schneeweiss et al., 2001; Perkins et al., 2004; Farley, Harley, & Devine, 
2006). 
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Statistical Analysis 
 Descriptive statistics including means and standard deviations will be used to describe the 
three prescription fill-based measures (simple prescription count, unique drug count, and 
medication exposure measure). Additionally, a Pearson product-moment correlation and an 
intraclass correlation coefficient for paired data were reported to test whether the medication 
exposure measure and the prescription count measures are distinct and also to examine the 
relationship between the measures (Deyo, Diehr, & Patrick, 1991).  
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SPECIFIC AIMS 2 & 3 – MEDICATION EXPOSURE MEASURE AS A RISK ADJUSTER 
The objective for Specific Aim 2 is to evaluate the predictive validity of the outpatient 
medication exposure measure for health and economic outcomes compared to unique drug count 
and simple prescription count for Medicare risk-adjustment models (CMS-HCC and 
CMS-RxHCC). The objective for Specific Aim 3 is to evaluate the predictive validity of these 
prescription measures on health and economic outcomes when coupled with non-CMS 
risk-adjustment models (i.e., Charlson’s Comorbidity Index, Elixhauser Index, and RxRisk). 
Independent Variable Measures 
Medication Exposure, Unique Drug, and Simple Prescription Count 
Medication exposure, unique drug count, and simple prescription count were calculated as 
described in Aim 1. 
Demographic Variables 
For the CMS risk-adjustment models, age and sex were included as a categorical predictor 
with 24 mutually exclusive age/sex cells (see Table 3) to be consistent with the CMS 
risk-adjustment methodology (Pope et al., 2004; Robst, Levy, & Ingber, 2007). Following the 
HCC and RxHCC model documentation, age on February 1 of the prediction year (2008) was 
calculated for all models. 
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Table 3 – HCC/RxHCC Age/Sex Groups 
Female Male 
0-34 Years 0-34 Years 
35-44 Years 35-44 Years 
45-54 Years 45-54 Years 
55-59 Years 55-59 Years 
60-64 Years 60-64 Years 
65-69 Years 65-69 Years 
70-74 Years 70-74 Years 
75-79 Years 75-79 Years 
80-84 Years 80-84 Years 
85-89 Years 85-89 Years 
90-94 Years 90-94 Years 
95 Years or Over 95 Years or Over 
 
Age was included as a continuous predictor for non-CMS risk-adjustment models, 
primarily because comparison between groups is not a major end point of this study for non-CMS 
risk-adjusted models. An indicator was used to flag beneficiaries whose original reason for 
Medicare eligibility is due to disability. Dual eligible beneficiaries were flagged with an indicator 
representing at least one month of Medicaid enrollment. 
Hierarchical Condition Categories (HCCs) and RxHCCs 
The hierarchical condition categories (HCCs) calculated for both CMS-HCC and 
CMS-RxHCC models were included as dummy coded categorical variables, where 1 indicates 
presence and 0 indicates absence of a HCC. Diagnoses used in the analysis were allowed only 
from providers listed in the accepted CMS provider code list located in the Appendix. Following 
the CMS SAS documentation for CMS-HCC and CMS-RxHCC, diagnoses were used from the 
following sources in the MedPAR file (excluding SNF diagnoses), hospital outpatient SAF, and 
carrier SAF files: 
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1. principal hospital inpatient; 
2. secondary hospital inpatient; 
3. hospital outpatient 
4. physician  
5. clinically-trained non-physicians (CMS, 2007). 
In addition to the HCC and RxHCC indicator categories, a risk score is also generated 
using the code provided by CMS. Each demographic grouping and HCC/RxHCC has a relative 
risk factor based on the expense associated with that demographic grouping or HCC/RxHCC. A 
relative risk factor of 1 would represent a beneficiary with predicted expenses equal to the mean of 
the entire group. Values greater (less) than 1 indicates the beneficiary has predicted expenses 
greater (less) than the average. These relative risk factors are summed to arrive at a single 
HCC/RxHCC risk score. This risk score provides a single summary relative risk of predicted 
expenditure for each beneficiary (Pope et al., 2011). Indicator variable scoring was used in the 
estimation of the CMS-HCC and CMS-RxHCC expense models. A single HCC or RxHCC risk 
score was used in the estimation of non-expense HCC and RxHCC models to ease interpretation 
and comparisons. 
Charlson’s Comorbidity Index (CCI) 
The Deyo-adaptation of Charlson’s Comorbidity Index was calculated for this study 
(Charlson, Pompei, Ales, & MacKenzie, 1987; Deyo, Cherkin, & Ciol, Adapting a clinical 
comorbidity index for use with ICD-9 administrative databases, 1992). A single, weighted CCI 
score was used in this study. 
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Elixhauser’s Index 
The Elixhauser Index was calculated as described in Elixhauser et al. (1998) using the 
Comorbidity Software Version 3.2 code obtained from the Agency for Healthcare Research and 
Quality (AHRQ, 2007). A single score was calculated by summing the individual Elixhauser 
categories (Farley, Harley, & Devine, 2006). 
RxRisk-V 
RxRisk-V was calculated as described in Sloan et al. (2003) using Cerner Multum 
categories and drug identification numbers to group NDCs into the RxRisk groups. The RxRisk-V 
classes representing neurogenic bladder, ostomy, and urinary incontinence were not used in this 
study due to the lack of appropriate supplies listed in the Multum database. While there were drug 
products that could be used as surrogates for these conditions, the original RxRisk and RxRisk-V 
classes grouped using medical supplies such as urinary catheters, ostomy supplies, and 
diapers/pads (Fishman et al., 2003; Sloan et al., 2003). 
Dependent Variable Measurement 
Expenditures 
In the context of the study, the term expenditure refers to health plan liability including 
charges reimbursed by the health plan by CMS, and excluding hospice expenditures and indirect 
medical education (IME) payments made by CMS to teaching hospitals (Pope et al., 2000a; Zhao 
et al., 2005). Expenditure excludes deductibles and copayments made by beneficiaries (Pope et al., 
2000a). Medical payments were summed from the Medicare Provider Analysis and Review 
(MedPAR) inpatient file, including skilled nursing facility (SNF) payments, the hospital outpatient 
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SAF, and the Part B Carrier SAF. Following Pope et al. (2000a), the payment amount from the 
MedPAR file was calculated as follows: 
Equation 6 – MedPAR Payment 
                                                                             
Pharmacy expenditures were calculated from the prescription drug event (PDE) SAF file. 
Pharmacy expenditure for the plan was calculated as follows: 
Equation 7 – Pharmacy Plan Payment 
                            (                                    ) 
Where: 
Patient Amount = Actual patient out-of-pocket amount 
LICS = Low-Income Cost-Sharing Subsidy Payment Amount 
Other TrOOP = Other True Out-of-Pocket Amount 
PLRO = Patient Liability Reduction due to Other Payer Amount 
Total medical cost (inpatient, outpatient and prescription), medical costs (total inpatient 
and outpatient costs minus pharmacy costs) and pharmacy costs were calculated for all CMS and 
non-CMS risk-adjustment models. The Medicare models were used to predict total, medical, and 
pharmacy expenditures separately; however, the discussion focused on the expenditures most 
relevant to the model (i.e., HCC model discussion focused on medical expenditures and RxHCC 
model discussion focused on pharmacy expenditures). In all cases, including mortality and 
member disenrollment, censored expenditure data were annualized by category (i.e., pharmacy, 
inpatient medical, etc.) based on the months eligible in the prediction year following the method 
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described in Ash et al. (1989) and Ellis et al. (1996). Annualized expenditure was calculated using 
the following formula: 
Equation 8 – Annualized Expenditure 
                                             
  
               
 
Health care cost data do not ordinarily follow a normal distribution, often having a positive 
skew and may have a large number of zeros for those individuals who did not utilize some part of 
the health care benefit during the study period (Diehr, Yanez, Ash, Hornbrook, & Lin, 1999). 
Many of the risk-adjustment models that predict cost are based on ordinary least squares 
regression, which assumes normality of the residual errors. Because the residual errors associated 
with utilization data usually have a distribution similar to the data, it is a common practice to 
transform the data so that it is normally distributed (Diehr, Yanez, Ash, Hornbrook, & Lin, 1999; 
Iezzoni, 2003). However, models estimated to risk-adjust capitated payments are not transformed 
due to the potential data smearing that occurs upon retransformation, thus affecting the ultimate 
payment made to Medicare Advantage plans (Duan, 1983; Iezzoni, 2003). According to Iezzoni 
(2003), it is most appropriate to transform continuous outcome variables if the study purpose is to 
determine the statistical qualities of the model, while it is best avoid transformation when the 
purpose is to determine risk-adjusted payments. Because of the broad scope and multiple 
perspectives of this study, both methods will be reported. When appropriate, cost data will be 
log-transformed and a value of $0.01 will be added to all cost data to avoid transformation errors 
(Duan, 1983; Iezzoni, 2003; Farley, Harley, & Devine, 2006). When data transformation is not 
performed, it is common to trim or truncate extreme outlier cases to minimize undue influence of 
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these outliers on the model. Truncation has an advantage over trimming data because the outlier 
occurred and should not be ignored (Iezzoni, 2003). On untransformed cost data, high cost cases 
were be truncated above the predetermined amounts $250,000 for annual medical expenditures 
and $100,000 for annual pharmacy expenditures (Winkelman & Mehmud, 2007). Both truncated 
and un-truncated models were reported. 
Clinical Outcomes 
The clinical outcome measures included year 2 (2008) all-cause hospitalization counts, 
all-cause emergency department visit counts, and all-cause mortality irrespective to diagnosis. 
Hospitalizations were identified by a “short stay hospital” indicator in the MedPAR file. 
Emergency department visits were identified using Revenue Center codes 0450, 0451, 0452, 0456, 
and 0459 in the Outpatient SAF file and all ER charge amounts greater than zero in the MedPAR 
file. The date of mortality for beneficiaries was found in the Beneficiary Summary File for 2008. 
Model Testing 
The basic model form to be tested is presented here: 
Equation 9 – Basic Research Model Form 
 𝑉   𝛽  𝛽            𝛽                   𝛽                        𝜀   
The core AAPCC model is represented by the AgeSex, OREC, and Dual variables, where 
OREC represents the original reason for coverage (OREC) and Dual represents beneficiaries 
eligible for Medicaid and Medicare (i.e., “dual eligibles”). The variable Risk represents the 
risk-adjusters selected for the study (HCC, RxHCC, Charlson and Elixhauser Indices, and 
RxRisk). The RxMeasure variable represents the prescription fill-based measures (simple 
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prescription count, unique drug count, and the medication exposure measure). The subscript i 
indicates the ith case, t represents the prediction year (2008), and t-1 is the base year (2007). Table 
4 lists the specific models tested in this study. Because institutionalized beneficiaries were 
excluded from the analysis, the CMS risk-adjustment models presented are commonly considered 
community models (Pope et al., 2000a; Pope et al., 2000b; Pope et al., 2004; Pope et al., 2011). 
When model variance explained (R
2
) is reported ordinary least squares (OLS) regression is 
implied, unless otherwise noted. 
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Table 4 – Models tested in the study 
Model Type Model Testing 
CMS Risk-adjustment Models 
AAPCC* 
AAPCC + Unique Rx 
AAPCC + Simple Rx 
AAPCC + MEM 
AAPCC + HCC 
AAPCC + HCC + Unique Rx 
AAPCC + HCC + Simple Rx 
AAPCC + HCC + MEM 
AAPCC + HCC + Unique Rx + Simple Rx + MEM 
AAPCC + RxHCC 
AAPCC + RxHCC + Unique Rx 
AAPCC + RxHCC + Simple Rx 
AAPCC + RxHCC + MEM 
AAPCC + RxHCC + Unique Rx + Simple Rx + MEM 
Non-CMS Risk-adjustment Models 
Demographics† + Charlson 
Demographics + Charlson + Unique Rx 
Demographics + Charlson + Simple Rx 
Demographics + Charlson + MEM 
Demographics + Elixhauser  
Demographics + Elixhauser + Unique Rx 
Demographics + Elixhauser + Simple Rx 
Demographics + Elixhauser + MEM 
Demographics + RxRisk-V 
Demographics + RxRisk-V + Unique Rx 
Demographics + RxRisk-V + Simple Rx 
Demographics + RxRisk-V + MEM 
*AAPCC represents the 24 mutually exclusive age/sex cells in the CMS risk-adjustment models 
†Demographics represents separate age (as a continuous variable) and sex variables 
Statistical Analysis 
Frequency distributions, means and standard deviations were calculated to describe the 
study sample and correlation coefficients were reported for all risk-adjustment measures. The 
number of subjects classified by each model was also reported. Year-2 predictive ratios were 
calculated and reported by decile and by the top 5% and top 1% expense categories. The average 
predictive ratio was also reported for the entire sample except cases where a large number of 
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payments were zero for entire deciles and some quintiles. Grouped R
2
 was estimated for cost 
measures (Ash, Porell, Gruenberg, Sawitz, & Beiser, Adjusting Medicare capitation payments 
using prior hospitalization data, 1989; Ash & Byrne-Logan, 1998; Fishman et al., 2003). Logistic 
regression models were estimated for dichotomous outcomes, including mortality, and the 
resulting c-statistics were reported. Zero-inflated negative binomial regression models were 
estimated for count data including hospitalizations and emergency department visits, due to the 
presence of overdispersion in the count data. Gamma-distributed generalized linear models with 
log links were estimated for some expenditure models where many beneficiaries had no medical 
expenditures (Buntin & Zaslavsky, 2004). Likelihood ratio tests were conducted on nested models 
of interest to determine the impact of variable inclusion. Analyses were conducted using SAS 
statistical software, version 9.22, with the exception of the zero-inflated negative binomial models, 
which were conducted using SAS version 9.3 and the intraclass correlation coefficients, which 
were conducted using SPSS release 20.0.0 (SAS Institute, Inc., 2008; IBM Corporation, 2011; 
SAS Institute, Inc., 2011).  
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CHAPTER IV – DATA ANALYSIS AND RESULTS 
Sample Description 
The sample was selected based on 12 months of continuous enrollment in Medicare Parts A, B, & 
D in 2007, with at least 1 month enrollment in Medicare Parts A, B, & D in 2008 from the 5% 
Medicare national sample (n=1,270,305). Beneficiaries eligible for Medicare due to end-stage 
renal disease (ESRD) (n=13,012) and long-term institutionalized beneficiaries (n=27,595) were 
excluded from the study, resulting in a final sample of 1,229,698 (Figure 3). 
 
Figure 3 – Sample selection 
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Table 5 provides descriptive statistics for the final study sample. The demographic 
characteristics of the final sample closely match the 5% national sample, with the only appreciable 
differences being in gender, Part D benefit phase, Medicaid dual eligible status, and low-income 
subsidy status. These differences are likely due to excluding institutionalized beneficiaries and to 
the Medicare Part D 12-month continuous enrollment requirement. The differences in gender may 
be attributable to the possibility that females may be more likely to have continuous enrollment in 
Medicare Part D from a longer lifespan or lack of coverage through a decedent spouse.  
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Table 5 – Final Sample Descriptive Statistics (n=1,229,698) 
Description 
Final Study Sample 
5% National 
Sample (2007) 
Frequency Percent / Range Percent 
Gender    
Male 445,114 36.20% 40.90% 
Female 784,584 63.80% 59.10% 
    
Age (mean±SD) 72.49±12.79 Range 21-112 72.22±12.46 
    
Race    
Caucasian 1,010,118 82.14% 83.67% 
African American 132,837 10.80% 9.90% 
Other 19,156 1.56% 1.77% 
Asian 24,107 1.96% 1.72% 
Hispanic 37,121 3.02% 2.34% 
North American Native 5,230 0.43% 0.42% 
Unknown 1,129 0.09% 0.18% 
    
Reason for Medicare Entitlement*    
Aged 918,253 74.67% 77.91% 
Disabled 311,445 25.33% 22.09% 
    
Medicaid Dual Eligible 1,158 0.09% 0.62% 
    
Low Income Subsidy (LICS) 384,519 35.31% 43.39% 
    
Part D Benefit Phase (year-1 end)    
Pre-Donut Hole 701,896 57.08% 52.01% 
Donut Hole 285,209 23.19% 21.14% 
Catastrophic 101,777 8.28% 7.58% 
No Prescription Records 140,816 11.45% 19.27% 
 
The lower rates of Medicaid dual-eligibles and low-income subsidy beneficiaries in 
already enrolled in Medicaid and/or have a low-income status may not seek out or stay enrolled in 
Medicare Part D plans throughout the plan year due to coverage through Medicaid or other 
providers. Beneficiaries included in the institutional models are more likely to be enrolled in 
Medicaid and/or have a low-income status, which would also help explain the lower proportion of 
dual eligible and LICS in the study sample compared to the Medicare 5% national sample (Pope et 
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al., 2011). Finally, the differences in benefit phase are likely due to the Part D continuous 
enrollment requirement – those with discontinuous coverage are less likely to fill prescriptions. 
Table 6 – Descriptive Statistics for Outcome Variables Used in the Study 
Variable Mean ± SD / Frequency Range / Percent 
   
Expenditures (2008)   
Total (Medical + Pharmacy) $7,302.03  ± $21,523.46 $0 – $8,217,717.92 
Medical $5,750.15  ± $21,060.84 $0 – $8,215,708.62 
Pharmacy $1,551.88  ± $3,141.91 $0 – $502,166.31 
Zero Medical Expenditures 471,815 38.37% 
Zero Pharmacy Expenditures 134,569 10.94% 
   
Hospitalization Count (2008)   
0 991,307 80.61% 
1 152,312 12.39% 
2 49,982 4.06% 
3+ 36,097 2.94% 
   
Emergency Department Count (2008)   
0 905,936 73.67% 
1 184,005 14.96% 
2 69,866 5.68% 
3 31,284 2.54% 
4 15,621 1.27% 
5+ 22,986 1.88% 
   
Deaths (2008) 60,103 4.89% 
   
Total Sample 1,229,698 100.00% 
 
 Table 6 provides study sample descriptive statistics for the outcome variables used in the 
study. Three expenditure categories were calculated: 1) medical, 2) pharmacy, and 3) total 
(medical + pharmacy). The medical expenditures represented the majority of total expenditures 
and had greater variability (coefficient of variation (cv) = 3.66) compared to prescription 
expenditures (cv = 2.02). This distinction is important in risk-adjustment because lower variability 
in prescription expenditures may have contributed to the superior prediction of year-2 prescription 
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expenses relative to year-2 medical expenditures for many of the models tested. The proportion of 
beneficiaries with zero year-2 (2008) medical expenditures was 38.37%. This number is 
substantially higher compared to other Medicare risk-adjustment studies whose sample selection 
did not include a Medicare Part D enrollment requirement. To confirm the accuracy of the 
methodology used to arrive at medical expenditures for this study, an analysis was conducted on 
the full 5% Medicare national sample using the exact methodology as for the study sample. Based 
on this analysis, slightly more than 10% of the Medicare 5% national sample had zero medical 
claims during 2008. Pope et al. (2011) reported slightly less than 10% of beneficiaries with zero 
medical claims using the 5% Medicare national sample of Part A and B beneficiaries, which 
provides support for the methodology used in this study. Despite the similarities in demographic 
information in Table 5, the large proportion of zero medical claims provides some indication that 
the sample selection employed in this study may have resulted in a healthier sample, using the 
proportion of beneficiaries with zero medical expenditures as a surrogate for relative health status, 
compared to the general Medicare population. 
 The hospitalization count data presented in Table 6 closely matched a study conducted by 
Pope et al. (2011), with less than 0.5% difference in any of the hospitalization count categories. An 
analysis of emergency department visits in the 5% Medicare national sample resulted in a similar 
distribution, with the category percentages varying less than 1%. The proportion of sample 
beneficiaries who died in 2008 (4.89%) was similar to a study of aged Medicare beneficiaries with 
a reported all-cause death rate of 5,075 per 100,000 in 1998 (Eggers & Greenberg, 2000). These 
similar proportions provide some level of validity to the mortality statistics reported in Table 6.  
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SPECIFIC AIM 1 – MEDICATION EXPOSURE MEASURE 
The purpose of specific aim 1 was to describe the medication exposure measure and to 
provide comparisons to other prescription-based measures, including a count of unique drugs and 
a simple prescription count.  
Prescription Fill-based Measures 
Three prescription fill-based measures were calculated for this study: 
1. Medication exposure measure 
2. Unique drug count 
3. Simple prescription count 
Of the 1,229,698 beneficiaries in the sample, there were 1,088,882 (88.5%) with a 
prescription fill-based measure calculated from 2007 prescription drug event (PDE) claims. A total 
of 140,816 (11.5%) did not have any prescription utilization during year-1 (2007) of the study 
period, thus the prescription count and unique drug count measures were zero for these 
individuals. A total of 3,360 beneficiaries with no prescription records in 2007 had some 
medication on-hand from the October 1, 2006 to December 31, 2006 lead-in period, which 
contributed to a small medication exposure measure for those beneficiaries in 2007 (0.164±0.227; 
range 0.003-3.041). Out of 56,317,330 prescription claims from October 1, 2006 to December 31, 
2007 in the PDE file, a total of 1,648 claims (0.00003%) had a day supply greater than 100 (range 
101 to 999). These claims were truncated to 100 to reduce the influence of likely erroneous days 
supply outliers.  
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Three benefit phase categories were created for Medicare Part D beneficiaries based on the 
final benefit phase they reached by the end of the 2007: 1) pre-donut hole, 2) donut hole, and 3) 
catastrophic. The variable benefit phase in the Medicare Part D PDE file is included with each paid 
claim and may be one of ten categories. The term donut hole is a colloquial term for the initial 
coverage limit (ICL). A “straddle PDE” is a claim that occurs between two different benefit 
phases. The status of the final claim for a particular beneficiary dictated which benefit phase the 
beneficiary had reached by the end of the year.  
Table 7 – Benefit Phase Groupings with PDE File Variable Descriptions 
Benefit Phase Grouping Code Description 
Pre-Donut Hole 
DD Deductible phase 
DP Deductible to pre-ICL (straddle PDE) 
PP Pre-ICL phase 
Donut Hole 
DI Deductible to ICL (coverage gap) Straddle PDE 
PI Pre-ICL to ICL Straddle PDE 
II ICL (coverage gap) Phase 
Catastrophic 
DC Deductible to Catastrophic Straddle PDE 
PC Pre-ICL to Catastrophic Straddle PDE 
IC ICL (coverage gap) to Catastrophic Straddle PDE 
CC Catastrophic phase 
 
Some plans receive additional payments for beneficiaries with income below a specified 
amount for the plan year. An indicator identifying whether the Part D plan received any low 
income subsidies (LICS) for a beneficiary was included. Like dually eligible beneficiaries, LICS 
beneficiaries have a lower payment liability for their drug benefit compared to non-duals and 
non-LICS beneficiaries. In turn, this lower payment liability may influence utilization and plan 
liability. Table 8 and Table 9 include descriptive statistics for each of the prescription-based 
measures stratified by benefit phase and LICS status. 
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Table 8 provides descriptive statistics for beneficiaries with a prescription claim in 2007 by 
the Medicare Part D benefit phase reached by the end of 2007 and for all phases. The descriptive 
statistics for the “All Beneficiaries” column accounts for the zero measures for those without 
prescription fills in 2007. The Medicare Part D benefit phase is a function of beneficiary 
out-of-pocket costs, except in the case of plans receiving low-income subsidy (LICS) payments for 
some beneficiaries, the increasing mean value for each prescription measure through the benefit 
phases is expected. Even after accounting for LICS status in Table 9, the average medication 
exposure and unique drug counts were marginally different, whereas the simple prescription count 
was considerably different throughout the benefit phases. 
  
6
4
 
Table 8 – Descriptive statistics for prescription-based measures by Part D benefit phase 
Measure 
Community Model 
All 
Beneficiaries 
Part D Benefit Phase 
All Phases 
Pre-DH DH Cat 
Mean±Std. Dev. (Min-Max) n=701,896 n=285,209 n=101,777 n=1,088,882 n=1,222,698 
Medication Exposure 
2.73±1.94 
(0-33.55) 
5.77±2.29 
(0.07-26.81) 
8.54±3.62 
(0.08-34.04) 
4.07±2.97 
(0-34.04) 
3.60±3.08 
(0-34.04) 
Unique Drug Count 
7.63±4.73 
(0-62) 
13.35±6.03 
(1-60) 
17.93±8.48 
(1-111) 
10.09±6.57 
(0-111) 
8.93±6.97 
(0-111) 
Simple Prescription Count 
26.54±20.74 
(1-842) 
59.20±28.50 
(1-368) 
101.12±48.18 
(3-796) 
42.07±35.57 
(1-842) 
37.25±36.05 
(1-842) 
Abbreviations: DH = donut hole; Cat = catastrophic 
Table 9 – Medication exposure measure and prescription-based descriptive statistics 
Measure 
Non-LICS Community Model LICS Community Model 
Part D Benefit Phase 
All Phases 
Part D Benefit Phase 
All Phases 
Pre-DH DH Cat Pre-DH DH Cat 
Mean±Std. Dev. 
(Min-Max) n=517,938 n=166,424 n=20,001 n=704,363 n=183,958 n=118,785 n=81,776 n=384,519 
Medication 
Exposure 
2.75±1.95 
(0-33.55) 
5.74±2.25 
(0.08-26.81) 
8.39±3.15 
(0.12-26.63) 
3.61±2.56 
(0-33.55) 
2.67±1.93 
(0-22.12) 
5.82±2.35 
(0.07-22.30) 
8.58±3.72 
(0.08-34.04) 
4.90±3.46 
(0-34.04) 
Unique Drug 
Count 
7.41±4.61 
(0-62) 
13.01±5.77 
(1-60) 
17.23±7.23 
(1-70) 
9.01±5.71 
(0-70) 
8.22±5.01 
(0-46) 
13.83±6.34 
(1-56) 
18.10±8.76 
(1-111) 
12.06±7.52 
(0-111) 
Simple 
Prescription 
Count 
25.44±20.27 
(1-842) 
54.15±26.46 
(1-368) 
89.20±39.71 
(3-475) 
34.04±27.36 
(1-842) 
29.63±21.71 
(1-437) 
66.27±29.74 
(2-363) 
104.03±49.60 
(3-796) 
56.78±43.33 
(1-796) 
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The mean values reported in Table 9 suggests that LICS beneficiaries fill more total 
prescriptions during the year regardless of benefit phase, as measured by the simple prescription 
count, compared to non-LICS beneficiaries. The marginal differences between the LICS and 
non-LICS measures for medication exposure and unique drug count suggest that these measures 
are relatively stable within comparable benefit phases. When the benefit phases are pooled and 
compared for LICS and non-LICS beneficiaries, the LICS beneficiaries have higher mean values 
for all prescription measures, with the greatest difference being simple prescription count. 
Relationship between the Prescription Measures 
Pearson product-moment correlation coefficients are reported in Table 10. Based on the 
correlation coefficients, the prescription measures were found to have strong, positive 
associations. The Pearson product-moment correlation coefficient is a measure of linear 
dependence that is often reported and provides insight on the level of covariation between two 
variables. These findings are similar to other reported correlations of unique drug count and simple 
prescription count measures (Schneeweiss et al., 2001; Perkins et al., 2004; Farley, Harley, & 
Devine, 2006). 
Table 10 – Pearson Product-Moment Correlation Coefficients for Prescription Measures 
Variable 
Unique Drug  
Count 
Simple 
Prescription 
Count 
Medication  
Exposure 
Unique Drug Count -   
Simple Prescription Count 0.777 -  
Medication Exposure 0.781 0.895 - 
 
Some have suggested reporting intraclass correlation coefficients (ICC) to account for the 
variability among subjects and measures, which Pearson product-moment correlations do not 
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consider (Deyo, Diehr, & Patrick, 1991; McGraw & Wong, 1996). A two-way mixed intraclass 
correlation coefficient modeled for absolute agreement among the measures was estimated to 
examine the relationship between the medication exposure measure and the prescription count 
measures, unique drug count and simple prescription count (Shrout & Fleiss, 1979; McGraw & 
Wong, 1996). 
Medication Exposure and Unique Drug Count 
The single measure intraclass correlation coefficient for the medication exposure measure 
and unique drug count was found to be 0.388 (95% CI -0.040-0.643), which was statistically 
significant (F=3.738; df=1,229,697; p<0.001). While the interpretation of intraclass correlation 
coefficients is somewhat subjective, some have suggested using the effect size criteria (i.e., around 
0.2-0.3 small, around 0.5 medium, and >0.8 large) proposed by Cohen, which is commonly used 
for interpreting Pearson correlation coefficients and the coefficient of determination (R
2
), among 
other measures of association (Cohen, 1988; McGraw & Wong, 1996). This suggests a small to 
medium level of agreement between the medication exposure measure and unique drug count. 
Additionally, the ANOVA test for equal means was found to be statistically significant 
(F=1,427,339; df=1; p<0.001), which suggests that the means of the two measures are 
significantly different from one another (MEM  ̅=3.60; Unique Drug Count  ̅=8.93). These 
findings provide evidence that the medication exposure measure is distinct from unique drug 
count; however, there is similar movement among the measures as reflected by the Pearson 
product-moment correlation coefficient (r=0.781) and the intraclass correlation coefficient 
(ICC=0.388). 
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Medication Exposure and Simple Prescription Count 
The single measure intraclass correlation coefficient for the medication exposure measure 
and simple prescription count was found to be 0.081 (95% CI -0.024-0.183) which was statistically 
significant (F=1.358; df=1,229,697; p<0.001). This suggests a very small level of agreement 
between the medication exposure measure and prescription count. Additionally, the ANOVA test 
for equal means was found to be statistically significant (F=1,253,613; df=1; p<0.001), indicating 
the means of the two measures are significantly different from one another (MEM  ̅=3.60; Simple 
Prescription Count  ̅=37.25). These findings suggest that the medication exposure measure is a 
distinct measure from a simple prescription count. The collective movement of the medication 
exposure measure with simple prescription count (ICC=0.081) is less pronounced compared to 
unique drug count (ICC=0.381); however, the Pearson correlation coefficient between the 
medication exposure measure and simple prescription count (r=0.895) suggests a very strong, 
positive relationship between the measures. The low ICC between the MEM and simple 
prescription count may be mostly explained by the large differences in means between measures. 
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SPECIFIC AIM 2 - CMS RISK-ADJUSTMENT MODELS 
The purpose of specific aim 2 is to test performance of the prescription-based measures as 
risk adjusters in CMS risk-adjustment capitated payment models for medical (HCC) and pharmacy 
(RxHCC) expenditures. In addition to expenditures, the HCC and RxHCC models will be tested 
with the prescription measures to predict hospitalization and emergency department visit counts, 
as well as predicting mortality. The CMS risk-adjustment models use year-1 data to predict year-2 
expenditures. Accordingly, the analyses conducted in this study adopted the same framework. 
Hierarchical Condition Category (HCC) Model  
Expenditures 
In HCC risk-adjustment models to estimate capitated payments for Medicare Advantage 
(Part C) plans, untransformed, untruncated, annualized medical expenditures are regressed onto 
the HCC indicators and demographic variables. The use of untransformed expenditures avoids 
errors in payment due to estimate smearing on retransformation, which is why this method prevails 
in capitated payment risk-adjustment models (Ellis & McGuire, 2007; Ellis, 2008). Additionally, 
truncated expenditure data is utilized in some cases where estimating the effect of reinsurance at 
specified expenditure levels is desired (Winkelman & Mehmud, 2007). In research, log 
transformation of expenditure data is common due to the assumptions of ordinary least squares 
regression. For these reasons, predictive models were estimated with both log-transformed and 
truncated expenditures in addition to untransformed, untruncated expenditures (Table 11). One 
cent ($0.01) was added to all zero expenditures to avoid log-transformation errors. All 
expenditures were annualized. 
 69 
Table 11 – Model R2 for AAPCC and HCC Models with Expenditures as DV 
Expenditure 
Type 
Model R
2
 
n=1,229,698 Expenditures 
Truncated 
Expenditures 
Log-Transformed 
Expenditures‡ 
Total 
Expenditures 
(Medical and 
Pharmacy) 
AAPCC Model 0.0057 0.0087 0.0230 
AAPCC + Unique Rx 0.0362 0.0550 0.1737 
AAPCC + Rx Count 0.0347 0.0532 0.1603 
AAPCC + MEM 0.0298 0.0457 0.1767 
    
HCC Model 0.0848 0.1267 0.1301 
HCC + Unique Rx 0.0903 0.1353 0.2136 
HCC + Rx Count 0.0910 0.1364 0.2037 
HCC + MEM 0.0903 0.1353 0.2220 
     
     
Medical 
Expenditures† 
AAPCC Model 0.0044 0.0070 0.0154 
AAPCC + Unique Rx 0.0220 0.0338 0.0451 
AAPCC + Rx Count 0.0184 0.0285 0.0533 
AAPCC + MEM 0.0150 0.0233 0.0449 
    
HCC Model 0.0698 0.1060 0.2117 
HCC + Unique Rx 0.0714 0.1084 0.2117 
HCC + Rx Count 0.0710 0.1078 0.2131 
HCC + MEM 0.0706 0.1072 0.2124 
     
     
Pharmacy 
Expenditures 
AAPCC Model 0.0327 0.0346 0.0219 
AAPCC + Unique Rx 0.1281 0.1364 0.2137 
AAPCC + Rx Count 0.1732 0.1845 0.2085 
AAPCC + MEM 0.1724 0.1837 0.2472 
    
HCC Model 0.1436 0.1523 0.0715 
HCC + Unique Rx 0.2047 0.2174 0.2263 
HCC + Rx Count 0.2434 0.2587 0.2166 
HCC + MEM 0.2451 0.2605 0.2557 
All models include the base AAPCC model, including demographics, Medicaid and OREC status 
†A large number of beneficiaries had zero medical claims (38.37%) in the prediction year 
‡ Represents the explained variance in log expenditures 
 
All models in Table 11 were estimated by ordinary least squares regression. The large 
number of beneficiaries with zero medical claims was addressed with an alternative model in the 
HCC+MEM model performance section. Similar to other published studies, the addition of HCC 
indicators to the AAPCC model improved the ability of the model to predict year-2 medical 
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expenditures (Pope et al., 2004; Pope et al., 2011). While the purpose of the studies conducted by 
Pope et al. was to determine the ability of the HCC model to predict medical expenditures, this 
study also includes pharmacy expenditures and total expenditures as outcomes. The HCC model 
predicts pharmacy expenditures much better than medical expenditures (R
2
=0.1436 vs. 
R
2
=0.0698) and predicts total expenditures moderately better than medical expenditures 
(R
2
=0.0848). The addition of the prescription measures only marginally improved the 
performance of the HCC model in predicting total and medical expenditures, with similar 
performance from all prescription measures; however, the prediction of pharmacy expenditures 
was greatly enhanced, particularly by the addition of simple prescription count (R
2
=0.2434) and 
medication exposure measure (R
2
=0.2451). Adding of prescription measures to the HCC models 
improved prediction for the total expenditure and pharmacy expenditure models, but was 
negligible for the medical expense prediction models. 
Influence of Part D Benefit Phase 
The potential influence of the Part D benefit phase on prescription drug utilization 
observed in Table 8 was addressed by including an interaction between the benefit phase variable 
and the prescription measures. The Medicare Part D benefit phases were grouped based on the 
categories outlined in Table 7. Because the primary interest in the HCC model is to examine its 
ability to improve capitated payments, the benefit phase interaction models were estimated using 
the unmodified annualized expenditures as the outcome variable. The HCC-based benefit phase 
interaction models are reported in Table 12. 
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Table 12 – Model R2 for the AAPCC and HCC models with Benefit Phase Interaction 
Expenditure Type Model 
R
2
 (Main 
Effects Only) 
R
2 
(w/ Benefit 
Phase 
Interaction) 
    
Total Expenditures 
(Annualized) 
AAPCC Model 0.0057 - 
AAPCC + Unique Rx 0.0362 0.0491 
AAPCC + Rx Count 0.0347 0.0412 
AAPCC + MEM 0.0298 0.0394 
   
HCC Model 0.0848 - 
HCC + Unique Rx 0.0903 0.0962 
HCC + Rx Count 0.0910 0.0948 
HCC + MEM 0.0903 0.0949 
    
    
Medical Expenditures 
(Annualized)† 
AAPCC Model 0.0044 - 
AAPCC + Unique Rx 0.0220 0.0273 
AAPCC + Rx Count 0.0184 0.0206 
AAPCC + MEM 0.0150 0.0186 
   
HCC Model 0.0698 - 
HCC + Unique Rx 0.0714 0.0735 
HCC + Rx Count 0.0710 0.0726 
HCC + MEM 0.0706 0.0724 
    
    
Pharmacy 
Expenditures 
(Annualized) 
AAPCC Model 0.0327 - 
AAPCC + Unique Rx 0.1281 0.2283 
AAPCC + Rx Count 0.1732 0.2351 
AAPCC + MEM 0.1724 0.2453 
   
HCC Model 0.1436 - 
HCC + Unique Rx 0.2047 0.2832 
HCC + Rx Count 0.2434 0.2931 
HCC + MEM 0.2451 0.3020 
    
All tested models include base demographic model (AAPCC) 
† A large number of beneficiaries had zero medical claims (38.37%) in the prediction year 
All models in Table 12 were estimated by ordinary least squares regression. The 
interaction between benefit phase and the prescription-based measures had the most impact on the 
pharmacy expenditures models (Table 12), which would suggest that the benefit phase influences 
the relationship between the prescription-based measures and year-2 predicted pharmacy 
expenditures. The benefit phase interaction resulted in very minor, but statistically significant 
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changes in model R
2
 for the medical expenditure models, suggesting that benefit phase influences 
the relationship between the prescription measures and predicting medical expenditures. While the 
interaction was found to be statistically significant (e.g., MEM*Benefit Phase 
F=605.48;df=2;p<0.0001), there may be little practical significance in including this interaction 
due to the limited influence of adding prescription-based measures to HCC models to predict 
medical expenditures. 
Because of the differences in the prescription measures for LICS and non-LICS 
beneficiaries (Table 9), separate models were estimated which included an interaction between 
LICS status and the prescription measures regressed on medical expenditures. These models 
performed similarly to the benefit phase interaction models, but in most cases, LICS interaction 
model performed worse, based on model R
2
, compared to the benefit phase interaction models. 
Therefore, only the benefit phase interaction models were reported in Table 12. 
HCC + MEM Model Performance 
The manipulable nature of unique drug and simple prescription count limits the usefulness 
of these measures as risk-adjusters for capitated payments. Therefore, the following analyses 
evaluated the value of adding the medication exposure measure to the HCC model to predict 
medical expenditures. In addition to ordinary least squares regression models, gamma-distributed, 
log-linked generalized linear models were estimated for medical expenditure outcomes due to the 
large number of beneficiaries with zero medical claims (38.37%) (Buntin & Zaslavsky, 2004). The 
mean predicted expenditures and predictive ratios for the base HCC model and for the HCC model 
with the medication exposure measure are reported in Table 13 for the ordinary least squares 
model and in Table 14 for the gamma-distributed, log-linked generalized linear model. 
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Table 13 – Predictive ratios for HCC + MEM model (Ordinary Least Squares Model) 
Group 
(by Actual 
Expenditure) 
Obs. 
Mean Actual 
Medical 
Expenditure 
Mean Predicted Medical 
Expenditure 
Predictive Ratio 
HCC HCC+MEM  HCC  
HCC+ 
MEM  
Bottom 38% 471,815 0 3,284.42 3,281.32 - - 
40
th 
percentile 20,063 27.90 4,961.55 4,792.00 177.86 171.78 
50
th
 percentile 122,971 269.26 4,607.15 4,476.91 17.11 16.63 
60
th 
percentile 122,970 828.02 5,613.74 5,574.16 6.78 6.73 
70
th 
percentile 122,970 1,714.46 6,506.86 6,519.33 3.80 3.80 
80
th 
percentile 122,970 3,481.72 7,356.97 7,403.88 2.11 2.13 
90
th 
percentile 122,970 8,680.28 8,832.66 8,912.92 1.02 1.03 
Top 10% 122,969 42,523.49 11,172.83 11,242.59 0.26 0.26 
Top 5% 61,484 63,931.95 12,143.55 12,202.31 0.19 0.19 
Top 1% 12,296 136,119.32 13,984.12 14,030.21 0.10 0.10 
- The predictive ratio for bottom 38% was not calculated due to the zero mean actual medical 
expenditure for that group 
Table 14 – Predictive ratios for HCC + MEM model (GzLM Gamma Distributed Model) 
Group  
(by Actual 
Expenditure) 
Obs. 
Mean Actual 
Medical 
Expenditure 
Mean Predicted Medical 
Expenditure 
Predictive Ratio 
HCC HCC+MEM  HCC  
HCC+ 
MEM  
Bottom 38% 471,815 0 3604.91 3,567.44 - - 
40
th 
percentile 20,063 27.90 5,682.02 5,541.28 203.66 198.61 
50
th
 percentile 122,971 269.26 4,828.71 4,677.84 17.93 17.37 
60
th 
percentile 122,970 828.02 5,871.35 5,773.47 7.09 6.97 
70
th 
percentile 122,970 1,714.46 7,131.88 7,078.19 4.16 4.13 
80
th 
percentile 122,970 3,481.72 8,750.88 8,724.98 2.51 2.51 
90
th 
percentile 122,970 8,680.28 12,317.25 12,281.88 1.42 1.41 
Top 10% 122,969 42,523.49 20,332.92 20,023.14 0.48 0.47 
Top 5% 61,484 63,931.95 12,143.55 24,080.19 0.19 0.38 
Top 1% 12,296 136,119.32 13,984.12 34,266.96 0.10 0.25 
- The predictive ratio for bottom 38% was not calculated due to the zero mean actual medical 
expenditure for that group 
Comparing the mean predicted expenditures and resulting predictive ratios in Table 13 and 
Table 14, the gamma-distributed, log-linked generalized linear model (γ-GzLM) did not perform 
as well as the ordinary least squares model. However, the γ-GzLM achieved predictive ratios 
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closer to one (1) for the top 5% and top 1% mean actual expenditure groups. See Figure 4 for a 
graphical comparison of these models. 
 
Figure 4 – HCC Models Predicted vs. Actual Medical Expenditures (by group) 
The γ-GzLM consistently overpredicts the cost groups compared to the OLS models, with 
the exception of the top 10
th
, 5
th
, and 1
st
 percentile groups. The addition of the medication exposure 
measure has very little influence on the OLS model; however, the top 5 and 1 percent groups of the 
γ-GzLM are greatly influenced. This finding may have little practical significance in risk-adjusted 
models for capitated payment since these models are designed to predict based on the entire 
population.  
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Figure 5 – HCC Predicted vs. Actual Medical Expenditures 
Grouped R
2
 is a measure of model fit that takes model grouping into account and thus, is a 
better representation of model fit compared to the traditional R
2 
(Ash & Byrne-Logan, 1998). The 
grouped R
2 
was calculated for both models presented in Figure 5. The grouped R
2
 for both of the 
γ-GzLMs perform better compared to the OLS model R2 (HCC R2=0.698; HCC+MEM 
R
2
=0.0706). The addition of MEM to the HCC model (grouped R
2
 = 0.2974) only slightly 
outperformed the HCC model alone (grouped R
2
 = 0.2937). Given these results, including a 
measure of medication exposure in the HCC models used to predict medical expenditures does not 
appear to be a useful method of enhancing risk-adjusted payments.  
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Hospitalizations 
 HCC model scores have been used to successfully predict hospitalization risk, but have not 
been used to predict hospitalization count (Mosley, Peterson, & Martin, 2009). The previous 
expenditure models discussed utilize HCC indicator categories to arrive at expected expenditures 
based on individual condition categories. The HCC models predicting expected hospitalization 
count utilized the single HCC score for ease of interpretation and because the predictive ability of 
the individual HCC indicators was not of interest for this study. The frequency of hospitalization 
count for year-2 (2008) is presented in Table 15. 
Table 15 – Frequency Distrubtion of Hospitalizations (2008) 
Hospitalization 
Count 
Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
0 991,307 80.61 991,307 80.61 
1 152,312 12.39 1,143,619 93.00 
2 49,982 4.06 1,193,601 97.06 
3 19,198 1.56 1,212,799 98.63 
4 8,540 0.69 1,221,399 99.32 
5 3,910 0.32 1,225,249 99.64 
6 2,034 0.17 1,227,283 99.80 
7 1,022 0.08 1,228,305 99.89 
8 562 0.05 1,228,867 99.93 
9 306 0.02 1,229,173 99.96 
10 194 0.02 1,229,367 99.97 
11 113 0.01 1,229,480 99.98 
12 57 <0.01 1,229,537 99.99 
13 45 <0.01 1,229,582 >99.99 
14 34 <0.01 1,229,616 >99.99 
15 29 <0.01 1,229,645 >99.99 
16 8 <0.01 1,229,653 >99.99 
17 14 <0.01 1,229,667 >99.99 
18 7 <0.01 1,229,674 >99.99 
19 6 <0.01 1,229,680 >99.99 
≥20 18 <0.01 1,229,698 100.00 
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A zero-inflated negative binomial regression model predicting year-2 hospitalization count 
was estimated using year-1 (2007) information, including demographics (age, gender, and race), 
the HCC community score index, and the prescription measures, unique drug count (Table 16), 
simple prescription count (Table 17), and the medication exposure measure (Table 18). Logit 
models were specified to predict excess zeros using each of these variables as well as a newly 
created HCC Count variable that is the count of all unique HCC diagnoses for each beneficiary. 
The new variable, HCC Count, was included because of the likelihood that having a HCC Score of 
zero would be related to a beneficiary having zero medical expenditures. 
Table 16 – HCC+Unique Drug Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.1328 0.0200 -1.1721 -1.0936 3,206.13 <0.0001 
Gender Male 1 0.0653 0.0048 0.0560 0.0746 188.90 <0.0001 
Age  1 -0.0013 0.0002 -0.0017 -0.0009 38.04 <0.0001 
HCC Score  1 0.3099 0.0033 0.3035 0.3164 8,871.29 <0.0001 
Unique Drug  1 0.0207 0.0004 0.0200 0.0214 3,324.33 <0.0001 
Dispersion  1 1.3228 0.0112 1.3011 1.3449   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.3500 0.0412 2.2693 2.4307 3,258.10 <0.0001 
HCC Count  1 0.4199 0.0205 0.3798 0.4601 420.57 <0.0001 
Age  1 -0.0020 0.0008 -0.0035 -0.0004 6.46 0.0110 
HCC Score  1 -3.3759 0.0668 -3.5067 -3.2451 2,557.44 <0.0001 
Unique Drug  1 -0.0667 0.0011 -0.0689 -0.0645 3,618.84 <0.0001 
 
 78 
Table 17 – HCC+Rx Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.9698 0.0195 -1.0080 -0.9317 2,480.01 <0.0001 
Gender Male 1 0.0365 0.0048 0.0272 0.0459 59.19 <0.0001 
Age  1 -0.0025 0.0002 -0.0030 -0.0021 142.63 <0.0001 
HCC Score  1 0.3503 0.0033 0.3438 0.3567 11,359.10 <0.0001 
Rx Count  1 0.0024 0.0001 0.0022 0.0025 1,356.01 <0.0001 
Dispersion  1 1.3770 0.0114 1.3547 1.3995   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.2666 0.0410 2.1862 2.3470 3,053.35 <0.0001 
HCC Count  1 0.4001 0.0209 0.3591 0.4412 364.97 <0.0001 
Age  1 -0.0023 0.0008 -0.0039 -0.0008 8.78 0.0030 
HCC Score  1 -3.3405 0.0676 -3.4731 -3.2080 2,440.17 <0.0001 
Rx Count  1 -0.0150 0.0003 -0.0155 -0.0145 3,198.22 <0.0001 
 
Table 18 – HCC+MEM Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.9429 0.0192 -0.9806 -0.9052 3,401.18 <0.0001 
Gender Male 1 0.0247 0.0047 0.0154 0.0340 27.19 <0.0001 
Age  1 -0.0030 0.0002 -0.0035 -0.0026 206.69 <0.0001 
HCC Score  1 0.3560 0.0033 0.3495 0.3624 11,598.50 <0.0001 
MEM  1 0.0276 0.0008 0.0260 0.0291 1,231.18 <0.0001 
Dispersion  1 1.3780 0.0115 1.3557 1.4007   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.0364 0.0405 1.9571 2.1158 2,530.70 <0.0001 
HCC Count  1 0.4515 0.0209 0.4105 0.4925 466.17 <0.0001 
Age  1 0.0020 0.0008 0.0005 0.0035 6.53 0.0106 
HCC Score  1 -3.6160 0.0685 -3.7502 -3.4819 2,789.96 <0.0001 
MEM  1 -0.1277 0.0025 -0.1327 -0.1228 2,575.71 <0.0001 
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HCC Count, HCC Score and the prescription measures were found to be significant 
predictors of excess zeros in all models. The variables gender and race were originally included as 
predictors in the logit models, but were removed due to the lack of significant contribution to the 
models. Additionally, race was included in the count model, but was subsequently removed due to 
lack of significance in predicting expected hospitalization count. The dispersion parameter 
estimate was found to be greater than 1 for all models, suggesting that the data are overdispersed, 
which justifies the use of a negative binomial model over a Poisson model. The zero-inflated 
negative binomial model was selected due to the large proportion of zeros in the count measures. 
Table 19 – HCC-based hospitalization count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
HCC + Unique Drug Count Model 
HCC Score 1 0.3099 0.0033 0.3035 0.3164 8,871.29 <0.0001 
Unique Drug 1 0.0207 0.0004 0.0200 0.0214 3,324.33 <0.0001 
        
HCC + Rx Count Model 
HCC Score 1 0.3503 0.0033 0.3438 0.3567 11,359.10 <0.0001 
Rx Count 1 0.0024 0.0001 0.0022 0.0025 1,356.01 <0.0001 
        
HCC + MEM Model 
HCC Score 1 0.3560 0.0033 0.3495 0.3624 11,598.50 <0.0001 
MEM 1 0.0276 0.0008 0.0260 0.0291 1,231.18 <0.0001 
        
 
Gender, age, HCC score and each of the prescription measures were found to be significant 
predictors of expected hospitalization count. All of the prescription measures were found to be 
significant predictors of hospitalization count; however, the HCC score had the largest parameter 
estimates in each of the models. Using the HCC+MEM model as an example, the expected change 
in log count for a one-unit increase in HCC score was 0.3560. This results in a 42.7% increase 
(             ) in expected year-2 hospitalization count for each additional one-unit increase in 
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HCC score, after accounting for the other variables in the model. By comparison, a one-unit 
increase in MEM results in a 2.8% increase (             ) in expected year-2 hospitalization 
count, holding all other variables constant. 
The addition of a prescription-based measure adds to the predictive ability of the HCC 
model. The HCC Score variable was the best predictor of expected hospitalization count in these 
models compared to all of the other variables. Because the estimates are in different units and are 
unstandardized, the interpretation may change when the estimates are standardized. The use of the 
HCC risk score was used to simplify interpretation compared to the 70 categories by using the 
HCC indicators. Other authors have taken this approach to allow for more direct comparisons 
between other single-indicator risk-adjusters, despite that indicator coding has been shown in 
some studies to provide marginally better predictive ability (Sundararajan et al., 2007; Li, Kim, & 
Doshi, 2010). 
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Emergency Department Visits 
The distribution of year-2 (2008) emergency department visits is presented in Table 20. The 
utilization of the emergency department for the study sample is slightly higher compared to 
hospitalizations (Table 15). 
Table 20 – Frequency Distrubtion of Emergency Department Visits (2008) 
Emergency 
Department Count 
Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
0 905,936  73.67  905,936  73.67  
1 184,005  14.96  1,089,941  88.63  
2 69,866  5.68  1,159,807  94.32  
3 31,284  2.54  1,191,091  96.86  
4 15,621  1.27  1,206,712  98.13  
5 8,348  0.68  1,215,060  98.81  
6 4,913  0.40  1,219,973  99.21  
7 2,934  0.24  1,222,907  99.45  
8 1,792  0.15  1,224,699  99.59  
9 1,233  0.10  1,225,932  99.69  
10 883  0.07  1,226,815  99.77  
11 530  0.04  1,227,345  99.81  
12 437  0.04  1,227,782  99.84  
13 310  0.03  1,228,092  99.87  
14 254  0.02  1,228,346  99.89  
15 173  0.01  1,228,519  99.90  
16 146  0.01  1,228,665  99.92  
17 137  0.01  1,228,802  99.93  
18 114  0.01  1,228,916  99.94  
19 81  0.01  1,228,997  99.94  
≥20 701 0.03 1,229,698 100.00 
 
A zero-inflated negative binomial regression model predicting year-2 emergency 
department visit count was estimated using year-1 (2007) information, including demographics 
(age, gender, and race), the HCC community score index, and the prescription measures, unique 
drug count (Table 21), simple prescription count (Table 22), and the medication exposure measure 
(Table 23). Logit models were specified to predict excess zeros using each of these variables as 
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well as the HCC Count variable. The variable race was originally included as a predictor in the 
zero-inflated model, but was removed due to the lack of significant contribution to the model. 
Additionally, race was included in the count model, but was subsequently removed due to lack of 
significance in predicting expected emergency department visit count. Gender was found to 
significantly predict excessive zeros in both the logit model and the expected year-2 emergency 
department visit count model, unlike in the HCC hospitalization count model, which it only 
significantly predicted expected hospitalization counts. The dispersion parameter estimate was 
found to be greater than 1 for all models, suggesting that the data are overdispersed, which justifies 
the use of a negative binomial model over a Poisson model. The zero-inflated negative binomial 
model was selected due to the large proportion of zeros in the count measures. 
Table 21 – HCC+Unique Drug Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.1027 0.0125 0.0783 0.1271 67.99 <0.0001 
Gender Male 1 -0.0409 0.0050 -0.0506 -0.0311 67.80 <0.0001 
Age  1 -0.0143 0.0001 -0.0146 -0.0141 9,758.59 <0.0001 
HCC Score  1 0.3575 0.0030 0.3515 0.3634 13,980.60 <0.0001 
Unique Drug  1 0.0282 0.0003 0.0276 0.0288 8,803.03 <0.0001 
Dispersion  1 1.4352 0.0073 1.4210 1.4495   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.6850 0.0442 -0.7716 -0.5985 240.64 <0.0001 
HCC Count  1 0.2319 0.0233 0.1862 0.2776 98.89 <0.0001 
Gender  1 0.2554 0.0135 0.2289 0.2819 356.65 <0.0001 
Age  1 0.0504 0.0009 0.0486 0.0521 3,224.46 0.0110 
HCC Score  1 -6.0325 0.0744 -6.1783 -5.8868 6,581.11 <0.0001 
Unique Drug  1 -0.0262 0.0010 -0.0281 -0.0243 738.04 <0.0001 
 
 83 
Table 22 – HCC+Rx Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.3403 0.0119 0.3170 0.3636 818.17 <0.0001 
Gender Male 1 -0.0831 0.0049 -0.0928 -0.0735 284.56 <0.0001 
Age  1 -0.0162 0.0001 -0.0165 -0.0159 12,814.60 <0.0001 
HCC Score  1 0.4071 0.0030 0.4012 0.4129 18,608.50 <0.0001 
Rx Count  1 0.0036 0.0001 0.0035 0.0037 4,179.24 <0.0001 
Dispersion  1 1.4766 0.0076 1.4622 1.4912   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.5386 0.0423 -06214 -0.4558 162.46 <0.0001 
HCC Count  1 0.2537 0.0233 0.2081 0.2993 118.82 <0.0001 
Gender  1 0.2076 0.0134 0.1813 0.2339 239.51 <0.0001 
Age  1 0.0485 0.0009 0.0468 0.0503 3,087.12 <0.0001 
HCC Score  1 -5.8707 0.0741 -6.0159 -5.7256 6,285.39 <0.0001 
Rx Count  1 -0.0097 0.0002 -0.0101 -0.0092 1,833.25 <0.0001 
 
Table 23 – HCC+MEM Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.4190 0.0118 0.3959 0.4421 1264.50 <0.0001 
Gender Male 1 -0.1002 0.0049 -0.1099 -0.0906 412.70 <0.0001 
Age  1 -0.0171 0.0001 -0.0173 -0.0168 14,255.60 <0.0001 
HCC Score  1 0.4293 0.0030 0.4234 0.4352 20,437.80 <0.0001 
MEM  1 0.0313 0.0007 0.0300 0.0326 2,222.02 <0.0001 
Dispersion  1 1.4948 0.0075 1.4802 1.5095   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.6947 0.0420 -0.7770 -0.6124 273.76 <0.0001 
HCC Count  1 0.2492 0.0233 0.2035 0.2949 114.25 <0.0001 
Gender  1 0.2292 0.0134 0.2030 0.2554 293.84 <0.0001 
Age  1 0.0507 0.0009 0.0490 0.0524 3,395.82 <0.0001 
HCC Score  1 -6.1294 0.0742 -6.2747 -5.9840 6,831.33 <0.0001 
MEM  1 -0.0542 0.0022 -0.0585 -0.0499 618.47 <0.0001 
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A summary of the predictive ability of the HCC score and prescription measures after 
accounting for gender and age is presented in Table 24. 
Table 24 – HCC-based emergency department visit count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
HCC + Unique Drug Count Model 
HCC Score 1 0.3575 0.0030 0.3515 0.3634 13,980.60 <0.0001 
Unique Drug 1 0.0282 0.0003 0.0276 0.0288 8,803.03 <0.0001 
        
HCC + Rx Count Model 
HCC Score 1 0.4071 0.0030 0.4012 0.4129 18,608.50 <0.0001 
Rx Count 1 0.0036 0.0001 0.0035 0.0037 4,179.24 <0.0001 
        
HCC + MEM Model 
HCC Score 1 0.4293 0.0030 0.4234 0.4352 20,437.80 <0.0001 
MEM 1 0.0313 0.0007 0.0300 0.0326 2,222.02 <0.0001 
        
 
As with the HCC hospitalization count models, the HCC Score variable was the best 
predictor of expected emergency department visits in these models. Using the HCC+MEM model 
as an example, the expected change in log count for a one-unit increase in HCC score was 0.4293. 
This results in a 53.6% increase (             ) in expected emergency department visits for 
each additional one-unit increase in HCC score, after accounting for the other variables in the 
model. By comparison, a one-unit increase in MEM results in a 3.2% increase (             ) 
in expected emergency department visits, holding all other variables constant. Because the 
estimates are in different units and are unstandardized, the interpretation may change when the 
estimates are standardized.  
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Mortality 
A logistic regression model predicting year-2 mortality was estimated using year-1 (2007) 
information, including demographics (age, gender, and race), the HCC community score index, 
and the prescription measures (Table 25). As with the count models, the HCC risk score was used 
to predict mortality rather than the HCC indictors. While this results in a small loss in predictive 
ability, a single composite variable eases parameter estimate interpretation compared to the 70 
HCC indicator variables representing the same construct. 
Table 25 – HCC Models Predicting Year-2 Mortality 
Model 
Cox & 
Snell R
2
 
Nagelkerke 
Adj. R
2
 
C χ2 (df; p-value) 
χ2 diff (dfdiff; 
p-value) 
HCC Model 0.0494 0.1530 0.777 
62,347.82 
(df=3; p<0.0001) 
- 
HCC + Unique Rx 0.0514 0.1590 0.783 
64,855.45 
(df=4; p<0.0001) 
2,507.63 
(dfdiff=1; p<0.0001) 
HCC + Rx Count 0.0524 0.1620 0.785 
66,125.49 
(df=4; p<0.0001) 
3,777.67 
(dfdiff=1; p<0.0001) 
HCC + MEM 0.0505 0.1564 0.781 
63,776.24 
(df=4; p<0.0001) 
1,428.42 
(dfdiff=1; p<0.0001) 
 
 As with the count models, race was initially included in the logistic models as a predictor 
of year-2 mortality, however it performed poorly and was subsequently removed from the model. 
Age and gender were found to be significant predictors in the models. All models were found to 
significantly predict year-2 mortality and the addition of the prescription measures significantly 
improved the model performance, though the effect of adding the prescription measures was 
marginal. Table 26 provides odds ratio and parameter estimates for the HCC models tested to 
predict year-2 mortality. The HCC score exhibited superior predictive ability compared to the 
other variables included in the models, followed by gender and age. 
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Table 26 – Odds Ratio and Parameter Estimates for HCC Models Predicting Year-2 Mortality 
Odds Ratio and Parameter Estimates 
Parameter 
Odds Ratio (95% 
Wald CI) 
Estimate 
Std. 
Error 
Wald χ2 Pr> χ2 
HCC Model 
Intercept - -9.1161 0.0384 56,429.72 <0.0001 
Gender (Female) 0.765 (0.751-0.779) -0.2684 0.0093 832.98 <0.0001 
Age 1.075 (1.074-1.076) 0.0720 0.0005 22,161.27 <0.0001 
HCC Score 2.096 (2.079-2.114) 0.7402 0.0043 2,546.93 <0.0001 
      
HCC + Unique Drug Count Model 
Intercept - -9.5315 0.0396 57,861.49 <0.0001 
Gender (Female) 0.713 (0.700-0.726) -0.3387 0.0094 1,294.08 <0.0001 
Age 1.078 (1.077-1.079) 0.0752 0.0005 23,556.75 <0.0001 
HCC Score 1.879 (1.861-1.897) 0.6308 0.0048 17,081.13 <0.0001 
Unique Drug 1.033 (1.031-1.034) 0.0322 0.0006 2,592.58 <0.0001 
      
HCC + Rx Count Model 
Intercept - -9.3565 0.0385 59,139.68 <0.0001 
Gender (Female) 0.705 (0.692-0.718) -0.3499 0.0094 1,377.77 <0.0001 
Age 1.076 (1.075-1.077) 0.0733 0.0005 23,186.53 <0.0001 
HCC Score 1.889 (1.872-1.906) 0.6360 0.0046 18,768.54 <0.0001 
Rx Count 1.007 (1.007-1.007) 0.0067 0.0001 4,052.23 <0.0001 
      
HCC + MEM Model 
Intercept - -9.3185 0.0389 57,368.24 <0.0001 
Gender (Female) 0.729 (0.716-0.743) -0.3156 0.0094 1,129.49 <0.0001 
Age 1.076 (1.075-1.077) 0.0729 0.0005 22,637.84 <0.0001 
HCC Score 1.983 (1.965-2.001) 0.6845 0.0046 22,622.02 <0.0001 
MEM 1.054 (1.051-1.057) 0.0525 0.0014 1,474.51 <0.0001 
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Rx Hierarchical Condition Category (RxHCC) Model  
Expenditures 
The primary objective of testing the RxHCC model is to assess its the ability to predict 
pharmacy expenditures. As a result, the analysis and discussion will primarily focus on this end; 
however, the model summaries are shown for total and medical expenditures as well. The RxHCC 
models are similar in structure to the HCC models, where untransformed, untruncated annualized 
pharmacy expenditures are regressed onto RxHCC disease indicators and demographic variables 
to estimate capitated payments for Medicare Part D plans. The RxHCC disease groupings were 
originally selected based on their ability to predict pharmacy expenditures, compared to the HCC 
model groupings, which were selected to predict medical expenditures (Robst, Levy, & Ingber, 
2007). As with the HCC models, the RxHCC models will be assessed using untransformed, 
untruncated annualized expenses, in addition to log-transformed and truncated expenditures as 
outcomes. Table 27 provides the model R
2
 values for the AAPCC and RxHCC models, both with 
and without the prescription measures. 
All models in Table 27 were estimated by ordinary least squares regression. The potential 
issue regarding the large number of beneficiaries with zero medical claims was addressed with an 
alternative model, which will be discussed in a later analysis. Similar to other published studies, 
the addition of RxHCC indicators to the AAPCC model improved the explanatory ability of the 
model in predicting all types of expenditures (pharmacy, medical, and total) (Robst, Levy, & 
Ingber, 2007). 
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Table 27 – Model R2 for AAPCC and RxHCC Models with Expenditures as DV 
Expenditure 
Type 
Model R
2
 
n=1,229,698 
Annualized 
Expenditures 
Truncated 
Expenditures 
Log-Transformed 
Expenditures‡ 
     
Total 
Expenditures 
(Medical and 
Pharmacy) 
AAPCC Model 0.0057 0.0087 0.0230 
AAPCC + Unique Rx 0.0362 0.0550 0.1737 
AAPCC + Rx Count 0.0347 0.0532 0.1603 
AAPCC + MEM 0.0298 0.0457 0.1767 
    
RxHCC Model 0.0880 0.1323 0.1795 
RxHCC + Unique Rx 0.0918 0.1381 0.2461 
RxHCC + Rx Count 0.0927 0.1397 0.2414 
RxHCC + MEM 0.0921 0.1387 0.2583 
     
     
Medical 
Expenditures† 
AAPCC Model 0.0044 0.0070 0.0154 
AAPCC + Unique Rx 0.0220 0.0338 0.0451 
AAPCC + Rx Count 0.0184 0.0285 0.0533 
AAPCC + MEM 0.0150 0.0233 0.0449 
    
RxHCC Model 0.0719 0.1099 0.3771 
RxHCC + Unique Rx 0.0726 0.1110 0.3804 
RxHCC + Rx Count 0.0724 0.1108 0.3772 
RxHCC + MEM 0.0722 0.1105 0.3774 
     
     
Pharmacy 
Expenditures 
AAPCC Model 0.0327 0.0346 0.0219 
AAPCC + Unique Rx 0.1281 0.1364 0.2137 
AAPCC + Rx Count 0.1732 0.1845 0.2085 
AAPCC + MEM 0.1724 0.1837 0.2472 
    
RxHCC Model 0.1485 0.1574 0.0855 
RxHCC + Unique Rx 0.2077 0.2204 0.2316 
RxHCC + Rx Count 0.2462 0.2615 0.2230 
RxHCC + MEM 0.2489 0.2644 0.2609 
     
All models include the base AAPCC model, including demographics, Medicaid and OREC status 
†A large number of beneficiaries had zero medical claims (38.37%) in the prediction year 
‡ Represents the explained variance in log expenditures 
All models in Table 27 were estimated by ordinary least squares regression. The addition 
of the prescription measures only marginally improved the performance of the RxHCC model in 
predicting total and medical expenditures, with similar performance from all prescription 
measures; however, the prediction of pharmacy expenditures was greatly enhanced, particularly 
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by the addition of simple prescription count (R
2
=0.2462) and medication exposure measure 
(R
2
=0.2489). Adding of prescription measures to the RxHCC models improved prediction for the 
pharmacy expenditure models, but was negligible for the medical expense prediction and total 
expenditure models. This also occurred with the HCC model predicting medical expenditures 
(Table 11).  
Patently similar to the HCC model, the RxHCC model predicted pharmacy expenditures 
much better than medical expenditures (R
2
=0.1485 vs. R
2
=0.0719) and fairly well for total 
expenditures (R
2
=0.0808). The addition of the prescription measures only marginally improved 
the performance of the RxHCC model in predicting total and medical expenditures; however, the 
prediction of pharmacy expenditures was greatly enhanced. Of particular note is the explanatory 
ability of the RxHCC+MEM model predicting untransformed, untruncated pharmacy expenditures 
(R
2
=0.2489). This is by far, the most marked improvement in a model that can be used to 
risk-adjust capitated payments. Simple prescription count performed similarly (R
2
=0.2462), 
although its usefulness as a risk adjuster is limited by its ability to be easily manipulated by plans 
and prescribers. This finding is not surprising, given the correlation between simple prescription 
count and the medication exposure measure (r=0.895). 
Influence of Part D Benefit Phase 
The potential influence of the Medicare Part D benefit phase on prescription drug 
utilization observed in Table 8 was addressed by including an interaction between the benefit 
phase variables and the prescription measures. The Medicare Part D benefit phases were grouped 
based on the categories outlined in Table 7. Because the primary interest in the HCC model is to 
examine its ability to improve capitated payments, the benefit phase interaction models were 
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estimated using the unmodified annualized expenditures as the outcome variable. The 
RxHCC-based interaction models are reported in Table 28. 
Table 28 – Model R2 for the AAPCC and RxHCC models with Benefit Phase Interaction 
Expenditure Type Model 
R
2
 (Main 
Effects) 
R
2 
(w/ Benefit 
Phase 
Interaction) 
    
Total Expenditures 
(Annualized) 
AAPCC Model 0.0057 - 
AAPCC + Unique Rx 0.0362 0.0464 
AAPCC + Rx Count 0.0347 0.0397 
AAPCC + MEM 0.0298 0.0382 
   
RxHCC Model 0.0880 - 
RxHCC + Unique Rx 0.0918 0.0958 
RxHCC + Rx Count 0.0927 0.0950 
RxHCC + MEM 0.0921 0.0950 
    
    
Medical Expenditures 
(Annualized)† 
AAPCC Model 0.0044 - 
AAPCC + Unique Rx 0.0220 0.0253 
AAPCC + Rx Count 0.0184 0.0199 
AAPCC + MEM 0.0150 0.0183 
   
RxHCC Model 0.0719 - 
RxHCC + Unique Rx 0.0726 0.0732 
RxHCC + Rx Count 0.0724 0.0728 
RxHCC + MEM 0.0722 0.0727 
    
    
Pharmacy 
Expenditures 
(Annualized) 
AAPCC Model 0.0327 - 
AAPCC + Unique Rx 0.1281 0.2243 
AAPCC + Rx Count 0.1732 0.2311 
AAPCC + MEM 0.1724 0.2408 
   
RxHCC Model 0.1485 - 
RxHCC + Unique Rx 0.2077 0.2805 
RxHCC + Rx Count 0.2462 0.2903 
RxHCC + MEM 0.2489 0.2989 
    
All tested models include base demographic model (AAPCC) 
† A large number of beneficiaries had zero medical claims (38.37%) in the prediction year 
 
The interaction between benefit phase and the prescription-based measures had the most 
impact on the pharmacy expenditures models (Table 28), which would suggest that the benefit 
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phase influences the relationship between the prescription-based measures and year-2 predicted 
pharmacy expenditures. Similar to the HCC models, there was some interest in a preliminary test 
of a model which includes LICS status. Because there were differences in the prescription 
measures for LICS and non-LICS beneficiaries (Table 9), separate models were estimated which 
included an interaction between LICS status and the prescription measures regressed on pharmacy 
expenditures. The LICS interaction models performed much worse than the benefit phase 
interaction models based on model R
2
; therefore, only the benefit phase interaction models are 
presented.  
Table 29 – Predictive ratios for RxHCC + MEM model (with Benefit Phase Interaction) 
Group Obs. 
Mean Actual 
Pharmacy 
Expenditure 
Mean Predicted Pharmacy 
Expenditure 
Predictive Ratio 
RxHCC RxHCC+MEM  RxHCC  
RxHCC+ 
MEM  
Bottom 10% 134,569 0 1,310.56 771.95 - - 
20
th 
percentile 111,370 64.89 1,205.02 753.46 18.57 11.61 
30
th 
percentile 122,970 264.90 1,251.23 844.84 4.72 3.19 
40
th 
percentile 122,971 530.09 1,289.11 927.61 2.43 1.75 
50
th
 percentile 122,968 841.23 1,341.76 1,034.97 1.59 1.23 
60
th 
percentile 122,971 1,201.10 1,422.98 1,237.54 1.18 1.03 
70
th 
percentile 122,985 1,548.34 1,585.24 1,624.91 1.02 1.05 
80
th 
percentile 122,955 1,761.25 1,701.07 1,849.17 0.97 1.05 
90
th 
percentile 122,970 2,184.44 1,720.83 2,078.83 0.79 0.95 
Top 10% 122,969 7,128.69 2,681.04 4,393.79 0.38 0.62 
Top 5% 61,484 10,674.91 3,342.69 5,519.41 0.31 0.52 
Top 1% 12,296 23,613.02 5,349.19 7,735.09 0.23 0.33 
- The predictive ratio for bottom decile was not calculated due to the zero mean actual pharmacy 
expenditure for that group 
The bottom 10% and the 20
th
 percentile differ from the other deciles due to the number of 
beneficiaries with zero year-2 pharmacy payments by the plan (n=134,549). The other minor 
differences between the deciles are due to pharmacy expenditure “ties” in the ranking procedure. 
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The addition of the medication exposure measure to the RxHCC model improved the mean 
predicted expenditure for most deciles of actual pharmacy expenditures, as well as for the top 5% 
and 1% groups. The seventh and eight deciles of expenditure were estimated to be slightly higher 
for the RxHCC + MEM group compared to the RxHCC group. As a corollary, the predictive ratio 
improved (i.e., were closer to 1) for most deciles groups of actual pharmacy expenditure. Figure 6 
provides a graphical depiction of the predicted and actual pharmacy expenditures by actual 
expenditure grouping outlined in Table 29. 
 
Figure 6 – RxHCC Model Predicted vs. Actual Pharmacy Expenditures (by grouping) 
 The line representing RxHCC+MEM is closer to the mean actual pharmacy expenditure 
line for most deciles of actual pharmacy expenditure compared to the RxHCC line, with the 
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exception being 70
th
 and 80
th
 percentile groups, where the RxHCC model performed marginally 
better. 
 
Figure 7 – RxHCC Predicted vs. Actual Pharmacy Expenditures 
The grouped R
2 
was calculated for both models presented in Figure 7. The 45 degree line 
represents perfect concordance between the actual and predicted pharmacy expenditures. The 
addition of MEM to the RxHCC model (grouped R
2
 = 0.7692) greatly outperformed the RxHCC 
model alone (grouped R
2
 = 0.3696). Given these results, including a measure of medication 
exposure in the RxHCC models appears to be an effective method of enhancing risk-adjusted 
payments for pharmacy expenditures. 
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Hospitalizations 
The previous RxHCC expenditure models utilized RxHCC indicator categories to arrive at 
predicted year-2 expenditures based on individual condition categories. The RxHCC models 
predicting expected hospitalization count utilized the single RxHCC score for ease of 
interpretation. A zero-inflated negative binomial regression model predicting year-2 
hospitalization count was estimated using year-1 (2007) information, including demographics 
(age, gender, and race), the RxHCC score, and prescription measures, unique drug count (Table 
30), simple prescription count (Table 31), and the medication exposure measure (Table 32). Logit 
models were specified to predict excess zeros using each of these variables as well as a newly 
created RxHCC Count variable that is the count of all unique RxHCC indicators for each 
beneficiary.  
Table 30 – RxHCC+Unique Drug Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.7695 0.0248 -1.8181 -1.7210 5,098.51 <0.0001 
Gender Male 1 0.2129 0.0048 0.2035 0.2224 1,936.86 <0.0001 
Age  1 0.0053 0.0002 0.0049 0.0058 502.12 <0.0001 
RxHCC Score  1 0.4804 0.0073 0.4660 0.4948 4,288.64 <0.0001 
Unique Drug  1 0.0246 0.0004 0.0238 0.0254 3,833.96 <0.0001 
Dispersion  1 1.3004 0.0148 1.2718 1.3297   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.5052 0.0429 2.4213 2.5892 3,418.07 <0.0001 
RxHCC Count  1 -0.2377 0.0048 -0.2472 -0.2283 2,427.81 <0.0001 
Age  1 -0.0260 0.0005 -0.0269 -0.0251 3,141.70 <0.0001 
RxHCC Score  1 0.2154 0.0264 0.1637 0.2671 66.67 <0.0001 
Unique Drug  1 -0.0649 0.0010 -0.0670 -0.0629 3,838.33 <0.0001 
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Table 31 – RxHCC+Rx Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.6449 0.0244 -1.6928 -1.5970 4,534.47 <0.0001 
Gender Male 1 0.1877 0.0049 0.1782 0.1972 1,497.10 <0.0001 
Age  1 0.0046 0.0002 0.0041 0.0051 372.80 <0.0001 
RxHCC Score  1 0.5620 0.0071 0.5482 0.5759 6,301.65 <0.0001 
Rx Count  1 0.0028 0.0001 0.0027 0.0030 1,549.92 <0.0001 
Dispersion  1 1.3613 0.0149 1.3324 1.3908   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.2694 0.0422 2.1867 2.3520 2,895.95 <0.0001 
RxHCC Count  1 -0.2667 0.0047 -0.2758 -0.2575 3,277.89 <0.0001 
Age  1 -0.0249 0.0005 -0.0258 -0.0239 2,832.97 <0.0001 
RxHCC Score  1 0.3976 0.0256 0.3475 0.4477 241.92 <0.0001 
Rx Count  1 -0.0144 0.0002 -0.0149 -0.0139 3,347.57 <0.0001 
 
Table 32 – RxHCC+MEM Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.6375 0.0246 -1.6856 -1.5893 4,435.38 <0.0001 
Gender Male 1 0.1798 0.0049 0.1703 0.1893 1,374.19 <0.0001 
Age  1 0.0042 0.0002 0.0038 0.0047 317.82 <0.0001 
RxHCC Score  1 0.5881 0.0071 0.5741 0.6021 6,775.94 <0.0001 
MEM  1 0.0305 0.0009 0.0288 0.0322 1,228.55 <0.0001 
Dispersion  1 1.3611 0.0156 1.3308 1.3920   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.1050 0.0416 2.0235 2.1864 2,564.65 <0.0001 
RxHCC Count  1 -0.2774 0.0047 -0.2867 -0.2681 3,414.82 <0.0001 
Age  1 -0.0231 0.0005 -0.0240 -0.0222 2,524.81 <0.0001 
RxHCC Score  1 0.3715 0.0248 0.3228 0.4202 223.86 <0.0001 
MEM  1 -0.1201 0.0024 -0.1247 -0.1154 2,557.56 <0.0001 
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RxHCC Count, RxHCC Score and the prescription measures were found to be significant 
predictors of excess zeros. The variables gender and race were originally included as predictors in 
the zero-inflated models, but were removed due to the lack of significant contribution to the 
models. Additionally, race was included in the count model, but was subsequently removed due to 
lack of significance in predicting expected hospitalization count. The dispersion parameter 
estimate was found to be greater than 1 for all models, suggesting that the data are overdispersed, 
which justifies the use of a negative binomial model over a Poisson model. The zero-inflated 
negative binomial model was selected due to the large proportion of zeros in the count measures. 
Table 33 – RxHCC-based hospitalization count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
RxHCC + Unique Drug Count Model 
RxHCC Score 1 0.4804 0.0073 0.4660 0.4948 4,288.64 <0.0001 
Unique Drug 1 0.0246 0.0004 0.0238 0.0254 3,833.96 <0.0001 
        
RxHCC + Rx Count Model 
RxHCC Score 1 0.5620 0.0071 0.5482 0.5759 6,301.65 <0.0001 
Rx Count 1 0.0028 0.0001 0.0027 0.0030 1,549.92 <0.0001 
        
RxHCC + MEM Model 
RxHCC Score 1 0.5881 0.0071 0.5741 0.6021 6,775.94 <0.0001 
MEM 1 0.0305 0.0009 0.0288 0.0322 1,228.55 <0.0001 
        
 
Gender, age, RxHCC score and each of the prescription measures were found to be 
significant predictors of expected hospitalization count. Although all of the prescription measures 
were found to be significant predictors of hospitalization count, the RxHCC score had the largest 
parameter estimate in each of the models. This finding is similar to the HCC models predicting 
counts. Taking the RxHCC+MEM model as an example, the expected change in log count for a 
one-unit increase in RxHCC score was 0.5881. This results in an 80.1% increase (        
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     ) in expected hospitalization count for each additional one-unit increase in RxHCC score, 
after accounting for the other variables in the model. By comparison, a one-unit increase in MEM 
will result in a 3.1% increase (             ) in expected hospitalization count, holding all other 
variables constant. 
The addition of prescription-based measures adds to the predictive ability of the RxHCC 
score in predicting expected hospitalization counts. The RxHCC Score variable was also found to 
be the best predictor of expected year-2 hospitalization count in these models compared to all of 
the other variables. Because the estimates are in different units and are unstandardized, the 
interpretation may change when the estimates are standardized. The use of the RxHCC risk score 
was used to simplify interpretation compared to the 82 categories by using the RxHCC indicators. 
Other authors have taken this approach to allow for more direct comparisons between other 
single-indicator risk-adjusters, despite that indicator coding has been shown in to provide 
marginally better predictive ability (Sundararajan et al., 2007; Li, Kim, & Doshi, 2010).  
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Emergency Department Visits 
 A zero-inflated negative binomial regression model predicting year-2 emergency 
department visit count was estimated using year-1 (2007) information, including demographics 
(age, gender, and race), the RxHCC community score index, and the prescription measures, unique 
drug count (Table 34), simple prescription count (Table 35), and the medication exposure measure 
(Table 36). Logit models were specified to predict excess zeros using each of these variables as 
well as the RxHCC Count variable. The variable race was originally included as a predictor in the 
zero-inflated model, but was removed due to the lack of significant contribution to the model. 
Additionally, race was included in the count model, but was subsequently removed due to lack of 
significance in predicting expected emergency department visit count. Gender was found to 
significantly predict excessive zeros in the logit model and the expected emergency department 
visit count model unlike the hospitalization count RxHCC model, which it only predicted expected 
hospitalization counts. The model parameter estimates are provided in the following tables. 
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Table 34 – RxHCC+Unique Drug Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.9698 0.0157 -1.0005 -0.9391 3,834.68 <0.0001 
Gender Male 1 0.0940 0.0047 0.0848 0.1033 396.24 <0.0001 
Age  1 -0.0060 0.0001 -0.0063 -0.0057 1,642.70 <0.0001 
RxHCC Score  1 0.7181 0.0064 0.7057 0.7306 12,707.20 <0.0001 
Unique Drug  1 0.0322 0.0003 0.0315 0.0328 10,533.50 <0.0001 
Dispersion  1 1.6582 0.0087 1.6413 1.6752   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.5136 0.0487 0.4181 0.6091 111.19 <0.0001 
RxHCC Count  1 -1.1923 0.0239 -1.2392 -1.1453 2,480.72 <0.0001 
Gender  1 0.0287 0.0151 -0.0008 0.0583 3.62 0.0569 
Age  1 -0.0058 0.0005 -0.0067 -0.0048 144.07 <0.0001 
RxHCC Score  1 0.7487 0.0421 0.6661 0.8312 315.83 <0.0001 
Unique Drug  1 -0.0127 0.0010 -0.0147 -0.0107 152.28 <0.0001 
 
Table 35 – RxHCC+Rx Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.7657 0.0156 -0.7962 -0.7351 2,409.86 <0.0001 
Gender Male 1 0.0692 0.0049 0.0597 0.0787 203.13 <0.0001 
Age  1 -0.0072 0.0001 -0.0075 -0.0069 2,358.43 <0.0001 
RxHCC Score  1 0.8131 0.0062 0.8009 0.8252 17,265.90 <0.0001 
Rx Count  1 0.0040 0.0001 0.0039 0.0041 4,411.98 <0.0001 
Dispersion  1 1.6276 0.0094 1.6094 1.6460   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.5167 0.0430 0.4323 0.6010 144.07 <0.0001 
RxHCC Count  1 -0.9390 0.0166 -0.9715 -0.9064 3,195.75 <0.0001 
Gender  1 0.0032 0.0145 -0.0253 0.0317 0.05 0.8256 
Age  1 -0.0042 0.0004 -0.0051 -0.0033 88.16 <0.0001 
RxHCC Score  1 0.8347 0.0341 0.7679 0.9015 600.48 <0.0001 
Rx Count  1 -0.0084 0.0002 -0.0089 -0.0079 1,290.00 <0.0001 
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Table 36 – RxHCC+MEM Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.7755 0.0156 -0.8060 -0.7449 2,474.75 <0.0001 
Gender Male 1 0.0601 0.0049 0.0506 0.0696 153.20 <0.0001 
Age  1 -0.0073 0.0001 -0.0076 -0.0070 2,402.81 <0.0001 
RxHCC Score  1 0.8940 0.0063 0.8817 0.9063 20,245.40 <0.0001 
MEM  1 0.0290 0.0007 0.0276 0.0304 1,723.64 <0.0001 
Dispersion  1 1.6714 0.0095 1.6529 1.6900   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.4377 0.0429 0.3537 0.5218 104.14 <0.0001 
RxHCC Count  1 -0.9777 0.0172 -1.0115 -0.9440 3,227.03 <0.0001 
Gender  1 0.0188 0.0147 -0.0100 0.0475 1.63 0.2012 
Age  1 -0.0048 0.0005 -0.0057 -0.0039 113.55 <0.0001 
RxHCC Score  1 0.8492 0.0339 0.7828 0.9156 627.69 <0.0001 
MEM  1 -0.0511 0.0024 -0.0558 -0.0465 469.58 <0.0001 
 
A summary of the predictive ability of the RxHCC score and prescription measures after 
accounting for gender and age is found in Table 37. 
Table 37 – RxHCC-based emergency department visit count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
RxHCC + Unique Drug Count Model 
RxHCC Score 1 0.7181 0.0064 0.7057 0.7306 12,707.20 <0.0001 
Unique Drug 1 0.0322 0.0003 0.0315 0.0328 10,533.50 <0.0001 
        
RxHCC + Rx Count Model 
RxHCC Score 1 0.8131 0.0062 0.8009 0.8252 17,265.90 <0.0001 
Rx Count 1 0.0040 0.0001 0.0039 0.0041 4,411.98 <0.0001 
        
RxHCC + MEM Model 
RxHCC Score 1 0.8940 0.0063 0.8817 0.9063 20,245.40 <0.0001 
MEM 1 0.0290 0.0007 0.0276 0.0304 1,723.64 <0.0001 
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As with the RxHCC hospitalization count models, the RxHCC score variable was the best 
predictor of expected emergency department visits in these models. Using the RxHCC+MEM 
model as an example, the expected change in log count for a one-unit increase in RxHCC score 
was 0.8940. This results in a 144% increase (            ) in expected emergency department 
visits for each additional one-unit increase in RxHCC score (compared to the 53.6% increase 
predicted by the HCC model), after accounting for the other variables in the model. By 
comparison, a one-unit increase in MEM results in a 2.9% increase (             ) in expected 
hospitalization count, holding all other variables constant. Because the estimates are in different 
units and are unstandardized, the interpretation may change when the estimates are standardized.  
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Mortality 
A logistic regression model predicting year-2 mortality was estimated using year-1 (2007) 
information, including demographics (age, gender, and race), the RxHCC score index, and the 
prescription measures (Table 38). As with the count models, the RxHCC risk score was used rather 
than the RxHCC indictors to predict year-2 mortality. While this results in a loss in predictive 
ability, a single composite variable makes parameter estimate interpretation more succinct 
compared to 82 indicator variables representing the same construct.  
Table 38 – RxHCC Model Predicting Year-2 Mortality 
Model 
Cox & 
Snell R
2
 
Nagelkerke 
Adj. R
2
 
C χ2 (df; p-value) 
χ2 diff (dfdiff; 
p-value) 
RxHCC Model 0.0348 0.1078 0.737 
43,595.79 
(df=3; p<0.0001) 
- 
RxHCC + Unique Rx 0.0405 0.1254 0.755 
50,873.66 
(df=4; p<0.0001) 
7,277.87 
(dfdiff=1; p<0.0001) 
RxHCC + Rx Count 0.0409 0.1264 0.755 
51,308.55 
(df=4; p<0.0001) 
7,712.76 
(dfdiff=1; p<0.0001) 
RxHCC + MEM 0.0375 0.1159 0.746 
46,961.34 
(df=4; p<0.0001) 
3,365.55 
(dfdiff=1; p<0.0001) 
 
As with the count models, race was initially included in the logistic models as a predictor 
of year-2 mortality, however it performed poorly and was subsequently removed from the model. 
Age and gender were found to be significant predictors in the models. All models were found to 
significantly predict year-2 mortality and the addition of the prescription measures significant, 
though marginal, improved the model performance. Table 39 provides odds ratio and parameter 
estimates for the RxHCC models tested. 
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Table 39 – Odds Ratio and Parameter Estimates for RxHCC Models Predicting Year-2 
Mortality 
Odds Ratio and Parameter Estimates 
Parameter 
Odds Ratio (95% 
Wald CI) 
Estimate 
Std. 
Error 
Wald χ2 Pr> χ2 
RxHCC Model 
Intercept - -10.1504 0.0404 63,122.32 <0.0001 
Gender (Female) 0.639 (0.627-0.651) -0.4480 0.0092 2,364.71 <0.0001 
Age 1.092 (1.091-1.093) 0.0880 0.0005 32,700.80 <0.0001 
RxHCC Score 2.381 (2.334-2.429) 0.8674 0.0102 7,291.08 <0.0001 
      
RxHCC + Unique Drug Count Model 
Intercept - -10.3646 0.0410 64,037.79 <0.0001 
Gender (Female) 0.610 (0.599-0.621) -0.4949 0.0093 2,844.42 <0.0001 
Age 1.092 (1.091-1.093) 0.0882 0.0005 32,333.97 <0.0001 
RxHCC Score 1.577 (1.543-1.613) 0.4558 0.0113 1,632.91 <0.0001 
Unique Drug 1.056 (1.055-1.057) 0.0544 0.0006 7,708.65 <0.0001 
      
RxHCC + Rx Count Model 
Intercept - -10.0276 0.0403 61,966.59 <0.0001 
Gender (Female) 0.607 (0.596-0.618) -0.4989 0.0093 2,869.30 <0.0001 
Age 1.089 (1.088-1.090) 0.0852 0.0005 30,887.76 <0.0001 
RxHCC Score 1.625 (1.590-1.661) 0.4854 0.0112 1,881.13 <0.0001 
Rx Count 1.010 (1.010-1.010) 0.0097 0.0001 8,350.95 <0.0001 
      
RxHCC + MEM Model 
Intercept - -10.1842 0.0406 62,840.93 <0.0001 
Gender (Female) 0.618 (0.607-0.630) -0.4805 0.0093 2,694.42 <0.0001 
Age 1.091 (1.090-1.092) 0.0868 0.0005 31,536.12 <0.0001 
RxHCC Score 1.877 (1.837-1.918) 0.6297 0.0110 3,280.65 <0.0001 
MEM 1.085 (1.082-1.088) 0.0820 0.0014 3,527.63 <0.0001 
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SPECIFIC AIM 3 – NON-CMS RISK-ADJUSTMENT MODELS 
The purpose of specific aim 3 was to test performance of the prescription-based measures 
as risk adjusters when coupled with other common risk adjusters found in the literature. This 
analysis included two diagnosis-based risk adjusters, Charlson’s Comorbidity Index and the 
Elixhauser Index, as well as one pharmacy-based risk adjuster, RxRisk. Similar to the Medicare 
risk-adjustment models examined in specific aim 2, these models were used to predict year-2 
outcomes including expenditures, hospitalizations, emergency department visits, and mortality. 
The Medicare risk-adjustment models use year-1 data to predict year-2 expenditures. The analyses 
conducted in this specific aim adopted the same framework. 
Charlson Comorbidity Index (CCI) 
 The Charlson Comorbidity Index was calculated for each beneficiary utilizing the same 
diagnostic sources as the HCC and RxHCC models. The Deyo adaptation of the CCI was 
employed to assign Charlson scores based on ICD-9 diagnosis codes (Deyo, Cherkin, & Ciol, 
1992). The CCI categories were assigned a weight derived from the original Charlson scoring 
(Charlson, Pompei, Ales, & MacKenzie, 1987). The vast majority of beneficiaries (88.1%) did not 
receive a Charlson score based on the 17 conditions included in the original model. These 
individuals were assigned a zero (0) Charlson score. This is not overly surprising considering the 
conditions selected for the CCI were based on their ability to predict 30-day in-hospital mortality. 
Table 40 provides the frequency of Charlson Comorbidity Index scores assigned to the study 
sample. 
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Table 40 – Charlson Comorbidity Index Descriptive Statistics 
CCI Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
0 1,083,329 88.10 1,083,329 88.10 
1 20,441 1.66 1,103,770 89.76 
2 25,011 2.03 1,128,781 91.79 
3 24,293 1.98 1,153,074 93.77 
4 21,381 1.74 1,174,455 95.51 
5 16,919 1.38 1,191,374 96.88 
6 12,731 1.04 1,204,105 97.92 
7 8,670 0.71 1,212,775 98.62 
8 6,119 0.50 1,218,894 99.12 
9 3,882 0.32 1,222,776 99.44 
10 2,617 0.21 1,225,393 99.65 
11 1,639 0.13 1,227,032 99.78 
12 1,006 0.08 1,228,038 99.87 
13 675 0.05 1,228,713 99.92 
14 411 0.03 1,229,124 99.95 
15 264 0.02 1,229,388 99.97 
16 144 0.01 1,229,532 99.99 
17 84 0.01 1,229,616 99.99 
18 43 <0.01 1,229,659 >99.99 
19 17 <0.01 1,229,676 >99.99 
20 14 <0.01 1,229,690 >99.99 
21 4 <0.01 1,229,694 >99.99 
22 3 <0.01 1,229,697 >99.99 
23 1 <0.01 1,229,698 100.00 
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Expenditures 
Table 41 – Charlson Comorbidity Index Model Summary (Expenditures) 
Expenditure 
Type 
Model* R
2
 
n=1,229,698 Expenditures 
Truncated 
Expenditures 
Log-Transformed 
Expenditures‡ 
Total 
Expenditures 
(Medical and 
Pharmacy) 
Demographic Model 0.0004 0.0006 0.0160 
Demo + CCI Model 0.0484 0.0724 0.0516 
CCI + Unique Rx 0.0631 0.0948 0.1803 
CCI + Rx Count 0.0666 0.1005 0.1729 
CCI + MEM 0.0637 0.0960 0.1897 
     
     
Medical 
Expenditures 
Demographic Model 0.0013 0.0020 0.0070 
Demo + CCI Model 0.0440 0.0670 0.0665 
CCI + Unique Rx 0.0502 0.0765 0.0785 
CCI + Rx Count 0.0507 0.0774 0.0905 
CCI + MEM 0.0490 0.0748 0.0841 
     
     
Pharmacy 
Expenditures 
Demographic Model 0.0169 0.0178 0.0152 
Demo + CCI Model 0.0320 0.0339 0.0261 
CCI + Unique Rx 0.1232 0.1311 0.2177 
CCI + Rx Count 0.1730 0.1843 0.2081 
CCI + MEM 0.1706 0.1818 0.2479 
*Models contain demographic variables from the HCC and RxHCC models (e.g., age and sex) plus race 
‡ Represents the explained variance in log expenditures 
 All models in Table 41 were estimated by ordinary least squares regression. The Charlson 
Comorbidity Index had relatively poor performance at predicting year-2 expenditures, regardless 
of outcome variable transformation or truncation; although, CCI did perform better than the 
demographic model. The addition of the pharmacy measures improved the predictive ability of the 
CCI model modestly for unmodified total and medical expenditures and substantially for all 
pharmacy expenditures. The addition of unique drug count (R
2
=0.1803) and simple prescription 
count (R
2
=0.1729) to CCI predicted log-transformed total expenditures and similar to a study 
published by Farley et al. (2006) using a similar study methodology.  
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Hospitalizations 
The HCC and RxHCC expenditure models utilized indicator categories to arrive at 
expected expenditures based on individual condition categories. Rather using than indicator 
categories for each of the conditions, the CCI models predicting expected hospitalization count 
utilized the CCI score, for ease of interpretation. A zero-inflated negative binomial regression 
model predicting year-2 hospitalization count was estimated using year-1 (2007) information, 
including demographics (age, gender, and race), the CCI score, and prescription measures, unique 
drug count (Table 42), simple prescription count (Table 43), and the medication exposure measure 
(Table 44). Logit models were specified to predict excess zeros using each of these variables. The 
CCI score was removed from the zero-inflated model because the algorithm failed to converge 
with it included in the model. Additionally, race was initially included in the model, but it was 
subsequently removed because it failed to consistently predict model outcomes.  
Table 42 – CCI+Unique Drug Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.2656 0.0224 -1.3095 -1.2217 3,197.31 <0.0001 
Gender Male 1 0.1309 0.0048 0.1215 0.1402 752.06 <0.0001 
Age  1 0.0019 0.0002 0.0014 0.0023 68.06 <0.0001 
CCI Score  1 0.1551 0.0011 0.1529 0.1572 20,287.40 <0.0001 
Unique Drug  1 0.0221 0.0004 0.0213 0.0229 3,020.51 <0.0001 
Dispersion  1 1.3610 0.0151 1.3316 1.3910   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.3969 0.0352 2.328 2.4659 4,639.68 <0.0001 
Age  1 -0.0283 0.0004 -0.0291 -0.0274 4,105.10 <0.0001 
Unique Drug  1 -0.1065 0.0012 -0.1088 -0.1041 7905.9 <0.0001 
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Table 43 – CCI+Rx Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.2919 0.0214 -1.3338 -1.2500 3,652.41 <0.0001 
Gender Male 1 0.1058 0.0048 0.0964 0.1152 491.16 <0.0001 
Age  1 0.0022 0.0002 0.0018 0.0026 95.87 <0.0001 
CCI Score  1 0.1761 0.0011 0.1740 0.1783 25,714.40 <0.0001 
Rx Count  1 0.0035 0.0001 0.0034 0.0037 2,296.04 <0.0001 
Dispersion  1 1.5485 0.0157 1.5181 1.5795   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.0370 0.0372 1.9641 2.1099 2,998.68 <0.0001 
Age  1 -0.0270 0.0005 -0.0279 -0.0261 3,213.39 <0.0001 
Rx Count  1 -0.0265 0.0004 -0.0273 -0.0258 5,096.79 <0.0001 
 
Table 44 – CCI+MEM Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.3663 0.0221 -1.4097 -1.3230 3,814.40 <0.0001 
Gender Male 1 0.0901 0.0048 0.0808 0.0995 356.21 <0.0001 
Age  1 0.0022 0.0002 0.0018 0.0027 94.62 <0.0001 
CCI Score  1 0.1877 0.0011 0.1855 0.1900 27300 <0.0001 
MEM  1 0.0435 0.0009 0.0417 0.0453 2,227.62 <0.0001 
Dispersion  1 1.6632 0.0181 1.6280 1.6991   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 1.5372 0.0391 1.4606 1.6138 1,547.04 <0.0001 
Age  1 -0.0237 0.0005 -0.0247 -0.0228 2,339.99 <0.0001 
MEM  1 -0.2341 0.0039 -0.2417 -0.2265 3,660.28 <0.0001 
 
Gender, age, CCI score and each of the prescription measures were found to be significant 
predictors of expected hospitalization count. The CCI score had the largest parameter estimate in 
each of the models, followed by gender and the prescription measures, with age having the lowest 
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predictive ability for hospitalization count. Taking the CCI+MEM model as an example, the 
expected change in log count for a one-unit increase in CCI score was 0.1877. This results in an 
20.6% increase (             ) in expected hospitalization count for each additional one-unit 
increase in CCI score, after accounting for the other variables in the model. By comparison, a 
one-unit increase in MEM will result in a 4.4% increase (              ) in expected 
hospitalization count, holding all other variables constant. Because the estimates are in different 
units and are unstandardized, the interpretation may change when the estimates are standardized. 
Table 45 – CCI-based hospitalization count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
CCI + Unique Drug Count Model 
CCI Score 1 0.1551 0.0011 0.1529 0.1572 20,287.40 <0.0001 
Unique Drug 1 0.0221 0.0004 0.0213 0.0229 3,020.51 <0.0001 
        
CCI + Rx Count Model 
CCI Score 1 0.1761 0.0011 0.1740 0.1783 25,714.40 <0.0001 
Rx Count 1 0.0035 0.0001 0.0034 0.0037 2,296.04 <0.0001 
        
CCI + MEM Model 
CCI Score 1 0.1877 0.0011 0.1855 0.1900 27300 <0.0001 
MEM 1 0.0435 0.0009 0.0417 0.0453 2,227.62 <0.0001 
        
 
The addition of prescription-based measures adds to the predictive ability of the CCI score 
in predicting expected hospitalization counts. Although CCI was found to significantly predict 
expected hospitalization count, the HCC and RxHCC models predict hospitalization count better 
by comparison. As with the HCC and RxHCC models, the medication exposure and unique drug 
count predicted expected hospitalization count much better than simple prescription count. The 
CCI score was also found to be the best predictor of expected year-2 hospitalization count in these 
models compared to all of the other variables.   
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Emergency Department Visits 
A zero-inflated negative binomial regression model predicting year-2 emergency 
department visit count was estimated using year-1 (2007) information, including demographics 
(age, gender, and race), the CCI, and the prescription measures, unique drug count (Table 46), 
simple prescription count (Table 47), and the medication exposure measure (Table 48). Logit 
models were specified to predict excess zeros using each of these variables. The variable race was 
originally included as a predictor in the zero-inflated model, but was removed due to the lack of 
significant contribution to the model. Additionally, race was included in the count model, but was 
subsequently removed due to lack of significance in predicting expected emergency department 
visit count. Gender was found to significantly predict excessive zeros in the logit model and the 
emergency department visit model. The CCI score was removed from the zero-inflated model 
because the algorithm failed to converge with it included in the model. 
Table 46 – CCI+Unique Drug Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.0241 0.0145 -0.0043 0.0526 2.77 0.0963 
Gender Male 1 -0.0086 0.0058 -0.0200 0.0029 2.16 0.1414 
Age  1 -0.0129 0.0001 -0.0132 -0.0126 7,462.57 <0.0001 
CCI Score  1 0.1636 0.0011 0.1615 0.1658 22,735.8 <0.0001 
Unique Drug  1 0.0326 0.0003 0.0319 0.0333 8,793.00 <0.0001 
Dispersion  1 1.8396 0.0123 1.8156 1.8639   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.5650 0.0367 0.4930 0.6370 236.45 <0.0001 
Gender  1 0.0290 0.0207 -0.0116 0.0697 1.96 0.1618 
Age  1 -0.0124 0.0004 -0.0132 -0.0116 916.22 <0.0001 
Unique Drug  1 -0.1254 0.0016 -0.1285 -0.1223 6140.76 <0.0001 
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Table 47 – CCI+Rx Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.2178 0.0131 0.1922 0.2434 277.17 <0.0001 
Gender Male 1 -0.0418 0.0055 -0.0526 -0.0309 56.66 <0.0001 
Age  1 -0.0140 0.0001 -0.0143 -0.0137 9,359.35 <0.0001 
CCI Score  1 0.1823 0.0011 0.1802 0.1844 28,808.60 <0.0001 
Rx Count  1 0.0052 0.0001 0.0051 0.0054 6,682.67 <0.0001 
Dispersion  1 1.8532 0.0116 1.8306 1.8761   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.3032 0.0339 0.2368 0.3695 80.16 <0.0001 
Gender  1 0.0070 0.0187 -0.0297 0.0436 0.14 0.7096 
Age  1 -0.0084 0.0004 -0.0092 -0.0077 448.88 <0.0001 
Rx Count  1 -0.0324 0.0004 -0.0332 -0.0316 5,710.80 <0.0001 
 
Table 48 – CCI+MEM Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.2270 0.0132 0.2010 0.2529 293.94 <0.0001 
Gender Male 1 -0.0614 0.0057 -0.0725 -0.0503 117.39 <0.0001 
Age  1 -0.0149 0.0001 -0.0151 -0.0146 10,465.50 <0.0001 
CCI Score  1 0.2004 0.0011 0.1982 0.2026 32,161.10 <0.0001 
MEM  1 0.0517 0.0008 0.0502 0.0533 4,336.39 <0.0001 
Dispersion  1 2.1013 0.0136 2.0748 2.1282   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.2480 0.0408 -0.3280 -0.1679 36.89 <0.0001 
Gender  1 0.0642 0.0247 0.0158 0.1125 6.76 0.0093 
Age  1 -0.0072 0.0005 -0.0081 -0.0063 246.89 <0.0001 
MEM  1 -0.3090 0.0056 -0.3200 -0.2979 3,009.25 <0.0001 
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A summary of the predictive ability of the CCI score and prescription measures after 
accounting for gender and age is found in Table 49.  
Table 49 –CCI-based emergency department visit count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
CCI + Unique Drug Count Model 
CCI Score 1 0.1636 0.0011 0.1615 0.1658 22,735.8 <0.0001 
Unique Drug 1 0.0326 0.0003 0.0319 0.0333 8,793.00 <0.0001 
        
CCI + Rx Count Model 
CCI Score 1 0.1823 0.0011 0.1802 0.1844 28,808.60 <0.0001 
Rx Count 1 0.0052 0.0001 0.0051 0.0054 6,682.67 <0.0001 
        
CCI + MEM Model 
CCI Score 1 0.2004 0.0011 0.1982 0.2026 32,161.10 <0.0001 
MEM 1 0.0517 0.0008 0.0502 0.0533 4,336.39 <0.0001 
        
 
As with the CCI hospitalization count models, the CCI score variable was found to be the 
best predictor of expected emergency department visits in these models. Taking the CCI+MEM 
model as an example, the expected change in log count for a one-unit increase in CCI score was 
0.2004. This results in a 22.2% increase (             ) in expected emergency department 
visits for each additional one-unit increase in CCI score, after accounting for the other variables in 
the model. By comparison, a one-unit increase in MEM results in a 5.3% increase (        
     ) in expected year-2 emergency department count, holding all other variables constant. 
Because the estimates are in different units and are unstandardized, the interpretation may change 
when the estimates are standardized.  
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Mortality 
A logistic regression model predicting year-2 mortality was estimated using year-1 (2007) 
information, including demographics (age, gender, and race), the CCI, and the prescription 
measures (Table 50). As with the count models, the CCI score was used rather than the CCI 
indictors to predict year-2 mortality. A single composite variable makes parameter estimate 
interpretation more succinct compared to the 17 CCI indicator variables representing the same 
construct. In addition, using the indicator scoring ignores the weights assigned to each diagnosis. 
This is a particularly important distinction for the CCI when used to predict mortality, considering 
the CCI was originally developed to predict mortality. However, the CCI is typically used to 
predict shorter-term mortality compared to the year-2 outcomes used in this study (Charlson, 
Pompei, Ales, & MacKenzie, 1987; Schneeweiss et al., 2001; Perkins et al., 2004). While using 
indicator variables score typically results in a gain in predictive ability compared to a single index, 
the CCI index model outperformed the CCI indicator models. This may be due to the loss of the 
condition weights in the indicator model. 
Table 50 – Charlson Comorbidity Index Model Predicting Year-2 Mortality 
Model* 
Cox & 
Snell 
R
2
 
Nagelkerke 
Adj. R
2
 
C χ2 (df; p-value) 
χ2 diff (dfdiff; 
p-value) 
Charlson Model 0.0410 0.1268 0.755 
51,460.90 
(df=3; p<0.0001) 
- 
Charlson + Unique Rx 0.0454 0.1406 0.768 
57,198.20 
(df=4; p<0.0001) 
5,737.30 
(dfdiff=1; p<0.0001) 
Charlson + Rx Count 0.0471 0.1458 0.773 
59,375.56 
(df=4; p<0.0001) 
7,914.66 
(dfdiff=1; p<0.0001) 
Charlson + MEM 0.0439 0.1359 0.764 
55,248.21 
(df=4; p<0.0001) 
3,787.31 
(dfdiff=1; p<0.0001) 
*Models contain demographic variables from the HCC and RxHCC models (e.g., age and sex) 
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Table 51 provides odds ratio and parameter estimates for the CCI models tested to predict 
year-2 mortality. The CCI score exhibited strong predictive ability compared to the other variables 
included in the models with the exception of gender, which was the best predictor of year-2 
mortality across the models. 
Table 51 – Odds Ratio and Parameter Estimates for CCI Models Predicting Year-2 Mortality 
Odds Ratio and Parameter Estimates 
Parameter 
Odds Ratio (95% 
Wald CI) 
Estimate 
Std. 
Error 
Wald χ2 Pr> χ2 
CCI Model 
Intercept - -9.6132 0.0408 55,400.34 <0.0001 
Gender (Male) 1.369 (1.345-1.394) 0.3143 0.0092 1,167.90 <0.0001 
Age 1.086 (1.085-1.087) 0.0824 0.0005 27,723.63 <0.0001 
CCI Score 1.233 (1.229-1.237) 0.2094 0.0016 17,822.79 <0.0001 
      
CCI + Unique Drug Count Model 
Intercept - -10.2498 0.0420 59,575.72 <0.0001 
Gender (Male) 1.500 (1.473-1.528) -0.4054 0.0093 1,897.51 <0.0001 
Age 1.088 (1.087-1.089) 0.0846 0.0005 29,140.38 <0.0001 
CCI Score 1.175 (1.171-1.179) 0.1613 0.0017 9,007.73 <0.0001 
Unique Drug 1.048 (1.047-1.049) 0.0467 0.0006 6,036.32 <0.0001 
      
CCI + Rx Count Model 
Intercept - -9.9884 0.0408 59,857.39 <0.0001 
Gender (Male) 1.516 (1.489-1.544) -0.4163 0.0093 1,986.35 <0.0001 
Age 1.085 (1.084-1.086) 0.0818 0.0005 28,024.47 <0.0001 
CCI Score 1.191 (1.188-1.195) 0.1752 0.0016 11,627.59 <0.0001 
Rx Count 1.009 (1.009-1.010) 0.0094 0.0001 8,713.58 <0.0001 
      
CCI + MEM Model 
Intercept - -9.9652 0.0414 57,909.20 <0.0001 
Gender (Male) 1.465 (1.439-1.492) -0.3822 0.0093 1,693.18 <0.0001 
Age 1.086 (1.085-1.087) 0.0825 0.0005 27,832.57 <0.0001 
CCI Score 1.206 (1.202-1.210) 0.1876 0.0016 13,575.79 <0.0001 
MEM 1.087 (1.084-1.090) 0.0834 0.0013 3,997.58 <0.0001 
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Elixhauser Index 
The Elixhauser Index was calculated for each beneficiary utilizing the same diagnostic 
sources as the HCC and RxHCC models. Similar to the Charlson analysis, very few beneficiaries 
(12.94%) received an Elixhauser Index. A total of 159,098 beneficiaries received an Elixhauser 
Index based on 29 diagnosis-based categories, the others were given zeros. The 29 indicators were 
summed to arrive at a single summary measure, which was used in the following models. Table 52 
provides frequencies for the summed Elixhauser Index.  
Table 52 – Elixhauser Index Distribution 
Elixhauser 
Index 
Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
0 1,070,600 87.06 1,070,600 87.06 
1 31,668 2.58 1,102,268 89.64 
2 41,536 3.33 1,143,804 93.02 
3 35,191 2.86 1,178,995 95.88 
4 23,374 1.90 1,202,369 97.78 
5 13,267 1.08 1,215,636 98.86 
6 7,064 0.57 1,222,700 99.43 
7 3,639 0.30 1,226,339 99.73 
8 1,887 0.15 1,228,226 99.88 
9 864 0.07 1,229,090 99.95 
10 387 0.03 1,229,477 99.98 
11 145 0.01 1,229,622 99.99 
12 57 <0.01 1,229,679 100.00 
13 13 <0.01 1,229,692 100.00 
14 6 <0.01 1,229,698 100.00 
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Expenditures 
Table 53 – Elixhauser Index Model Summary (Expenditures) 
Expenditure 
Type 
Model* R
2
 
n=1,229,698 
Annualized 
Expenditures 
Truncated 
Expenditures 
Log-Transformed 
Expenditures‡ 
Total 
Expenditures 
(Medical and 
Pharmacy) 
Demographic Model 0.0004 0.0006 0.0160 
Demo + Elix 0.0477 0.0712 0.0512 
Elix + Unique Rx 0.0626 0.0939 0.1804 
Elix + Rx Count 0.0659 0.0992 0.1727 
Elix + MEM 0.0631 0.0950 0.1896 
     
     
Medical 
Expenditures† 
Demographic Model 0.0013 0.0020 0.0070 
Demo + Elix 0.0427 0.0650 0.0625 
Elix + Unique Rx 0.0491 0.0748 0.0752 
Elix + Rx Count 0.0495 0.0755 0.0874 
Elix + MEM 0.0479 0.0730 0.0807 
     
     
Pharmacy 
Expenditures 
Demographic Model 0.0169 0.0178 0.0152 
Demo + Elix 0.0421 0.0445 0.0274 
Elix + Unique Rx 0.1317 0.1399 0.2184 
Elix + Rx Count 0.1805 0.1920 0.2085 
Elix + MEM 0.1785 0.1899 0.2484 
*Models contain demographic variables from the HCC and RxHCC models (e.g., age and sex) plus race 
‡ Represents the explained variance in log expenditures 
 All models in Table 53 were estimated by ordinary least squares regression. The 
Elixhauser Index performed well when coupled with the prescription measures to predict 
pharmacy expenditures. The similar performance of the simple prescription count and MEM 
models in predicting pharmacy expenditures is likely due to the strong correlation (r=0.895) 
between the two prescription measures. The addition of pharmacy measures to the truncated and 
log-transformed expenditures improved the model R
2
 particularly well for pharmacy expenditures, 
but improved only slightly for medical expenditures. The addition of the prescription measures to 
the Elixhauser Index greatly improved prediction of pharmacy expenditures compared to the 
Elixhauser Index alone.  
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Hospitalizations 
A zero-inflated negative binomial regression model predicting year-2 hospitalization count 
was estimated using year-1 (2007) information, including demographics (age, gender, and race), 
the Elixhauser Index, and the prescription measures, unique drug count (Table 54), simple 
prescription count (Table 55), and the medication exposure measure (Table 56). Logit models 
were specified to predict excess zeros using each of these variables. Race was initially included in 
the model, but it was subsequently removed because it failed to consistently predict model 
outcomes. The parameter estimates for the count and zero-inflated models are presented in the 
following tables.  
Table 54 – ELIX+Unique Drug Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.1898 0.0201 -1.2292 -1.1503 3,493.32 <0.0001 
Gender Male 1 0.1445 0.0047 0.1352 0.1538 928.69 <0.0001 
Age  1 0.0021 0.0002 0.0017 0.0025 94.46 <0.0001 
ELIX Index  1 0.1564 0.0016 0.1533 0.1595 9,864.52 <0.0001 
Unique Drug  1 0.0213 0.0004 0.0206 0.0221 3,408.45 <0.0001 
Dispersion  1 1.2728 0.0115 1.2506 1.2955   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.8704 0.0332 2.8053 2.9355 7,474.67 <0.0001 
Age  1 -0.0315 0.0004 -0.0323 -0.0306 5,308.83 <0.0001 
ELIX Index  1 -1.7062 0.0880 -1.8787 -1.5337 375.76 <0.0001 
Unique Drug  1 -0.0867 0.0011 -0.0888 -0.0845 6,099.59 <0.0001 
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Table 55 – ELIX+Rx Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.0500 0.0194 -1.0879 -1.0120 2,936.84 <0.0001 
Gender Male 1 0.1234 0.0047 0.1141 0.1327 678.94 <0.0001 
Age  1 0.0012 0.0002 0.0008 0.0017 33.56 <0.0001 
ELIX Index  1 0.1733 0.0016 0.1703 0.1764 12,346.00 <0.0001 
Rx Count  1 0.0031 0.0001 0.0030 0.0033 2,273.82 <0.0001 
Dispersion  1 1.3041 0.0113 1.2821 1.3265   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.7485 0.0331 2.6837 2.8133 6,911.39 <0.0001 
Age  1 -0.0313 0.0004 -0.0322 -0.0304 5,075.59 <0.0001 
ELIX Index  1 -1.8211 0.0871 -1.9918 -1.6505 437.45 <0.0001 
Rx Count  1 -0.0185 0.0003 -0.0190 -0.0180 5,192.39 <0.0001 
 
Table 56 – ELIX+MEM Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.0174 0.0190 -1.0545 -0.9802 2,875.98 <0.0001 
Gender Male 1 0.1118 0.0047 0.1025 0.1211 557.25 <0.0001 
Age  1 0.0007 0.0002 0.0003 0.0011 11.16 0.0008 
ELIX Index  1 0.1751 0.0016 0.1720 0.1781 12,381.60 <0.0001 
MEM  1 0.0368 0.0008 0.0352 0.0384 2,072.53 <0.0001 
Dispersion  1 1.3034 0.0111 1.2818 1.3254   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.5051 0.0318 2.4427 2.5675 6,196.96 <0.0001 
Age  1 -0.0288 0.0004 -0.0296 -0.0280 4,635.22 <0.0001 
ELIX Index  1 -2.0656 0.0998 -2.2613 -1.8700 428.21 <0.0001 
MEM  1 -0.1597 0.0023 -0.1643 -0.1551 4,621.44 <0.0001 
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Gender, age, Elixhauser Index and each of the prescription measures were found to be 
significant predictors of expected hospitalization count. Originally, race was included in the count 
model but was subsequently removed due to lack of significance in predicting expected 
hospitalization count. The dispersion parameter estimate was found to be greater than 1 for all 
models, suggesting that the data are overdispersed, which justifies the use of a negative binomial 
model over a Poisson model. The zero-inflated negative binomial model was selected due to the 
large proportion of zeros in the count measures. 
Table 57 – Elixhauser-based hospitalization count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
ELIX + Unique Drug Count Model 
ELIX Index 1 0.1564 0.0016 0.1533 0.1595 9,864.52 <0.0001 
Unique Drug 1 0.0213 0.0004 0.0206 0.0221 3,408.45 <0.0001 
        
ELIX + Rx Count Model 
ELIX Index 1 0.1733 0.0016 0.1703 0.1764 12,346.00 <0.0001 
Rx Count 1 0.0031 0.0001 0.0030 0.0033 2,273.82 <0.0001 
        
ELIX + MEM Model 
ELIX Index 1 0.1751 0.0016 0.1720 0.1781 12,381.60 <0.0001 
MEM 1 0.0368 0.0008 0.0352 0.0384 2,072.53 <0.0001 
        
 
Table 57 provides a summary of the parameter estimates for the Elixhauser Index and the 
prescription measures, after accounting for gender and age. The Elixhauser Index had the largest 
parameter estimate in each of the models, followed by gender and the prescription measures, with 
age having the lowest predictive ability for hospitalization count. This trend was present in the CCI 
model predicting hospitalization counts as well. Taking the Elixhauser+MEM model as an 
example, the expected change in log count for a one-unit increase in the Elixhauser Index was 
0.1751. This results in an 19.1% increase (             ) in expected hospitalization count for 
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each additional one-unit increase in the Elixhauser Index, after accounting for the other variables 
in the model. By comparison, a one-unit increase in MEM will result in a 3.7% increase (        
     ) in expected hospitalization count, holding all other variables constant.  
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Emergency Department Visits 
The Elixhauser Index was combined with the prescription measures to predict year-2 
emergency department visits. The resulting model parameter estimates are provided in the 
following tables. 
Table 58 – ELIX+Unique Drug Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.1040 0.0144 -0.1323 -0.0758 52.24 <0.0001 
Gender Male 1 0.0109 0.0058 -0.0005 0.0222 3.53 0.0603 
Age  1 -0.0112 0.0001 -0.0115 -0.0109 5,681.47 <0.0001 
ELIX Score  1 0.2425 0.0014 0.2397 0.2453 28,390.30 <0.0001 
Unique Drug  1 0.0298 0.0003 0.0291 0.0305 7,324.54 <0.0001 
Dispersion  1 1.7859 0.0120 1.7625 1.8096   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.4816 0.0371 0.4088 0.5544 168.22 <0.0001 
Gender  1 0.0545 0.0206 0.0141 0.0950 6.99 0.0082 
Age  1 -0.0111 0.0004 -0.0119 -0.0103 727.08 <0.0001 
Unique Drug  1 -0.1283 0.0016 -0.1314 -0.1251 6,392.09 <0.0001 
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Table 59 – ELIX+Rx Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.0468 0.0130 0.0213 0.0723 12.92 0.0003 
Gender Male 1 -0.0172 0.0055 -0.0280 -0.0064 9.72 0.0018 
Age  1 -0.0119 0.0001 -0.0122 -0.0116 6,831.51 <0.0001 
ELIX Score  1 0.2645 0.0014 0.2617 0.2672 34,762.60 <0.0001 
Rx Count  1 0.0049 0.0001 0.0047 0.0050 5,773.69 <0.0001 
Dispersion  1 1.8006 0.0114 1.7785 1.8231   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.1819 0.0346 0.1141 0.2497 27.66 <0.0001 
Gender  1 0.0339 0.0188 -0.0030 0.0708 3.24 0.0718 
Age  1 -0.0069 0.0004 -0.0077 -0.0061 290.63 <0.0001 
Rx Count  1 -0.0330 0.0004 -0.0339 -0.0322 5,737.20 <0.0001 
 
Table 60 – ELIX+MEM Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.0267 0.0132 0.0009 0.0525 4.12 0.0423 
Gender Male 1 -0.0339 0.0056 -0.0449 -0.0228 36.15 <0.0001 
Age  1 -0.0126 0.0001 -0.0128 -0.0123 7541.22 <0.0001 
ELIX Score  1 0.2896 0.0015 0.2868 0.2925 38,576.80 <0.0001 
MEM  1 0.0490 0.0008 0.0475 0.0505 3,868.55 <0.0001 
Dispersion  1 2.0511 0.0133 2.0253 2.0773   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.4254 0.0430 -0.5096 -0.3411 97.98 <0.0001 
Gender  1 0.1062 0.0256 0.0560 0.1565 17.16 <0.0001 
Age  1 -0.0054 0.0005 -0.0063 -0.0045 130.97 <0.0001 
MEM  1 -0.3185 0.0059 -0.3301 -0.3069 2,881.54 <0.0001 
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The variable race was originally included as a predictor in the zero-inflated model, but was 
removed due to the lack of significant contribution to the model. Additionally, race was included 
in the count model, but was subsequently removed due to lack of significance in predicting 
expected emergency department visit count. Gender was found to significantly predict excessive 
zeros in the logit model and the emergency department visit model. As with the CCI count models, 
the Elixhauser Index was removed from the zero-inflated model because the algorithm failed to 
converge while it was included in the model. A summary of the predictive ability of the Elixhauser 
Index and prescription measures after accounting for gender and age is provided in Table 61. 
Table 61 – Elixhauser-based emergency department visit count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
ELIX + Unique Drug Count Model 
ELIX Score 1 0.2425 0.0014 0.2397 0.2453 28,390.30 <0.0001 
Unique Drug 1 0.0298 0.0003 0.0291 0.0305 7,324.54 <0.0001 
        
ELIX + Rx Count Model 
ELIX Score 1 0.2645 0.0014 0.2617 0.2672 34,762.60 <0.0001 
Rx Count 1 0.0049 0.0001 0.0047 0.0050 5,773.69 <0.0001 
        
ELIX + MEM Model 
ELIX Score 1 0.2896 0.0015 0.2868 0.2925 38,576.80 <0.0001 
MEM 1 0.0490 0.0008 0.0475 0.0505 3,868.55 <0.0001 
        
 
As with the Elixhauser hospitalization count models, the Elixhauser Index variable was the 
best predictor of expected year-2 emergency department counts in these models. Among the 
prescription measures, the medication exposure measure was found to have the best predictive 
ability (est. = 0.0490), followed by unique drug count (est. = 0.0298) and simple prescription count 
(est. = 0.0049). Taking the Elixhauser+MEM model as an example, the expected change in log 
count for a one-unit increase in the Elixhauser Index was 0.2896. This results in a 33.6% increase 
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(             ) in expected emergency department visits for each additional one-unit increase 
in the Elixhauser Index, after accounting for the other variables in the model. By comparison, a 
one-unit increase in MEM results in a 5.0% increase (             ) in expected year-2 
emergency department count, holding all other variables constant. 
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Mortality 
A logistic regression model predicting year-2 mortality was estimated using year-1 (2007) 
information, including demographics (age, gender, and race), the Elixhauser index, and the 
prescription measures (Table 62). As with the count models, a summed Elixhauser score was used 
rather than the Elixhauser indictors to predict year-2 mortality. While this results in a slight loss in 
predictive ability, a single composite variable makes parameter estimate interpretation more 
succinct compared to 29 indicator variables representing the same construct.  
Table 62 – Elixhauser Index Model Predicting Year-2 Mortality 
Model* 
Cox & 
Snell R
2
 
Nagelkerke 
Adj. R
2
 
C χ2 (df; p-value) χ2 diff (dfdiff; p-value) 
Elixhauser Model 0.0402 0.1245 0.753 
50,493.32 
(df=3; p<0.0001) 
- 
Elixhauser + 
Unique Rx 
0.0446 0.1379 0.776 
56,045.88 
(df=4; p<0.0001) 
5,552.56 
(dfdiff = 1; p<0.0001) 
Elixhauser +  
Rx Count 
0.0461 0.1426 0.770 
58,033.33 
(df=4; p<0.0001) 
7,540.01 
(dfdiff = 1; p<0.0001) 
Elixhauser + 
MEM 
0.0430 0.1330 0.762 
54,024.96 
(df=4; p<0.0001) 
3,531.64 
(dfdiff = 1; p<0.0001) 
*Models contain demographic variables from the HCC and RxHCC models (e.g., age and sex) 
As with the count models, race was initially included in the logistic models as a predictor 
of year-2 mortality, however it performed poorly and was subsequently removed from the model. 
Age and gender were found to be significant predictors in the models. All models were found to 
significantly predict year-2 mortality and the addition of the prescription measures significant, 
though marginal, improved the model performance. Table 63 provides odds ratio and parameter 
estimates for the RxHCC models tested. 
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Table 63 – Odds Ratio and Parameter Estimates for Elixhauser Models (Year-2 Mortality) 
Odds Ratio and Parameter Estimates 
Parameter 
Odds Ratio (95% 
Wald CI) 
Estimate 
Std. 
Error 
Wald χ2 Pr> χ2 
ELIX Model 
Intercept - -9.6644 0.0405 56,870.83 <0.0001 
Gender (Male) 1.426 (1.400-1.452) 0.3548 0.0092 1,493.09 <0.0001 
Age 1.086 (1.085-1.087) 0.0828 0.0005 28,505.24 <0.0001 
ELIX Score 1.349 (1.342-1.355) 0.2990 0.0023 16,644.36 <0.0001 
      
ELIX + Unique Drug Count Model 
Intercept - -10.2923 0.0417 60,773.56 <0.0001 
Gender (Male) 1.548 (1.520-1.576) 0.4369 0.0093 2,216.81 <0.0001 
Age 1.089 (1.088-1.090) 0.0850 0.0005 29,874.94 <0.0001 
ELIX Score 1.248 (1.242-1.254) 0.2214 0.0026 7,548.07 <0.0001 
Unique Drug 1.048 (1.046-1.049) 0.0465 0.0006 5,838.52 <0.0001 
      
ELIX + Rx Count Model 
Intercept - -10.0365 0.0406 61,154.90 <0.0001 
Gender (Male) 1.567 (1.539-1.596) 0.4491 0.0093 2,323.30 <0.0001 
Age 1.086 (1.085-1.087) 0.0824 0.0005 28,851.28 <0.0001 
ELIX Score 1.272 (1.266-1.278) 0.2403 0.0024 9,851.83 <0.0001 
Rx Count 1.009 (1.009-1.009) 0.0093 0.0001 8,293.85 <0.0001 
      
ELIX + MEM Model 
Intercept - -10.0075 0.0411 59,174.81 <0.0001 
Gender (Male) 1.518 (1.491-1.546) 0.4174 0.0093 2,028.57 <0.0001 
Age 1.086 (1.085-1.087) 0.0829 0.0005 28,621.78 <0.0001 
ELIX Score 1.300 (1.293-1.306) 0.2620 0.0024 11,941.17 <0.0001 
MEM 1.085 (1.082-1.087) 0.0812 0.0013 3,722.07 <0.0001 
      
 
The Elixhauser Index exhibited strong predictive ability compared to the other variables 
included in the models with the exception of gender, which was the best predictor of year-2 
mortality across the models.   
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RxRisk 
In contrast to the other diagnosis-based risk adjusters presented, RxRisk utilizes 
pharmacy-based inputs (NDC codes) which are mapped to individual drugs and drug classes and 
ultimately to disease categories. This resulted in a much higher proportion of individuals receiving 
a non-zero RxRisk score (86.5%) compared to the Charlson Comorbidity Index (11.9%) and the 
Elixhauser Index (12.9%). The 55 RxRisk indicators were summed to arrive at a single summary 
measure used in the following models. Table 64 provides frequencies for the RxRisk score. 
Table 64 – RxRisk Score Distribution 
RxRisk Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
0 165,761 13.48 165,761 13.48 
1 83,018 6.75 248,779 20.23 
2 114,517 9.31 363,296 29.54 
3 138,947 11.30 502,243 40.84 
4 148,813 12.10 651,056 52.94 
5 142,267 11.57 793,323 64.51 
6 122,685 9.98 916,008 74.49 
7 99,061 8.06 1,015069 82.55 
8 74,757 6.08 1,089,826 88.63 
9 52,367 4.26 1,142,193 92.88 
10 35,350 2.87 1,177,543 95.76 
11 22,522 1.83 1,200,065 97.59 
12 13,732 1.12 1,213,797 98.71 
13 7,787 0.63 1,221,584 99.34 
14 4,122 0.34 1,225,706 99.68 
15 2,207 0.18 1,227,913 99.85 
16 1,046 0.09 1,228,959 99.94 
17 447 0.04 1,229,406 99.98 
18 191 0.02 1,229,597 99.99 
19 64 0.01 1,229,611 >99.99 
20 23 <0.01 1,229,684 >99.99 
21 9 <0.01 1,229,693 >99.99 
22 2 <0.01 1,229,695 >99.99 
23 2 <0.01 1,229,697 >99.99 
25 1 <0.01 1,229,698 100.00 
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Expenditures 
Table 65 – RxRisk Model Summary (Expenditures) 
Expenditure 
Type 
Model* R
2
 
n=1,229,698 
Annualized 
Expenditures 
Truncated 
Expenditures 
Log-Transformed 
Expenditures‡ 
Total 
Expenditures 
(Medical and 
Pharmacy) 
Demographic Model 0.0004 0.0006 0.0160 
Demo + RxRisk 0.0417 0.0633 0.2028 
RxRisk + Unique Rx 0.0462 0.0702 0.2087 
RxRisk + Rx Count 0.0457 0.0697 0.2093 
RxRisk + MEM 0.0441 0.0672 0.2112 
     
Medical 
Expenditures† 
Demographic Model 0.0013 0.0020 0.0070 
Demo + RxRisk 0.0249 0.0382 0.0550 
RxRisk + Unique Rx 0.0279 0.0427 0.0583 
RxRisk + Rx Count 0.0261 0.0401 0.0650 
RxRisk + MEM 0.0252 0.0386 0.0593 
     
Pharmacy 
Expenditures 
Demographic Model 0.0169 0.0178 0.0152 
Demo + RxRisk 0.2195 0.2337 0.2785 
RxRisk + Unique Rx 0.2284 0.2430 0.2825 
RxRisk + Rx Count 0.2603 0.2770 0.2866 
RxRisk + MEM 0.2687 0.2860 0.2941 
*Models contain demographic variables from the HCC and RxHCC models (e.g., age and sex) plus race 
‡ Represents the explained variance in log expenditures 
 All models in Table 65 were estimated by ordinary least squares regression. The RxRisk 
model performed very well at predicting pharmacy expenditures, but relatively poor for both 
medical and total expenditures. RxRisk was originally developed to predict health care costs, but 
was found to underperform the HCC model in predicting total health care costs (Fishman et al., 
2003). However, the study conducted by Fishman et al. (2003) did not examine the RxRisk 
model’s ability to predict pharmacy expenditures. The addition of the prescription measures added 
to model R
2
, notably well for simple prescription count (R
2
=0.2603) and the medication exposure 
measure (R
2
=0.2687).  
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Hospitalizations 
 A zero-inflated negative binomial regression model predicting year-2 hospitalization count 
was estimated using year-1 (2007) information, including demographics (age, gender, and race), 
the RxRisk score, and prescription measures. Logit models were specified to predict excess zeros 
using each of these variables. Race was initially included in the model, but it was subsequently 
removed because it failed to consistently predict model outcomes. The parameter estimates for the 
count and zero-inflated models are presented in the following tables. Table 69 provides a summary 
of the parameter estimates for the RxRisk model with the prescription measures, after accounting 
for gender and age. 
Table 66 – RxRisk+Unique Drug Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.1499 0.0224 -1.1938 -1.1060 2,638.25 <0.0001 
Gender Male 1 0.1737 0.0048 0.1642 0.1831 1,293.30 <0.0001 
Age  1 0.0009 0.0002 0.0005 0.0014 16.00 <0.0001 
RxRisk Score  1 0.0307 0.0018 0.0272 0.0342 292.36 <0.0001 
Unique Drug  1 0.0248 0.0008 0.0233 0.0264 1,035.50 <0.0001 
Dispersion  1 1.3078 0.0164 1.2761 1.3403   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.4803 0.0320 2.4175 2.5430 5,996.46 <0.0001 
Age  1 -0.0274 0.0004 -0.0282 -0.0265 4,422.66 <0.0001 
RxRisk Score  1 -0.0386 0.0044 -0.0473 -0.0299 75.33 <0.0001 
Unique Drug  1 -0.0690 0.0022 -0.0734 -0.0647 961.29 <0.0001 
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Table 67 – RxRisk+Rx Count Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.0261 0.0221 -1.0694 -0.9828 2,157.49 <0.0001 
Gender Male 1 0.1542 0.0048 0.1447 0.1637 1,017.73 <0.0001 
Age  1 -0.0006 0.0002 -0.0010 -0.0002 7.06 0.0079 
RxRisk Score  1 0.0699 0.0013 0.0674 0.0725 2,977.03 <0.0001 
Rx Count  1 0.0011 0.0001 0.0009 0.0013 109.64 <0.0001 
Dispersion  1 1.3483 0.0168 1.3159 1.3816   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.3573 0.0316 2.2954 2.4192 5,569.15 <0.0001 
Age  1 -0.0264 0.0004 -0.0272 -0.0256 4,363.14 <0.0001 
RxRisk Score  1 -0.0881 0.0030 -0.0940 -0.0821 844.33 <0.0001 
Rx Count  1 -0.0098 0.0003 -0.0105 -0.0092 895.92 <0.0001 
 
Table 68 – RxRisk+MEM Model Predicting Hospitalization Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -1.0089 0.0221 -1.0521 -0.9657 2,093.61 <0.0001 
Gender Male 1 0.1441 0.0048 0.1346 0.1535 889.91 <0.0001 
Age  1 -0.0009 0.0002 -0.0013 -0.0004 14.67 0.0001 
RxRisk Score  1 0.0860 0.0014 0.0832 0.0887 3,722.25 <0.0001 
MEM  1 -0.0068 0.0014 -0.0094 -0.0041 24.79 <0.0001 
Dispersion  1 1.3436 0.0173 1.3101 1.3779   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 2.2543 0.0311 2.1933 2.3153 5,249.76 <0.0001 
Age  1 -0.0250 0.0004 -0.0257 -0.0242 4080.40 <0.0001 
RxRisk Score  1 -0.1579 0.0033 -0.1644 -0.1514 2,264.99 <0.0001 
MEM  1 -0.0111 0.0033 -0.0176 -0.0046 11.14 0.0008 
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Table 69 – RxRisk-based hospitalization count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
RxRisk + Unique Drug Count Model 
RxRisk Score 1 0.0307 0.0018 0.0272 0.0342 292.36 <0.0001 
Unique Drug 1 0.0248 0.0008 0.0233 0.0264 1,035.50 <0.0001 
        
RxRisk + Rx Count Model 
RxRisk Score 1 0.0699 0.0013 0.0674 0.0725 2,977.03 <0.0001 
Rx Count 1 0.0011 0.0001 0.0009 0.0013 109.64 <0.0001 
        
RxRisk + MEM Model 
RxRisk Score 1 0.0860 0.0014 0.0832 0.0887 3,722.25 <0.0001 
MEM 1 -0.0068 0.0014 -0.0094 -0.0041 24.79 <0.0001 
        
 
Gender, age, RxRisk score and each of the prescription measures were found to be 
significant predictors of expected hospitalization count. Unlike the previously tested 
hospitalization count models, the medication exposure measure was found to negatively predict 
expected hospitalization count (est. = -0.0068). The unique drug count (est. = 0.0248) and 
prescription count measures (est. = 0.0011) predicted expected hospitalization count very 
marginally, though significant. Comparison of parameter estimates between models is not 
intended because the estimates are in different units and are unstandardized. Gender had the largest 
parameter estimate in each of the models, which was also a deviation from the other count models 
where the model namesake usually outperformed the other predictors (e.g., the HCC score 
variable performed best among the HCC models). Taking the RxRisk+MEM model as an example, 
the expected change in log count for a one-unit increase in the RxRisk score was 0.0860. This 
results in an 9.0% increase (             ) in expected year-2 hospitalization count for each 
additional one-unit increase in the RxRisk score, after accounting for the other variables in the 
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model. By comparison, a one-unit increase in MEM will result in a 0.7% decrease (         
     ) in expected year-2 hospitalization count, holding all other variables constant.  
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Emergency Department Visits 
A zero-inflated negative binomial regression model predicting year-2 emergency 
department visit count was estimated using year-1 (2007) information, including demographics 
(age, gender, and race), the RxRisk score, and the prescription measures, unique drug count (Table 
70), simple prescription count (Table 71), and the medication exposure measure (Table 72). Logit 
models were specified to predict excess zeros using each of these variables. The variable race was 
originally included as a predictor in the zero-inflated model, but was removed due to the lack of 
significant contribution to the model. Additionally, race was included in the count model, but was 
subsequently removed due to lack of significance in predicting expected emergency department 
visit count. Gender was found to significantly predict excessive zeros in the logit model and the 
emergency department visit model. A summary of the predictive ability of the RxRisk and 
prescription measures after accounting for gender and age is found in Table 73. 
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Table 70 – RxRisk+Unique Drug Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 -0.1262 0.0149 -0.1553 -0.0971 72.22 <0.0001 
Gender Male 1 0.0775 0.0061 0.0657 0.0894 163.46 <0.0001 
Age  1 -0.0108 0.0002 -0.0111 -0.0105 4,804.27 <0.0001 
RxRisk Score  1 0.0053 0.0015 0.0023 0.0083 12.25 0.0005 
Unique Drug  1 0.0448 0.0007 0.0435 0.0461 4,647.81 <0.0001 
Dispersion  1 1.9045 0.0143 1.8766 1.9328   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.3379 0.0358 0.2678 0.4079 89.31 <0.0001 
Gender  1 0.1787 0.0186 0.1422 0.2151 92.47 <0.0001 
Age  1 -0.0091 0.0004 -0.0099 -0.0083 528.32 <0.0001 
RxRisk Score  1 -0.0407 0.0063 -0.0531 -0.0284 41.95 <0.0001 
Unique Drug  1 -0.0839 0.0033 -0.0903 -0.0775 662.17 <0.0001 
 
Table 71 – RxRisk+Rx Count Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.0830 0.0141 0.0554 0.1105 34.84 <0.0001 
Gender Male 1 0.0444 0.0059 0.0329 0.0558 57.30 <0.0001 
Age  1 -0.0130 0.0001 -0.0133 -0.0127 7,712.37 <0.0001 
RxRisk Score  1 0.0690 0.0011 0.0669 0.0712 3,966.82 <0.0001 
Rx Count  1 0.0028 0.0001 0.0026 0.0029 945.76 <0.0001 
Dispersion  1 1.9165 0.0137 1.8899 1.9435   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.2003 0.0336 0.1345 0.2661 35.63 <0.0001 
Gender  1 0.1416 0.0169 0.1085 0.1748 70.07 <0.0001 
Age  1 -0.0072 0.0004 -0.0079 -0.0065 383.89 <0.0001 
RxRisk Score  1 -0.0055 0.0039 -0.0132 0.0022 1.95 0.1625 
Rx Count  1 -0.0238 0.0005 -0.0249 -0.0228 2,013.22 <0.0001 
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Table 72 – RxRisk+MEM Model Predicting Emergency Department Counts 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.0735 0.0145 0.0450 0.1020 25.57 <0.0001 
Gender Male 1 0.0369 0.0061 0.0249 0.0489 36.41 <0.0001 
Age  1 -0.0137 0.0001 -0.0140 -0.0134 8,330.83 <0.0001 
RxRisk Score  1 0.1059 0.0012 0.1036 0.1083 7,711.96 <0.0001 
MEM  1 -0.0105 0.0011 -0.0127 -0.0082 83.33 <0.0001 
Dispersion  1 2.0355 0.0157 2.0050 2.0665   
 
Analysis of Maximum Likelihood Zero Inflation Parameter Estimates 
Parameter Level DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
Intercept  1 0.0677 0.0365 -0.0038 0.1392 3.44 0.0636 
Gender  1 0.1927 0.0199 0.1537 0.2316 93.83 <0.0001 
Age  1 -0.0075 0.0004 -0.0082 -0.0067 374.35 <0.0001 
RxRisk Score  1 -0.1752 0.0048 -0.1847 -0.1657 1,306.52 <0.0001 
MEM  1 -0.0242 0.0048 -0.0337 -0.0148 25.26 <0.0001 
 
Table 73 – RxRisk-based emergency department visit count model summary 
Analysis of Maximum Likelihood Parameter Estimates 
Parameter DF Estimate 
Std. 
Error 
Wald 95% CI Wald χ2 Pr> χ2 
RxRisk + Unique Drug Count Model 
RxRisk Score 1 0.0053 0.0015 0.0023 0.0083 12.25 0.0005 
Unique Drug 1 0.0448 0.0007 0.0435 0.0461 4,647.81 <0.0001 
        
RxRisk + Rx Count Model 
RxRisk Score 1 0.0690 0.0011 0.0669 0.0712 3,966.82 <0.0001 
Rx Count 1 0.0028 0.0001 0.0026 0.0029 945.76 <0.0001 
        
RxRisk + MEM Model 
RxRisk Score 1 0.1059 0.0012 0.1036 0.1083 7,711.96 <0.0001 
MEM 1 -0.0105 0.0011 -0.0127 -0.0082 83.33 <0.0001 
        
 
The RxRisk score variable was found to be the best predictor of expected emergency 
department visits in the RxRisk+MEM model (est. = .1059), but it was found to be the worst in the 
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RxRisk+Unique Drug model (est. = .0053). Similar to the RxRisk models predicting 
hospitalization count, the medication exposure measure was found to have a negative parameter 
estimate (est. = -0.0105). The simple prescription count (est. = 0.0049) was and unique drug count 
(est. = 0.0448) significantly predicted year-2 emergency department visits, but both were 
marginal. Taking the RxRisk+MEM model as an example, the expected change in log count for a 
one-unit increase in the RxRisk score was 0.1059. This results in a 11.2% increase (        
     ) in expected emergency department visits for each additional one-unit increase in the 
RxRisk score, after accounting for the other variables in the model. By comparison, a one-unit 
increase in MEM results in a 1.0% decrease (              ) in expected year-2 emergency 
department count, holding all other variables constant.  
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Mortality 
A logistic regression model predicting year-2 mortality was estimated using year-1 (2007) 
information, including demographics (age, gender, and race), the RxRisk score, and the 
prescription measures (Table 74). As with the count models, a summed RxRisk score was used 
rather than the RxRisk categories to predict year-2 mortality. While this results in a loss in 
predictive ability, a single composite variable makes parameter estimate interpretation more 
succinct compared to 55 indicator variables representing the same construct.  
Table 74 – RxRisk Model Predicting Year-2 Mortality 
Model* 
Cox & 
Snell R
2
 
Nagelkerke 
Adj. R
2
 
C χ2 (df; p-value) 
χ2 diff (dfdiff; 
p-value) 
RxRisk Model 0.0385 0.1192 0.749 
48,309.21 
(df=3; p<0.0001) 
- 
RxRisk + Unique Rx 0.0397 0.1227 0.752 
49,769.80 
(df=4; p<0.0001) 
1,460.59 
(df=511; p<0.0001) 
RxRisk + Rx Count 0.0404 0.1250 0.754 
50,721.85 
(df=4; p<0.0001) 
2,412.64 
(df=51; p<0.0001) 
RxRisk + MEM 0.0385 0.1192 0.749 
48,324.17 
(df=4; p<0.0001) 
14.96 
(df=1; p=0.0002) 
*Models contain demographic variables from the HCC and RxHCC models (e.g., age and sex) 
Table 75 provides odds ratio and parameter estimates for the RxRisk models tested to 
predict year-2 mortality. The RxRisk score exhibited strong predictive ability compared to the 
other variables included in the models with the exception of gender, which was the best predictor 
of year-2 mortality across the models. 
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Table 75 – Odds Ratio and Parameter Estimates for RxRisk Models Predicting Year-2 
Mortality 
Odds Ratio and Parameter Estimates 
Parameter 
Odds Ratio (95% 
Wald CI) 
Estimate 
Std. 
Error 
Wald χ2 Pr> χ2 
RxRisk Model 
Intercept - -10.2920 0.0415 61,377.26 <0.0001 
Gender (Male) 1.543 (1.515-1.571) 0.4336 0.0092 2,231.21 <0.0001 
Age 1.087 (1.086-1.088) 0.0837 0.0005 28,830.81 <0.0001 
RxRisk Score 1.150 (1.147-1.153) 0.1399 0.0013 11,668.36 <0.0001 
      
RxRisk + Unique Drug Count Model 
Intercept - -10.4523 0.0417 62,745.60 <0.0001 
Gender (Male) 1.573 (1.544-1.601) 0.4527 0.0092 2,418.82 <0.0001 
Age 1.089 (1.088-1.090) 0.0855 0.0005 29,974.02 <0.0001 
RxRisk Score 1.058 (1.052-1.063) 0.0559 0.0025 484.90 <0.0001 
Unique Drug 1.045 (1.042-1.047) 0.0437 0.0011 1,521.60 <0.0001 
      
RxRisk + Rx Count Model 
Intercept - -10.2049 0.0411 61,593.08 <0.0001 
Gender (Male) 1.585 (1.557-1.614) 0.4608 0.0092 2,489.10 <0.0001 
Age 1.086 (1.085-1.087) 0.0828 0.0005 28,978.56 <0.0001 
RxRisk Score 1.072 (1.068-1.076) 0.0693 0.0020 1,253.29 <0.0001 
Rx Count 1.008 (1.007-1.008) 0.0075 0.0002 2,510.54 <0.0001 
      
RxRisk + MEM Model 
Intercept - -10.2918 0.0416 61,349.80 <0.0001 
Gender (Male) 1.540 (1.513-1.568) 0.4319 0.0092 2,208.78 <0.0001 
Age 1.087 (1.086-1.088) 0.0837 0.0005 28,821.50 <0.0001 
RxRisk Score 1.158 (1.153-1.163) 0.1465 0.0021 4,691.36 <0.0001 
MEM 0.991 (0.987-0.996) -0.0086 0.0022 14.93 <0.0001 
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CHAPTER V - SUMMARY AND CONCLUSIONS 
SPECIFIC AIM 1 – MEDICATION EXPOSURE MEASURE 
Major Findings 
In the sample, 88.5% received a prescription during the base year, making 
prescription-based measures accessible as a potential risk adjuster. Among the prescription 
measures, the medication exposure measure was found to be most similar to simple prescription 
count (r=0.895) compared to unique drug count (r=0.781). The intraclass correlation coefficients 
between the medication exposure measure and simple prescription count (ICC=0.388) and 
between the MEM and unique drug count (ICC=0.081) differ from the Pearson product-moment 
correlation coefficients due to differences in scale and as a result, ICC may not be the best measure 
to describe the relationship between the measures. The similarity between the medication exposure 
measure and unique drug count is conceivable because the calculation of medication exposure 
measure uses unique drug count as a foundation, prior to incorporating the estimation of exposure 
to the unique drug. These numbers do not necessarily grow with each new prescription fill, as the 
simple prescription count does. This also explains why the mean for the simple prescription count 
( ̅=37.25) is much greater than that of the medication exposure measure ( ̅=3.60) or unique drug 
count ( ̅=8.93). The prescription measures differed throughout the Medicare Part D benefit 
phases; however, the marginal differences between the LICS and non-LICS measures for 
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medication exposure and unique drug count suggest that these measures are relatively stable 
within comparable benefit phases.  
SPECIFIC AIM 2 – CMS RISK-ADJUSTMENT MODELS 
Major Findings 
Expenditure Outcomes 
The HCC and RxHCC models performed equally well in predicting all types of health 
expenditures (medical, pharmacy, and total), in both the modified (transformed or truncated) and 
unmodified models. These models were conceived using very similar methodologies, with the 
only remarkable difference being that the HCC disease groupings were selected based on their 
ability to predict year-2 medical expenditures and likewise, the RxHCC disease grouping were 
selected for their ability to predict year-2 pharmacy expenditures. The HCC and RxHCC models 
also performed consistently in the Medicare Part D benefit phase interaction models, with benefit 
phase having the most influence on the prescription measures when predicting year-2 pharmacy 
expenditures. This is intuitive given the similar methodology by which they were developed. 
The addition of any prescription measure to the HCC and RxHCC models did not improve 
model performance in predicting year-2 medical expenditures. However, adding the prescription 
measures, particularly the medication exposure measure, to the HCC and RxHCC models 
markedly improved prediction of year-2 pharmacy expenditures. Simply adding simple 
prescription count or the medication exposure measure to the demographic (AAPCC) models 
provides better prediction of year-2 pharmacy expenditures than the core HCC or RxHCC base 
 141 
models provide alone. The addition of the medication exposure measure to the RxHCC model 
provided the best overall fit of any variable combination (R
2
=0.2489) in predicting year-2 
pharmacy expenditures for the CMS risk-adjustment models. 
When coupled with the variables from the AAPCC model, the prescription-based measures 
predict medical and pharmacy expenditures comparably, and in some cases, better than the HCC 
and RxHCC models alone. In particular, the unique drug count and medication exposure measure 
outperformed the HCC model for medical expenses, as well as the RxHCC model for pharmacy 
expenses, based on model R
2
 values. Prescription drug expenditures and utilization are generally 
stable over time, particularly when estimated at the group level, which partially explains the ability 
of the RxHCC model to predict year-2 prescription expenses, particularly when coupled with the 
prescription utilization measures (Wrobel, Doshi, Stuart, & Briesacher, 2003-2004; Ellis & 
McGuire, 2007; Lee et al., 2007; Hsu et al., 2009). The strong, positive relationship between the 
medication exposure measure and simple prescription count (r=0.895) helps explain the similar 
performance of the two measures in predicting expenditure outcomes. 
Clinical Outcomes 
 The HCC and RxHCC scores were generally found to be the best predictors of year-2 count 
outcomes, compared to the other variables included in the models. The HCC model predicted 
expected year-2 hospitalization and emergency department counts similarly, with an estimated 36 
to 54% increase in expected year-2 hospitalization or emergency department count for each 
additional one-unit increase in the HCC score. The RxHCC model predicted year-2 
hospitalizations well, with an estimated 60 to 80% increase in expected year-2 hospitalization 
count for each additional one-unit increase in RxHCC score. The RxHCC model predicted year-2 
 142 
emergency department counts much better, with an estimated 100 to 144% increase in expected 
year-2 emergency department visit count for each additional one-unit increase in RxHCC score. 
Compared to the HCC and RxHCC models, the prescription measures were much more 
modest in their ability to predict these counts. Among the prescription-based measures, the 
medication exposure measure was generally found to be the best predictor of year-2 
hospitalization and emergency department counts, with unique drug count being the second best 
prescription-based measure for most models. Simple prescription count was found to be the worst 
predictor of the two count outcomes evaluated in specific aim 2 (hospitalization count and 
emergency department visits). 
The HCC and RxHCC models were not notably different in their ability to predict year-2 
mortality; however, the HCC model did perform slightly better (c-statistic range 0.777-0.785) 
compared to the RxHCC model (c-statistic range 0.737-0.755). The predictive validity gained by 
adding the prescription measures to these models was found to be statistically significant, albeit 
fairly small. For both the HCC and RxHCC models, the medication exposure measure was found 
to be the best prescription-based measure to predict year-2 mortality. 
SPECIFIC AIM 3 – NON-CMS RISK-ADJUSTMENT MODELS 
Major Findings 
Expenditure Outcomes 
Similar to the concordant prediction of the HCC and RxHCC models, the Charlson- and 
Elixhauser-based models were closely matched with their ability to predict all-types of 
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expenditure outcomes, including truncated and log-transformed. The addition of the prescription 
measures performed similarly in each of these models as well, with simple prescription count and 
the medication exposure measure outperforming the unique drug count. Compared to the CCI and 
Elixhauser models, the RxRisk model performed slightly worse in predicting medical 
expenditures and the addition of prescription measures did not markedly improve this prediction.  
The RxRisk model vastly outperformed the CCI and Elixhauser models in predicting 
year-2 prescription expenditures, which was made more pronounced with the addition of the 
prescription measures. The simple prescription count and the medication exposure measure 
provided nearly equal improvements in the predictive ability of the RxRisk model (R
2
=0.2603 and 
R
2
=0.2687, respectively). The similar performance of the CCI and Elixhauser models can likely be 
explained by their relatively low number of individuals who were assigned a score and due to their 
similar makeup of diagnostic categories, which were selected based on their ability to predict 
clinical outcomes, including hospitalization and mortality. Conversely, more beneficiaries were 
assigned a score in the RxRisk model and further, the RxRisk model was initially developed to 
predict health expenditures. 
Clinical Outcomes 
 The CCI and Elixhauser models performed equally well in predicting expected year-2 
hospitalization and emergency department visit counts, with an estimated 16 to 22% increase in 
expected year-2 hospitalization or emergency department count for each additional one-unit 
increase in the respective scores. The Elixhauser model predicted moderately better for the 
expected year-2 emergency department visit counts, with an estimated 27 to 33% increase in 
expected year-2 emergency department visit count for each additional one-unit increase in the 
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Elixhauser Index. As with the HCC and RxHCC models, the prescription measures were again 
more modest in their ability to predict year-2 counts. The RxRisk score performed much worse 
than the CCI or Elixhauser in predicting year-2 expected counts and the medication exposure 
parameter estimate was near zero and uncharacteristically negative in the RxRisk model predicting 
expected year-2 counts. The non-CMS risk-adjuster models were nearly indistinguishable in 
predicting year-2 mortality, in terms of the model c-statistics. As an individual predictor, the 
Elixhauser Index variable modestly outperformed the CCI and the RxRisk composite variables. 
Implications 
Based on the findings of this study, incorporating the medication exposure measure into 
Medicare Part D risk-adjustment calculations (i.e., with RxHCC) would provide an intractable 
measure that would improve risk-adjusted capitated payments from both the perspectives of CMS 
and the health plans. In addition to enhancing risk adjustment for capitated payment models, the 
results of this study may be used by researchers to use in studies requiring risk-adjusted estimates 
of some health outcome. While researchers may not be particularly interested in the intractable 
design of the medication exposure measure, there are some benefits to using medication exposure 
as a risk-adjuster in research. In many cases, the predictive ability of the MEM paralleled simple 
prescription count, particularly in predicting year-2 pharmacy expenditures. However, there were 
a few cases when the medication exposure measure was found to be the best prescription-based 
measure. In particular, the medication exposure measure performed particularly well when 
predicting year-2 expected hospitalization and emergency department visit counts and year-2 
mortality, except when paired with RxRisk. 
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Study Limitations 
Beneficiaries with 12 months enrollment in Parts A, B and D in the base year were 
included in this study. The CMS-HCC model also allows for “new eligible” enrollees to be 
included in the model. While the overall number is small relative to the continuously enrolled 
population, future studies could explore this expanded eligibility option. The study sample may be 
healthier than the general population (less medical expenses), possibly due to the 12-month 
continuous enrollment requirement, but the sample is still representative of the group that would 
be eligible for risk adjustment based on this proposal. 
The proportion of Medicare beneficiaries with no medical claims for the prediction year 
was 38.37%, which is substantially higher than the general Medicare population at around 10% of 
the eligible beneficiaries with zero medical claims (Pope et al., 2011). A gamma-distributed 
generalized linear model (γ-GzLM) was estimated to account for this large number of zero claims, 
which differs from the typical HCC risk-adjustment statistical methodology of ordinary least 
squares or weighted least squares regression (Pope et al., 2000a; Pope et al., 2000b; Pope et al., 
2004; Pope et al., 2011). The γ-GzLM HCC model did not perform as well as the OLS HCC model 
in predicting year-2 medical expenses, despite positively skewed distribution of the outcome 
variable due to the large number of zero medical claims. Two-part models have also been used in 
estimating risk-adjusted capitated payments where large numbers of individuals do not use health 
services over the base or prediction years (Madden, Mackay, Skillman, Ciol, & Diehr, 2000). 
However, Buntin and Zaslovsky (2004) demonstrated that a gamma-distributed, one-part 
generalized linear model with a log link generally outperforms and is more readily interpretable 
than one- and two-part models with various transformations. Additionally, others have estimated 
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transformed one-part and two-part models for risk adjustment and have reported very low or 
negative R
2
 values (Ellis & McGuire, 2007). The use of OLS prevails in the estimation of 
risk-adjusted payment models because many of the potential estimation problems that might arise 
due to skewed outcome data or to high outliers is mitigated by very large sample sizes (Ellis & 
McGuire, 2007; Ellis, 2008). 
No interaction terms between health conditions were proposed for the HCC or RxHCC 
models. Some HCC models have included interaction terms with disability status and select 
disease states, but have limited additional predictive validity (Pope et al., 2004). Several studies 
have evaluated nonlinear models, including interaction terms between health conditions and 
reasons for eligibility, as well as expenditure variable transformations; however, the ordinary least 
squares model remains for risk-adjusted capitated payments for both Medicare Part C & D plans 
(Veazie, Manning, & Kane, 2003; Ellis & McGuire, 2007; Ellis, 2008; Pope et al., 2011). 
Many other studies report results from both the community and institutional model; 
however, only the community models for HCC and RxHCC were estimated in this study (Pope et 
al., 2000a; Pope et al., 2004; Pope et al., 2011). Future research may include the medication 
exposure measure and other utilization-based measures for institutionalized beneficiaries. 
Additionally, this study did not include hospice care or durable medical equipment (DME) for 
expenditures or as a source of diagnosis codes. Previous studies found that adding DME claims did 
not significantly contribute toward the overall variance explained or predictive ratios for the model 
and Medicare Advantage plans are not responsible for hospice payments (Pope et al., 2000a; Pope 
et al., 2004; Pope et al., 2011). 
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The validity of a pharmacy-based risk-adjustor is highly dependent on the extent of drug 
benefit coverage and pharmacy access, which differs among Medicare Part D plans. The 
generalizability of risk-adjustment models vary depending on the sample. Medicare models are 
highly different than models developed for Medicaid and commercial insurers. (Cucciare & 
O'Donohue, 2006). Using the HCC and RxHCC models to predict non-expenditure outcomes (i.e., 
hospitalizations, emergency department utilization, and mortality) may be enhanced by altering 
the time in which predictions are made, rather than predicting year-2 outcomes. 
The study only included medications which were captured in Medicare claims data. Thus, 
it did not include drugs purchased “out-of-pocket” and some over-the-counter drugs – this is the 
case with all risk-adjustment models based on information provided by administrative claims data. 
Additionally, drugs billed on the medical benefit as J-code drugs were not included in the analysis 
because of the difficulty calculating possession measures across the myriad of drugs billed as 
J-code drugs. Unlike outpatient prescription drugs, days supply is not submitted on the medical 
claims form with J-code billed drugs. Because of the increasing costs and the decreasing 
reimbursement of J-code billed drugs, many prescribers are less likely to “take title” over the drugs 
and assume the associated risk. There are problems associated with incorporating J-code billed 
drugs into the medication exposure measure. Simply adding a count for J-code billed drugs defeats 
the premise of estimating actual medication possession. Comparison between the new and old 
measure would simply add the J-code billed drugs equally – thus, not adding to the discriminatory 
ability of the new measure compared to the old measure. To compound this argument, it is rare to 
find a study that includes J-code billed drugs in a prescription count or compliance estimate due to 
these issues. 
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Future Research 
The purpose of this study was to develop and validate a measure of medication exposure 
for the general Medicare population, not focusing on a particular disease. Future research could 
examine specific conditions of interest. For example, grouping the HCC model on a particular 
disease state may help explain a core proposition of this study – that differing values of medication 
exposure measured for a similar group (e.g., persons with diabetes) would further enhance our 
ability to predict outcomes for that group (see Figure 1). Adding the medication exposure measure 
(or any prescription measure) to the HCC model did not enhance prediction of year-2 medical 
expenditures for the overall group. In addition to testing the models based on actual year-2 medical 
expenditure deciles, grouping the HCC model on select disease states may provide additional 
insight into this proposition. 
The interaction between the Medicare Part D benefit phase and the prescription-based 
measures was estimated to account for the influence of potential differences in the medication 
exposure measure between the benefit phase groups. A discontinuous longitudinal model may 
provide a different approach to account for differences or “instability” of the medication exposure 
measure as beneficiaries progress through the coverage stages. The eventual phase out of the donut 
hole, as proposed under the Patient Protection and Affordable Care Act, will lessen the necessity of 
accounting for fluctuating beneficiary drug benefit liability, and thus, will stabilize medication use 
(Patient Protection and Affordable Care Act, 2010). An alternative method to account for possible 
differences in utilization due to beneficiary liability would be to group beneficiaries based on their 
Medicare Cost Share Group Code found in the Medicare beneficiary summary file. This approach 
differs from the benefit phase approach by grouping beneficiaries based on their monthly 
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copayment and low-income subsidy structure, rather than on their ultimate benefit phase reached 
by the end of the plan year, regardless of beneficiary liability. It could be argued that the latter 
approach would more appropriately reflect the beneficiary’s liability, and ultimately the behavior 
that might manifest from that liability. 
The risk adjusters used in this study could be included in the regression models as 
indicators or as a composite score. Both of these types were used depending on the objective of the 
model. For example, the full indicator scoring was used for the HCC and RxHCC models in 
predicting year-2 expenditures. This was done to make more direct comparisons to the extant 
literature, as well as to imitate the current methodology which CMS uses to risk adjust capitated 
payments. In other cases, a composite score was used to make interpretation of parameter 
estimates less laborious. The overall model fit was certainly impacted by this in some cases, but 
science is often plagued with balancing complexity with parsimony. While some studies have 
examined this, future studies could compare indicator- and score-based models for the risk 
adjusters included in this study. In the end, the researcher should select the risk adjuster and model 
based on the study objective and the research question. Full indicator models may make sense at 
times, and the composite variables may make sense in others. 
In this study, the medication exposure measure was calculated using an entire year of data. 
Considering the medication exposure measure is novel to the literature, the year baseline data was 
used to ensure the stability of the measure for the study. Future research may evaluate estimating 
the medication exposure measure using a shorter timeframe or alternative methods of calculating 
the MEM without using matrices, which was the method employed in this study. 
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Conclusions 
The primary purpose of this study was to develop an intractable measure of outpatient 
medication exposure from administrative claims data to be used for risk-adjusting Medicare 
payments to health and pharmacy plan participants, and to test the predictive validity of this 
measure when coupled with diagnosis- and pharmacy-based risk-adjustment measures. Overall, 
the addition of the prescription-based measures to risk-adjustment models resulted in enhanced 
predictive validity and variance explanation compared to the risk-adjustment model alone. The 
medication exposure measure performed particularly well on many of the outcomes. The 
intractable nature of the medication exposure measure lends well to incorporation into 
risk-adjusted capitated payment models. Although adding a measure of medication exposure to the 
HCC models used to predict medical expenditures does not appear to be a useful method of 
enhancing risk-adjusted payments, the medication exposure measure performed particularly well 
with the RxHCC in the prediction of year-2 prescription expenditures.  
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